WO2013119923A1 - Different states of cancer stem cells - Google Patents
Different states of cancer stem cells Download PDFInfo
- Publication number
- WO2013119923A1 WO2013119923A1 PCT/US2013/025306 US2013025306W WO2013119923A1 WO 2013119923 A1 WO2013119923 A1 WO 2013119923A1 US 2013025306 W US2013025306 W US 2013025306W WO 2013119923 A1 WO2013119923 A1 WO 2013119923A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- emt
- stem cells
- cancer stem
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 458
- 201000011510 cancer Diseases 0.000 title claims abstract description 379
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 327
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims abstract description 125
- 238000000034 method Methods 0.000 claims abstract description 125
- 102100032912 CD44 antigen Human genes 0.000 claims abstract description 108
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims abstract description 108
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 55
- 239000000203 mixture Substances 0.000 claims abstract description 49
- 108091032902 miR-93 stem-loop Proteins 0.000 claims abstract description 38
- 101150084967 EPCAM gene Proteins 0.000 claims abstract description 18
- 238000012216 screening Methods 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 329
- 230000014509 gene expression Effects 0.000 claims description 120
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 97
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 97
- 150000001875 compounds Chemical class 0.000 claims description 90
- 208000026310 Breast neoplasm Diseases 0.000 claims description 70
- 206010006187 Breast cancer Diseases 0.000 claims description 68
- 238000012360 testing method Methods 0.000 claims description 68
- 239000003814 drug Substances 0.000 claims description 61
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 229940124597 therapeutic agent Drugs 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 108091028049 Mir-221 microRNA Proteins 0.000 claims description 23
- 108091061917 miR-221 stem-loop Proteins 0.000 claims description 23
- 108091063489 miR-221-1 stem-loop Proteins 0.000 claims description 23
- 108091055391 miR-221-2 stem-loop Proteins 0.000 claims description 23
- 108091031076 miR-221-3 stem-loop Proteins 0.000 claims description 23
- 239000003112 inhibitor Substances 0.000 claims description 21
- 230000037361 pathway Effects 0.000 claims description 21
- 102000000905 Cadherin Human genes 0.000 claims description 19
- 108050007957 Cadherin Proteins 0.000 claims description 19
- -1 FOXCl Proteins 0.000 claims description 19
- 239000002246 antineoplastic agent Substances 0.000 claims description 16
- 108091007773 MIR100 Proteins 0.000 claims description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 238000012544 monitoring process Methods 0.000 claims description 14
- 108010065472 Vimentin Proteins 0.000 claims description 13
- 102100035071 Vimentin Human genes 0.000 claims description 13
- 210000005048 vimentin Anatomy 0.000 claims description 13
- 102000013814 Wnt Human genes 0.000 claims description 12
- 108050003627 Wnt Proteins 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 108090001005 Interleukin-6 Proteins 0.000 claims description 11
- 108010070047 Notch Receptors Proteins 0.000 claims description 11
- 102000005650 Notch Receptors Human genes 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 230000000890 antigenic effect Effects 0.000 claims description 10
- 102000004889 Interleukin-6 Human genes 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 8
- 238000001959 radiotherapy Methods 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 8
- 241000237858 Gastropoda Species 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- 108050000637 N-cadherin Proteins 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 102000002029 Claudin Human genes 0.000 claims description 4
- 108050009302 Claudin Proteins 0.000 claims description 4
- 102100037362 Fibronectin Human genes 0.000 claims description 4
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 4
- 101000723833 Homo sapiens Zinc finger E-box-binding homeobox 2 Proteins 0.000 claims description 4
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 4
- 101150047834 SNAI2 gene Proteins 0.000 claims description 4
- 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 claims description 4
- 230000002147 killing effect Effects 0.000 claims description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 102100028914 Catenin beta-1 Human genes 0.000 claims description 3
- 102000029792 Desmoplakin Human genes 0.000 claims description 3
- 108091000074 Desmoplakin Proteins 0.000 claims description 3
- 102100021083 Forkhead box protein C2 Human genes 0.000 claims description 3
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims description 3
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 claims description 3
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims description 3
- 101000818305 Homo sapiens Forkhead box protein C2 Proteins 0.000 claims description 3
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 3
- 108090000304 Occludin Proteins 0.000 claims description 3
- 102000003940 Occludin Human genes 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 238000011275 oncology therapy Methods 0.000 claims description 3
- 102100021084 Forkhead box protein C1 Human genes 0.000 claims description 2
- 101000818310 Homo sapiens Forkhead box protein C1 Proteins 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 241000027355 Ferocactus setispinus Species 0.000 claims 4
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 3
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 3
- 230000007705 epithelial mesenchymal transition Effects 0.000 abstract description 157
- 230000007704 transition Effects 0.000 abstract description 24
- 238000011282 treatment Methods 0.000 abstract description 23
- 108091092072 miR-100 stem-loop Proteins 0.000 abstract description 18
- 108091070501 miRNA Proteins 0.000 abstract description 18
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 121
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 87
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 87
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 70
- 102100032816 Integrin alpha-6 Human genes 0.000 description 70
- 239000000090 biomarker Substances 0.000 description 41
- 210000001519 tissue Anatomy 0.000 description 41
- 239000002679 microRNA Substances 0.000 description 31
- 108700011259 MicroRNAs Proteins 0.000 description 27
- 238000000338 in vitro Methods 0.000 description 27
- 238000003556 assay Methods 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 25
- 210000000481 breast Anatomy 0.000 description 23
- 206010027476 Metastases Diseases 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 230000009401 metastasis Effects 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 238000011529 RT qPCR Methods 0.000 description 17
- 230000002018 overexpression Effects 0.000 description 17
- 230000001105 regulatory effect Effects 0.000 description 17
- 230000008685 targeting Effects 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000003550 marker Substances 0.000 description 16
- 238000001514 detection method Methods 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 15
- 210000004216 mammary stem cell Anatomy 0.000 description 14
- 102100040069 Aldehyde dehydrogenase 1A1 Human genes 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 238000002512 chemotherapy Methods 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 230000002062 proliferating effect Effects 0.000 description 11
- 101710150756 Aldehyde dehydrogenase, mitochondrial Proteins 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 108010082117 matrigel Proteins 0.000 description 10
- 230000001394 metastastic effect Effects 0.000 description 10
- 206010061289 metastatic neoplasm Diseases 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 9
- 210000005075 mammary gland Anatomy 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 8
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 230000003292 diminished effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000003995 blood forming stem cell Anatomy 0.000 description 7
- 230000009400 cancer invasion Effects 0.000 description 7
- 231100000504 carcinogenesis Toxicity 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 108091023663 let-7 stem-loop Proteins 0.000 description 7
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 7
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 7
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 7
- 208000005623 Carcinogenesis Diseases 0.000 description 6
- 244000060234 Gmelina philippensis Species 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 206010064390 Tumour invasion Diseases 0.000 description 6
- 230000036952 cancer formation Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000003828 downregulation Effects 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 6
- 238000011503 in vivo imaging Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000000381 tumorigenic effect Effects 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- 101000785626 Homo sapiens Zinc finger E-box-binding homeobox 1 Proteins 0.000 description 5
- 108091062154 Mir-205 Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 102100026457 Zinc finger E-box-binding homeobox 1 Human genes 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 5
- 231100000588 tumorigenic Toxicity 0.000 description 5
- 239000012099 Alexa Fluor family Substances 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108091027977 Mir-200 Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 229960000961 floxuridine Drugs 0.000 description 4
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000002122 leukaemogenic effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 108091029119 miR-34a stem-loop Proteins 0.000 description 4
- 229960004857 mitomycin Drugs 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 125000006239 protecting group Chemical class 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- FOVRGQUEGRCWPD-UHFFFAOYSA-N (5aR)-9t-beta-D-Glucopyranosyloxy-5t-(4-hydroxy-3,5-dimethoxy-phenyl)-(5ar,8at)-5,8,8a,9-tetrahydro-5aH-furo[3',4';6,7]naphtho[2,3-d][1,3]dioxol-6-on Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(OC3C(C(O)C(O)C(CO)O3)O)C3C2C(OC3)=O)=C1 FOVRGQUEGRCWPD-UHFFFAOYSA-N 0.000 description 3
- YVCVYCSAAZQOJI-JHQYFNNDSA-N 4'-demethylepipodophyllotoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YVCVYCSAAZQOJI-JHQYFNNDSA-N 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 3
- 108700020463 BRCA1 Proteins 0.000 description 3
- 102000036365 BRCA1 Human genes 0.000 description 3
- 101150072950 BRCA1 gene Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 description 3
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- 102000004106 Claudin-3 Human genes 0.000 description 3
- 108090000599 Claudin-3 Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010015899 Glycopeptides Proteins 0.000 description 3
- 102000002068 Glycopeptides Human genes 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 101000890570 Homo sapiens Aldehyde dehydrogenase 1A1 Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 238000007807 Matrigel invasion assay Methods 0.000 description 3
- 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 238000011789 NOD SCID mouse Methods 0.000 description 3
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000004709 cell invasion Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000004563 mammosphere formation Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 108091047084 miR-9 stem-loop Proteins 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000012340 reverse transcriptase PCR Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 229960003087 tioguanine Drugs 0.000 description 3
- 229960005267 tositumomab Drugs 0.000 description 3
- 230000005748 tumor development Effects 0.000 description 3
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 241001156002 Anthonomus pomorum Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 102100033553 Delta-like protein 4 Human genes 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 2
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000026633 IL6 Human genes 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 2
- 108091033773 MiR-155 Proteins 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 108010043958 Peptoids Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 108010092935 Snail Family Transcription Factors Proteins 0.000 description 2
- 102000016845 Snail Family Transcription Factors Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000007818 agglutination assay Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000069 breast epithelial cell Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004640 cellular pathway Effects 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- 229950004683 drostanolone propionate Drugs 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011223 gene expression profiling Methods 0.000 description 2
- 238000009650 gentamicin protection assay Methods 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 108091074450 miR-200c stem-loop Proteins 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- UBWXUGDQUBIEIZ-QNTYDACNSA-N nandrolone phenpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-QNTYDACNSA-N 0.000 description 2
- 210000000441 neoplastic stem cell Anatomy 0.000 description 2
- 229950008835 neratinib Drugs 0.000 description 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 229960001218 pegademase Drugs 0.000 description 2
- 108010027841 pegademase bovine Proteins 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 2
- 229960005353 testolactone Drugs 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 210000005102 tumor initiating cell Anatomy 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- HYJVYOWKYPNSTK-UONOGXRCSA-N (2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoic acid Chemical compound N([C@H]([C@@H](O)C(O)=O)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 HYJVYOWKYPNSTK-UONOGXRCSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- OQRAALAMUQMADN-UHFFFAOYSA-N 1-[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione dihydrochloride Chemical compound Cl.Cl.OCCNCCNc1cccc2C(=O)c3ccccc3C(=O)c12 OQRAALAMUQMADN-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- IOASODGEZSLHHY-UHFFFAOYSA-N 1-thia-4-azaspiro[4.5]decane;hydrochloride Chemical compound Cl.N1CCSC11CCCCC1 IOASODGEZSLHHY-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 102000052030 Aldehyde Dehydrogenase 1 Family Human genes 0.000 description 1
- 101710196131 Aldehyde dehydrogenase 1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 238000007808 Cell invasion assay Methods 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 102100036723 Discoidin domain-containing receptor 2 Human genes 0.000 description 1
- 101710127786 Discoidin domain-containing receptor 2 Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 101150098893 GEM gene Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108700039143 HMGA2 Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 1
- 101150073387 Hmga2 gene Proteins 0.000 description 1
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 description 1
- 101000869796 Homo sapiens Microprocessor complex subunit DGCR8 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000702544 Homo sapiens SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 102000000426 Integrin alpha6 Human genes 0.000 description 1
- 102000012355 Integrin beta1 Human genes 0.000 description 1
- 108010022222 Integrin beta1 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102100032459 Microprocessor complex subunit DGCR8 Human genes 0.000 description 1
- 108091027966 Mir-137 Proteins 0.000 description 1
- 108091062170 Mir-22 Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 1
- 101100437777 Mus musculus Bmpr1a gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- QWZRZYWLWTWVLF-UHFFFAOYSA-N O.OP(O)=O Chemical compound O.OP(O)=O QWZRZYWLWTWVLF-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 102100031028 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 Human genes 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101150084279 TM gene Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 102000002232 Twist Transcription Factors Human genes 0.000 description 1
- 108010000120 Twist Transcription Factors Proteins 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 1
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- MBHRHUJRKGNOKX-UHFFFAOYSA-N [(4,6-diamino-1,3,5-triazin-2-yl)amino]methanol Chemical compound NC1=NC(N)=NC(NCO)=N1 MBHRHUJRKGNOKX-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 229940060205 adagen Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229940064305 adrucil Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 229940087620 aromasin Drugs 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 batimastat Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008195 breast development Effects 0.000 description 1
- 208000024119 breast tumor luminal A or B Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229950007998 demcizumab Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 102000006795 dihydrofolate reductase activity proteins Human genes 0.000 description 1
- 108040000939 dihydrofolate reductase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 229940017825 dromostanolone Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 229940087477 ellence Drugs 0.000 description 1
- 229940120655 eloxatin Drugs 0.000 description 1
- 229940000733 emcyt Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000004293 human mammary gland Anatomy 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108091007423 let-7b Proteins 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 229940100029 lysodren Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 108091056924 miR-124 stem-loop Proteins 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000024799 morphogenesis of a branching structure Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940090009 myleran Drugs 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- 229960001133 nandrolone phenpropionate Drugs 0.000 description 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000003956 nonsteroidal anti androgen Substances 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940045681 other alkylating agent in atc Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000013197 protein A assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- RCINICONZNJXQF-VAZQATRQSA-N s1150_selleck Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-VAZQATRQSA-N 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- ZFMRLFXUPVQYAU-UHFFFAOYSA-N sodium 5-[[4-[4-[(7-amino-1-hydroxy-3-sulfonaphthalen-2-yl)diazenyl]phenyl]phenyl]diazenyl]-2-hydroxybenzoic acid Chemical compound C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C(C=C4C=CC(=CC4=C3O)N)S(=O)(=O)O)N=NC5=CC(=C(C=C5)O)C(=O)O.[Na+] ZFMRLFXUPVQYAU-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000004991 spatiotemporal regulation Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229950007435 tarextumab Drugs 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000012036 ultra high throughput screening Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229940001814 uvadex Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229940054937 valstar Drugs 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
Definitions
- the present invention relates to compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment, based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states.
- breast cancer stems cells have been characterized by expression of the cell surface markers ESA and CD44 in the absence of expression of the marker CD24. These cells have been termed "breast cancer stem cells" (BCSCs). As few as 200 ESA- positive CD44+/CD24-lin- cells were able to generate tumors in immunocompromised NOD- SCID mice, whereas 100-fold more cells without these markers isolated from the same tumors were non-tumorigenic. Furthermore, the tumor-initiating populations regenerated tumors that recapitulated the heterogeneity of the initial tumor.
- BCSCs breast cancer stem cells
- the art has also developed an in vitro "mammosphere” assay as a means of quantitating normal and malignant stem cells. More recently, the art described the expression of aldehyde dehydrogenase (ALDH) as assessed by the Aldefluor assay (StemCell Technologies, Canada) or the isoform ALDH1 by immunohistochemistry (IHC) as a means of further identifying and enriching for tumor initiating CSC populations in human BCs. Interestingly, it was reported that these markers identify overlapping, but not identical cell populations. Furthermore, it has been found that these markers can be utilized to isolate CSC populations from established breast cancer cell lines, as well as primary tumor xenografts.
- ALDH aldehyde dehydrogenase
- IHC immunohistochemistry
- BCSC breast cancer stem cell
- the present invention relates to compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment, based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states.
- a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells.
- the different states of cancer stem cells are distinguished based on markers CD44 + CD24 " , EpCam " CD49F + (for EMT cancers stem cells), ALDH + (or ADLH1 isoform) and
- EPCam + CD49 for MET cancers stem cells
- CD44 + CD24 " ALDH + for EMT-MET cancer stem cells
- micro RNAs are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).
- the present invention provides methods of reducing the frequency of EMT and MET type cancer stem cells in a subject with the EMT and MET type cancer stem (or a subject suspected of having EMT and MET type cancer stem cells) cells comprising co-administering to the subject an effective amount of: a) a first therapeutic agent directed against EMT type cancer stem cells, and b) a second therapeutic agent directed against MET type cancer stem cells, wherein the frequency of both the EMT and the MET type cancer stem cells in the subject are reduced (e.g., tumor size is reduced).
- the first therapeutic agent, targeting EMT cancer stem cells comprises an inhibitor of a protein or nucleic acid encoding a protein selected from the group consisting of: IL-6 and an IL-6 pathway member (e.g., IL-6 antibody, IL-6R antibody, STAT3 inhibitor), Notch and a Notch pathway member (e.g., GSI), Wnt and Wnt pathway members, Hedgehog and Hedgehog pathway members, and Tgf- ⁇ and Tgf- ⁇ pathway members.
- the first therapeutic is an agent targeting Notch (e.g., U.S. Pat. 8,088,617; WO2008100563, WO201 1088215, and WO20088091641, all of which are herein incorporated by reference); WNT (e.g., U.S. Pat. Pub. 201 10305695 and
- frizzled e.g.,
- the first therapeutic agent, targeting EMT cancer stem cells is an antibody (or small molecule) being developed by Oncomed Pharmaceuticals selected from: Anti-DLL4 (OMP-21M18, demcizumab); Anti- DLL4/VEGF bispecific; Anti-Notch2/3 (OMP-59R5); Anti-Notchl; Anti-Fzd7 (OMP-18R5); and Fzd8Fc. Information about these therapeutic agents can be found on Oncomed
- the second therapeutic agent, targeting MET cancer stem cells comprises a Pan-erb blocker (e.g., Canertinib dihydrochloride, Neratinib, JNJ-
- Pan-erb blocker e.g., Canertinib dihydrochloride, Neratinib, JNJ-
- the second therapeutic targets BMPR e.g., WO201 11 16212, herein incorporated by reference in its entirety.
- the first or second therapeutic agent is a cancer stem cell targeting agent against: i) human mesenchymal-epithelial transition receptor binder (e.g., U.S. Pat. Pub.
- LGR G-protein coupled receptor
- integrin beta 1 e.g., WO20090091 14, herein incorporated by reference in its entirety
- discoidin domain receptor 2 e.g., WO2008070090, herein incorporated by reference in its entirety.
- the first therapeutic agent is an IL6R antibody (e.g., tocilizumab) and the second therapeutic agent is anti-Her2 antibody (e.g., HERCEPTIN).
- IL6R antibody e.g., tocilizumab
- anti-Her2 antibody e.g., HERCEPTIN
- any and all combinations of first and second therapeutic agents may be co-administered with any additional bulk cancer killing agent, such as those described in Table 1 below.
- a patient may be administered and IL6R antibody, an anti-HER2 antibody, and one or more compositions from Table 1.
- the subject comprises bulk cancer cells that are not cancer stem cells
- the method further comprises co-administering a third therapeutic agent to the subject, wherein the third therapeutic agent is capable of killing or inhibiting the bulk cancer cells, and wherein the frequency of the bulk cancer cells is reduced.
- the EMT cancer stem cells are CD44 CD24 " and EpCam " CD49F + .
- the EMT cancer stem cells express at least one of the following: vimentin, N-cadherin, slug, snail, and twist.
- the EMT cancer stem cells express miR-221 and/or miR-100.
- the MET cancer stem cells are ALDH + (or ALDH1 + ) and EpCam + CD49F + .
- the MET cancer stem cells express miR-93.
- the subject further comprises EMT-MET cancer stem cells, and the co-administering reduces the frequency of the EMT-MET cancer stem cells in the subject.
- the EMT-MET cancer stem cells are characterized as CD44 + CD24 " and ALDH + .
- the subject has a solid tumor and the solid tumor comprises the EMT and MET type cancer stem cells.
- the present invention provides compositions, systems, and kits for reducing the frequency of EMT and MET type cancer stem cells in a subject comprising: a) a first therapeutic agent directed against EMT type cancer stem cells (e.g., anti-IL6 receptor antibody), and b) a second therapeutic agent directed against MET type cancer stem cells (e.g., anti-HER2 antibody).
- the first therapeutic agent comprises a Pan-erb blocker or a Her-2 pathway inhibitor.
- the second therapeutic agent comprises an inhibitor of a protein or nucleic acid encoding a protein selected from the group consisting of: IL-6, Notch, Wnt, Hedgehog, or Tgf- ⁇ .
- kits, system, and compositions further comprise a third therapeutic agent capable of killing or inhibiting bulk cancer cells that are not cancer stem cells.
- the present invention provides methods of identifying a test compound useful for treating EMT and/or MET type cancer stem cells: a) providing a population of cancer cells, wherein the majority (e.g., greater than 50% ... 65% ... 75% ... 90% ... 95% ... 99% ...
- cancer cells in the population are a type of cancer cell or mixture of cancer cells selected from the group consisting of: i) EMT type cancer stem cells, ii) MET type cancer stem cells, iii) a mixture of EMT and MET cancer stem cells, and iv) EMT -MET cancer stem cells; and b) administering the test compound to the cancer cells; c) monitoring the response of the cancer cells to the test compound; and d)
- the methods further comprise screening the test compound identified in step d) against a population of normal cells and/or population of normal stem cells to determine if the test compound harms the normal cells and/or normal stem cells.
- the EMT cancer stem cells over-express miR-100 and/or miR-221 (e.g., forced over-expression via an expression vector).
- the MET cancer stem cells over-express miR-93.
- altering the cancer cells comprises inhibiting proliferation of the cancer cells.
- altering the cancer cells comprises inhibiting survival of the cancer cells.
- the monitoring the response of the cells is selected from the group consisting of monitoring the proliferation of the cells; monitoring the survival of the cells; monitoring the cell cycle status of the cells; monitoring gene expression in the cells; monitoring protein expression and/or activity in the cells; and monitoring cellular pathways.
- the monitoring gene expression identifies a cancer stem cell biomarker.
- the monitoring gene expression comprises use of a microarray.
- the monitoring gene expression comprises measuring mRNA.
- the monitoring cellular pathways comprises measuring the activity of the pathways.
- the test compound is selected from a test compound library comprising a plurality of test compounds.
- the test compound library is selected from a test compound library comprising carbohydrates, monosaccharides, oligosaccharides, polysaccharides, amino acids, peptides, oligopeptides, polypeptides, proteins, nucleosides, nucleotides, oligonucleotides, polynucleotides, lipids, retinoids, drugs, antibodies, prodrugs, steroids, glycopeptides, glycoproteins, proteoglycans, and synthetic small molecule organic compounds.
- the present invention provides methods comprising: assaying a sample from a subject with cancer and identifying the presence or absence of EMT, MET, and/or EMT -MET cancer stem cells in the sample.
- the presence of EMT cancer stem cells are identified in the sample, and wherein the method further comprises administering a therapeutic to the subject directed to EMT cancer stem cells.
- the presence of MET cancer stem cells are identified in the sample, and wherein the method further comprises administering a therapeutic to the subject directed to MET cancer stem cells.
- the presence of both EMT and MET cancer stem cells, and/or the presence of EMT -MET cancer stem cells are identified in the sample, and wherein the method further comprises administering a first therapeutic to the subject directed to EMT cancer stem cells and a second therapeutic to the subject directed to MET cancer stem cells.
- the EMT cancer stem cells are identified based on being CD44 + CD24 " and EpCam " CD49F + .
- the MET cancer stem cells are identified based on being ALDH + and EpCam + CD49F + .
- the EMT cancer stem cells are identified based on expression of miR-100 and/or miR-221.
- the MET cancer stem cells are identified based on expression of miR-93.
- the identifying comprises viewing results of an assay performed on a sample from the subject which shows which type or types of cancer stem cells are present.
- the present invention provides compositions comprising: an isolated cancer stem cell over-expressing miR-93, miR-100, and/or miR-221.
- the cancer stem cell comprises an expression vector configured for expressing miR-93, miR-100, and/or miR-221.
- the present invention provides methods comprising: administering a composition to a subject, wherein the subject has cancer, and wherein the composition comprises an expression vector configured to express miR-93, miR-100, and/or miR-221.
- the present invention provides methods of converting a cancer stem cell from one type to another comprising: i) contacting a MET cancer stem cell with an miR-100, miR-9, and/or miR-221 expression vector such that miR-100, miR-9 and/or miR- 221 is over expressed by said MET cancer stem cell thereby converting said MET cancer stem cell to a EMT cancer stem cell; and/or ii) contacting an EMT cancer stem cell with a miR-93, miR-200, and/or miR-205 expression vector such that miR-93, miR-200, and/or miR-205 is over expressed by said EMT cancer stem cell thereby converting said EMT cancer stem cell to a MET cancer stem cell.
- the EMT cancer cells are identified by detecting elevated expression, and/or MET cancer stem cells are identified by detecting decreased expression, of at least one of the following markers: vimentin, N-cadherin, slug, snail, ZEB 1, ZEB2, CT B1, MMP2, MMP9, FOXC1, FOXC2, Fibronectin 1, and twist.
- the MET cancer cells are identified by detecting elevated expression, and/or EMT cancer cells are identified by detecting decreased expression of, of at least one of the following markers: EpCam, E-cadherin, occludin, desmoplakin, Ki67, cadherin 1, or a claudin.
- the present invention provides methods of treating cancer in a subject comprising: treating a subject with antigen presenting cells such that at least some cancer cells in the subject are killed, wherein the antigen presenting cells have been exposed to: i) EMT and MET cancer stem cells or at least an antigenic portion of the EMT and MET cancer stem cells; and/or ii) EMT-MET cancer stem cells or at least an antigenic portion of the EMT-MET cancer stem cells.
- the antigen presenting cells have been exposed to a lysate from the EMT and MET cancer stem cells, and/or the EMT-MET cancer stem cells.
- the antigen presenting cells comprise dendritic cells.
- the antigen presenting cells comprise macrophages.
- the antigen presenting cells comprise B-cells.
- the subject is a human.
- the subject has a cancer selected from the group consisting of: melanoma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, liver cancer, brain cancer, skin cancer, and colon cancer.
- the methods further comprise treating the subject with a chemotherapeutic agent.
- the methods further comprise treating the subject with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells.
- the methods further comprise treating the subject with radiation therapy.
- the present invention provides compositions, systems, and kits comprising: antigen presenting cells that have been exposed to: i) EMT and MET cancer stem cells or at least an antigenic portion of said EMT and MET cancer stem cells; and/or ii) EMT- MET cancer stem cells or at least an antigenic portion of said EMT-MET cancer stem cells.
- compositions, systems, and kits further comprise at least one component selected from: i) a device configured to emit radiation used during external radiation cancer therapy; ii) a chemotherapeutic agent; iii) a first therapeutic that targets EMT cancer stem cells (e.g., as described herein); and iv) a second therapeutic that targets MET cancer stem cells (e.g., as described herein).
- a device configured to emit radiation used during external radiation cancer therapy
- ii) a chemotherapeutic agent e.g., a first therapeutic that targets EMT cancer stem cells (e.g., as described herein); and iv) a second therapeutic that targets MET cancer stem cells (e.g., as described herein).
- Figure 1 shows a characterization of EMT and MET cells as described in Example 1.
- EpCAM + CD49 cells and EpCAM " CD49 cells were sorted by flow cytometry (A). 200k cells were plated in T25 flasks and phase micrographs were shown in (A). Total RNA was isolated from the sorted cells right after sorting and the expression MET marker (B) and EMT markers (C) were measured by qRT-PCR in both cell populations.
- Figure 2 shows CD24 " CD44 + cells are enriched in EMT population. Cells grown in T75 flasks at about 85% confluency were analyzed with Aldefluor, CD24 and CD44 as described in Example 1.
- FIG. 3 shows ALDH + cells are enriched in MET population.
- Cells grown in T75 flasks at about 85% confluency were analyzed with Aldefluor, EpCAM and CD49f as described in Example 1.
- FIG. 4 shows the inter-conversion of EMT and MET cells.
- EpCAM + CD49f cells and EpCAM " CD49f cells were sorted by flow cytometry. 200k cells were plated in T75 flasks and cultured for 1 1 days, and then the cells were dissociated and analyzed for CD49f and EpCAM.
- Figure 5 shows that the inter-conversion between EMT and MET is regulated by microRNAs.
- Cells were transduced with pTRIPZ-microRNA-RFP lentiviruses with inducible systems and selected with puromycin, and microRNAs were induced with or without (CONTROL) Doxycycline and analyzed for RFP, EpCAM and CD49f.
- Figure 6 shows microRNAs regulate cell invasion in vitro.
- the invasive capability of pTRIPZ-mir-93-RFP cells or pTRIPZ-mir-100-RFP cells with or without (CONTROL) Doxycycline was assessed by matrigel invasion assay. 10000k cells were plated in Matrigel and serum was utilized as the attractant.
- FIG. 7A shows a non-limiting model in which breast cancer stem cells (BCSCs) can exist in two alternative states: one, an EMT state which is EpCAM " CD49f expresses the stem cell markers CD24 " CD44 + , and an MET population which is EpCAM + CD49 (double- positive) and expresses the CSC marker ALDH.
- Figure 7B shows the two stem cell states are interconvertable, which is regulated by the microRNA networks.
- Such as: mir-9, mir-100, mir-221 and mir-155 can induce EMT stem cells; mir-200, mir-205 and mir-93 can induce MET stem cells.
- Figure 8 shows a non-limiting hypothetical model in which CSCs located inside the tumor mass exist predominantly in the MET state in which they are highly proliferative and express ALDH (ALDH + ), in contrast at the tumor invasive front are located with EMT CSCs which are characterized as CD24 " CD44 + and are highly invasive, and mediates tumor invasion and metastasis.
- the intermediate CSCs (CD24 " CD44 + ALDH + ) also reside inside the tumor mass, and they are highly proliferative with invasive potential.
- Figure 9A shows the nucleic acid sequence of miR-93 (SEQ ID NO: l)
- figure 9B shows the nucleic acid sequence of miR-100 (SEQ ID NO:2)
- figure 9C shows the nucleic acid sequence of miR-221 (SEQ ID NO: 3).
- CD24 " CD44 + and ALDH + cells display reciprocal EMT-MET profiles in primary human breast cancer.
- A Venn diagram of the intersection between genes elevated in CD24 " CD44 + compared with other flow-sorted cells (others) and genes diminished in ALDH + compared with ALDH " cells (
- B Venn diagram of the intersection between genes diminished in CD24 " CD44 + vs. others and genes elevated in ALDH + vs. ALDH " .
- C Heat map of genes with opposite expression patterns between CD24 " CD44 + and ALDH + (from parts A and B). Each row represents a RNA transcript; each column represents a sample (red: high expression).
- FIG. 1 Role of EMT-MET plasticity in tumor metastasis.
- Basal breast cancer cell line SUM 149 was immunostained with CD24 and CD44 antibodies and subsequently with ALDEFLUOR.
- the four cell subpopulations defined by the ALDEFLUOR and CD24 " CD44 + phenotypes were separated by FACS.
- the percentages shown in the diagram show the representation of the cell subpopulations in the total tumor cell population and the overlap between the ALDEFLUOR phenotype and the CD24 " CD44 + phenotype.
- B The unsorted SUM 149 cells and the sorted CD24 " CD44 + and ALDH + populations as described in (A) were placed in culture for 10 days and resulting cells were re-analyzed by FACS for
- D Cells were immunostained with EpCAM and CD49f antibodies, and subsequently stained with CD24/CD44 or
- E Cells were immunostained with CD24 and CD44 antibodies and subsequently with ALDEFLUOR. The four cell subpopulations defined by the ALDEFLUOR and CD24 " CD44 + phenotypes were separated by FACS. The percentages shown in the diagram depict cell subpopulations and the overlap between the ALDEFLUOR-positive phenotype and the CD24 " CD44 + phenotype.
- F Total RNA was extracted from the four populations as described in (E) and used for Affymatrix array (Hul33 plus 2.0) analysis. The fold change for EMT/MET markers was compared between ALDH + and ALDFf , CD24 " CD44 + and others. * P ⁇ 0.05; Error bars represent mean ⁇ STDEV.
- FIG. 13 Normal human breast contained distinct basal and luminal stem cells which express EMT/MET markers respectively.
- A Cells isolated from reduction mammoplasty tissue were immunostained with Lineage markers (Lin ), EpCAM and CD49f antibodies, and were first gated based on viability (DAPL) and lineage markers. The sorted cells (Lin " EpCAM + CD49 cells and Lin “ EpCAM " CD49f cells) were injected into the 4 th mammary gland fatpads which were previously humanized with normal human breast fibroblasts. After about 2 months, mice were sacrificed and the outgrowths generated in the fatpads were accessed by Hematoxylin and eosin staining.
- EpCAM + CD49 ALDH " cells) were grown in differentiating conditions on collage-coated plates for 12 days and the number of colonies generated was accessed.
- D Sorted cells (Lin " EpCAM + CD49 ALDH + cells and Lin " EpCAM + CD49 ALDH " cells) were cultured in 3D Matrigel culture for 3 weeks and the number of branched structures generated were accessed.
- E Localization of CD24 (Magenta), CD44 (Green), ALDH1 (Red), and DAPI (Blue) in normal breast tissue as accessed by immunofluorescence staining. Yellow arrow, CD24 " CD44 + cells; Red arrow, ALDH1 + cells. Bar, lOOum.
- Figure 14A shows a venn diagram showing the intersection between genes elevated in cancer mammospheres vs. primary cancers, genes elevated in CD24- CD44+ vs. others, and genes elevated in ALDH+ vs. ALDH- cells (
- Figure 14B is the same as 14A but for genes diminished in cancer mammospheres vs. primary cancers, genes diminished in CD24- CD44+ vs. others, and genes diminished in ALDH+ vs. ALDH- cells.
- P-value of overlap between any two datasets is smaller than 2.2E-16.
- Figure 15 shows that specific EMT markers have opposite expression patterns in CD24-CD44+ and ALDH+ cells.
- A For CD24-CD44+ vs. others flow-sorted profile datasets, heat map of EMT markers (
- B As with A but for ALDH+ vs. ALDH- profile datasets.
- Figure 16 shows EMT/MET marker expression obtained with Affymatrix array Hul33 plus2.0.
- A Expression of EMT/MET markers in CD24-CD44+ vs. others and ALDH+ vs. ALDH- of SUM149 cell line.
- B Expression of EMT/MET markers in CD24- CD44+ vs. others and ALDH+ vs. ALDH- of primary xenograft MCI .
- Figure 17 shows validation of gene expression results by qRT-PCR.
- EMT/MET markers the mR A expression level for Vimentin, ZEB1, Claudin 3 and ki67 were measured in SUM 149 cells.
- A and primary xenograft MCI (B) sorted for ALDH+/ALDH-, CD24-CD44+/others by qRT-PCR.
- Gene expression levels measured by qRT-PCR confirm the results obtained with affymatrix array Hul33 plus2.0. Error bars represent mean ⁇ STDEV.
- Figure 18 shows results of validation of gene expression results by qRT-PCR.
- mRNA expression level for Vimentin, ZEB 1, Claudin 3 and ki67 were measured in MCF10A cells sorted for
- Figure 19 shows results of characterization of CD24-CD44+ cells and ALDH+ epithelial cells isolated from normal breast tissues.
- A Cells were immunostained with CD24 and CD44 antibodies and were subsequently stained with ALDEFLUOR. The four cell subpopulations defined by the ALDEFLUOR and CD24-CD44+ phenotypes were separated by FACS. The percentages in the diagram represent the cell subpopulations as a
- Figure 20 shows results regarding evaluation of the differentiation potential of Lin-
- EpCAM+CD49f+ALDH+ cells and Lin-EpCAM+CD49f+ALDH- cells isolated from normal breast tissue Primary cells isolated from reduction mammoplasties were immunostained with Lineage markers (Lin-), EpCAM and CD49f antibodies, and were subsequently stained with ALDEFLUOR. The cells were first gated based on viability (DAPI-) and lineage markers. The sorted cells (Lin-EpCAM+CD49f+ALDH+ cells and Lin-
- EpCAM+CD49f+ALDH- cells were grown in differentiating conditions on collage-coated plates for 12 days and the grown colonies were stained by IHC with lineage-specific markers (ckl4-Purple, ckl8-Red).
- Figure 21 shows results regarding evaluation of the branching morphogenesis of Lin- EpCAM+CD49f+ALDH+ cells and Lin-EpCAM+CD49f+ALDH- cells isolated from normal breast tissue.
- Primary cells isolated from reduction mammoplasties were immunostained with Lineage markers (Lin-), EpCAM and CD49f antibodies, and were subsequently stained with ALDEFLUOR. The cells were first gated based on viability (DAPI-) and lineage markers.
- the sorted cells (Lin-EpCAM+CD49f+ALDH+ cells and Lin-EpCAM+CD49f+ALDH- cells) were grown in 3D Matrigelfor 3 weeks.
- the term “subject” refers to any animal (e.g., a mammal), including, but not limited to, humans, non-human primates, rodents, and the like (e.g., which is to be the recipient of a particular treatment, or from whom cancer stem cells are harvested).
- the terms “subject” and “patient” are used interchangeably, unless indicated otherwise herein.
- the term "subject is suspected of having cancer” refers to a subject that presents one or more signs or symptoms indicative of a cancer (e.g., a noticeable lump or mass) or is being screened for a cancer (e.g., during a routine physical).
- a subject suspected of having cancer may also have one or more risk factors.
- a subject suspected of having cancer has generally not been tested for cancer.
- a "subject suspected of having cancer” encompasses an individual who has received a preliminary diagnosis (e.g., a CT scan showing a mass) but for whom a confirmatory test (e.g., biopsy and/or histology) has not been done or for whom the stage of cancer is not known.
- the term further includes people who once had cancer (e.g., an individual in remission).
- a "subject suspected of having cancer” is sometimes diagnosed with cancer and is sometimes found to not have cancer.
- the term "subject diagnosed with a cancer” refers to a subject who has been tested and found to have cancerous cells.
- the cancer may be diagnosed using any suitable method, including but not limited to, biopsy, x-ray, blood test, and the diagnostic methods of the present invention.
- a "preliminary diagnosis” is one based only on visual
- cancer cells refers to individual cells of a cancer. Such cells may include, for example, tumorigenic cells (e.g., capable of generating a tumor), leukemogenic cells (e.g., capable of generating leukemia), cancer stem cells (e.g., capable of forming new tumors or transferring disease upon transplantation into an
- immunocompromised host as well as cells that are not tumorigenic, leukemogenic or that are capable of forming new tumors or transferring disease upon transplantation (e.g., mesenchymal and endothelial cells).
- tissue sample e.g., including but not limited to, the presence of
- the term "providing a prognosis” refers to providing information regarding the impact of the presence of cancer (e.g., as determined by the diagnostic methods of the present invention) on a subject's future health (e.g., expected morbidity or mortality, the likelihood of getting cancer, and the risk of metastasis).
- non-human animals refers to all non-human animals including, but are not limited to, vertebrates such as rodents, non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, aves, etc.
- an effective amount refers to the amount of a composition sufficient to effect beneficial or desired results.
- An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.
- the term "administration” refers to the act of giving a drug, prodrug, or other agent, or therapeutic treatment (e.g., compositions of the present invention) to a subject (e.g., a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs).
- a subject e.g., a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs.
- exemplary routes of administration to the human body can be through the eyes (ophthalmic), mouth
- oral oral
- skin transdermal
- nose nasal
- lungs inhalant
- oral mucosa e.g., oral mucosa, subcutaneously, intratumorally, intraperitoneally, etc.
- injection e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.
- Co-administration refers to administration of more than one chemical agent or therapeutic treatment (e.g., radiation therapy) to a physiological system (e.g., a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs).
- a physiological system e.g., a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs.
- “Co-administration” of the respective chemical agents and therapeutic treatments may be concurrent, or in any temporal order or physical combination.
- Enriched as in an enriched population of cells, can be defined based upon the increased number of cells having a particular marker in a fractionated set of cells as compared with the number of cells having the marker in the unfractionated set of cells.
- the term "enriched" can also be defined by tumorigenic function as the minimum number of cells that generate a cancer (e.g., a tumor) at a limited dilution frequency (e.g., in a mouse model). For example, if 500 cancer stem cells form tumors in 63% of test animals, but 5000 unfractionated tumor cells are required to form tumors in 63% of test animals, then the cancer stem cell population is 10-fold enriched for tumorigenic activity.
- test compound and “candidate compound” refer to any chemical entity, pharmaceutical, drug, and the like that is a candidate for use to treat or prevent a disease, illness, sickness, or disorder of bodily function (e.g., cancer (e.g., tumorigenic cells, leukemogenic cells or cancer stem cells)).
- Test compounds comprise both known and potential therapeutic compounds.
- a test compound can be determined to be therapeutic by screening using the screening methods of the present invention.
- test compounds include, but are not limited to, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, amino acids, peptides, oligopeptides, polypeptides, proteins, nucleosides, nucleotides, oligonucleotides, polynucleotides, including DNA and DNA fragments, RNA and RNA fragments and the like, lipids, retinoids, steroids, drug, antibody, prodrug, glycopeptides, glycoproteins, proteoglycans and the like, and synthetic analogues or derivatives thereof, including peptidomimetics, small molecule organic compounds and the like, and mixtures thereof (e.g., that is a candidate for use to treat or prevent a disease, illness, sickness, or disorder of bodily function (e.g., cancer (e.g., tumorigenic cells, leukemogenic cells or cancer stem cell growth)).
- a disease, illness, sickness, or disorder of bodily function e.g.
- Test compounds comprise both known and potential therapeutic compounds.
- a test compound can be determined to be therapeutic by screening using the screening methods of the present invention.
- a "known therapeutic compound” refers to a therapeutic compound that has been shown (e.g., through animal trials or prior experience with administration to humans) to be effective in such treatment or prevention.
- test compounds are anticancer agents.
- test compounds are anticancer agents that induce apoptosis in cells.
- test compound library refers to a mixture or collection of one or more compounds generated or obtained in any manner. Preferably, the library contains more than one compound or member.
- the test compound libraries employed in this invention may be prepared or obtained by any means including, but not limited to, combinatorial chemistry techniques, fermentation methods, plant and cellular extraction procedures and the like. Methods for making combinatorial libraries are well-known in the art (See, for example, E. R. Felder, Chimia 1994, 48, 512-541 ; Gallop et al, J. Med. Chem. 1994, 37, 1233-1251; R. A. Houghten, Trends Genet.
- drug and “chemotherapeutic agent” refer to
- pharmacologically active molecules that are used to diagnose, treat, or prevent diseases or pathological conditions in a physiological system (e.g., a subject, or in vivo, in vitro, or ex vivo cells, tissues, and organs).
- Drugs act by altering the physiology of a living organism, tissue, cell, or in vitro system to which the drug has been administered. It is intended that the terms "drug” and “chemotherapeutic agent” encompass anti-hyperproliferative and antineoplastic compounds as well as other biologically therapeutic compounds.
- sample is used in its broadest sense. In one sense, it is meant to include a specimen or culture obtained from any source, as well as biological and environmental samples. Biological samples may be obtained from animals (including humans) and encompass fluids, solids, tissues, and gases. Biological samples include blood products, such as plasma, serum and the like.
- the present invention relates to compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment, based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states.
- a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells.
- the different states of cancer stem cells are distinguished based on markers CD44 + CD24 " , EpCam " CD49F + (for EMT cancers stem cells), ALDH + and EPCam + CD49 (for MET cancers stem cells), and CD44 + CD24 " ALDH + (for EMT-MET cancer stem cells).
- micro R As are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).
- cancer stem cells which mediate tumor metastasis and contribute to treatment resistance and relapse.
- CSCs cancer stem cells
- ADH Aldehyde dehydrogenase
- EMT CSCs have a mesenchymal morphology, are largely quiescent, invasive and characterized by expression of the CSC markers CD24 " CD44 + and are EpCAM-CD49f .
- the MET (mesenchymal epithelial transition) state of CSCs is characterized by active self-renewal and expression of the CSC markers ALDH and EpCAM + CD49F + .
- a subpopulation of cells expressing both CD24 " CD44 + and ALDH may represent cells in transition between these states.
- microRNAs Each microRNA is capable of regulating the expression of multiple proteins and as a result, can have very potent effects on cellular functions.
- the miRNA gene is first transcribed by RNA polymerase II into a primary transcript (pri-miRNA) in the nucleus, where the hairpin stem-loop structure is processed into precursor miRNA (pre-miRNA) by a microprocessing complex, which includes Drosha and DGCR8.
- a microprocessing complex which includes Drosha and DGCR8.
- the 60-70 nt-long pre-miRNAs is exported from the nucleus.
- the RNAse III enzyme Dicer processes the pre-miRNA to yield the 18-25 nt mature miRNAs which mediate gene silencing through imperfect hybridization to 3' untranslated regions (3' UTR) in target mRNAs by modulating and modulate a variety of cellular processes including regulating m-RNA stability and proliferation, differentiation translation, microRNAs and apoptosis.
- microRNAs regulate cancer stem cells CSCs. Recent studies have demonstrated a link between dysregulated expression of miRNAs and carcinogenesis. A number of miRNAs have been shown to function as oncogenes or tumor suppressors during carcinogenesis. In addition, emerging evidence suggests that miRNAs also play essential roles in stem cell self-renewal and differentiation by negatively regulating the expression of key stem cell regulating genes. Furthermore, abnormal miRNA expression may result in dysregulation of self-renewal in cancer stem cells during cancer progression.
- Silber et al reported that mirl24 and mirl37 induce differentiation of neural and glioblastoma stem cells and induce cell cycle arrest.
- miRNA181 and miRNA 17-92 clusters were shown to be up-regulated in hepatocellular carcinoma (HCC) CSCs. More recently, Tang's group showed that prostate cancer stem and/or progenitor cell populations have lower levels of miR-34a and let-7b compared to bulk tumor cells. In addition, they reported that miR34a targets CD44, resulting in impaired tumor growth and decreased metastases in mouse models of prostate cancer. The increased survival of mice treated with systemically delivered miR34a suggests a novel strategy to target prostate CSCs, thereby inhibiting tumor growth and metastasis.
- HCC hepatocellular carcinoma
- EMT Epithelial to mesenchymal transition
- epithelial cells lose cell-cell contacts and undergo cytoskeletal remodeling and polarity changes, resulting in acquisition of a mesenchymal morphology as well as enhanced migratory ability.
- EMT is reversible and these cells can undergo a mesenchymal to epithelial transition (MET), so that polarized epithelium can be generated at a new site.
- MET mesenchymal to epithelial transition
- Both EMT and MET play central roles in embryogenesis.
- EMT epithelial-mesenchymal transition
- the EMT state has been associated with loss of epithelial characteristics including apical basal polarity and expression of E-Cadherin and acquisition of mesenchymal characteristics including loss of polarity and increased expression of the transcription factors slug, snail and twist and mesenchymal proteins including vimentin and fibronectin.
- epithelial organs e.g., kidney and ovary
- TGF- ⁇ can induce EMT characterized by downregulation of epithelial markers such as E-cadherin and upregulation of EMT-inducing factors, such as Twist and Snail. It has been proposed that EMT plays an important role in tumorigenesis and progression. Furthermore, a number of developmental pathways such as the Wnt and HGF- cMet pathways which are frequently deregulated in cancers are also regulators of EMT. Both the inflammatory immune response and the hypoxic tumor environment induce EMT in cancers. It is increasingly recognized that EMT plays an important role in the metastasis of breast cancer and other types of carcinoma. EMT has also been implicated in therapeutic resistance and tumor recurrence. Since EMT is a key developmental program that is often activated during cancer invasion and metastasis, and CSCs that maintain and initiate tumors have also been implicated in invasion and metastasis, the relationship between EMT and CSCs is an important question.
- CSCs A defining characteristic of CSCs is their ability to self-renew, a property that endows these cells with the ability to initiate and sustain tumor growth.
- EMT state has been linked to tumor invasion and metastasis, EMT cells are largely quiescent.
- the differences in invasive and proliferative characteristics of CSCs and EMT cells has led to the proposition that CSCs and EMTs are mutually exclusive.
- EpCAM and CD49f can be used to define functional populations of normal mouse and human mammary cells.
- EpCAM-CD49f cells represent mammary stem cells, EpCAM + CD49 + (double-positive cells): luminal progenitors; EpCAM + CD49f : epithelial cells; and EpCAM " CD49f : stromal cells.
- double-positive (EpCAM + CD49f ) so-called luminal progenitor cells have been found to give rise to basal as well as luminal cells when cultured in vitro.
- EpCAM + CD49 population may also contain a sub-population with stem cell characteristics.
- CD24 " CD44 + and ALDH identify overlapping, but not identical cell populations.
- Work conducted during the development of embodiments of the present invention generated data indicating that EpCAM + CD49f cells (MET) contain an ALDH enriched population, whereas CD24 " CD44 + cells are mainly contained in EpCAM " CD49f population (EMT).
- EpCAM + CD49f cells MET
- CD24 " CD44 + cells are mainly contained in EpCAM " CD49f population (EMT).
- BCSCs isolated from primary breast tumors and metastatic pleural effusions express EMT markers. However, there is less evidence linking BCSCs and MET. Consistent with the expression of EMT markers by BCSCs, these cells also express EMT related microR As. miR A expression profiling of BCSCs isolated from human breast tumors compared to the remaining breast cancer cells revealed high levels of expression of EMT-inducing miR-155. Furthermore, mir-200 which is downregulated in BCSCs is associated with MET.
- EpCAM + CD49f and EpCAM + CD49f populations EpCAM + CD49f and EpCAM + CD49f populations. Furthermore, forced over-expression of mir-100 or mir-221 increased the proportion of EpCAM " CD49f ⁇ cells in non-transformed MCF- IOA cells as well as primary normal human mammary cells isolated from reduction mammoplasty specimens. This resulted in an increase in the proportion of CD247CD44 + CSC cells with a concomitant decrease in the ALDH + CSC population. These results indicate that mir-93, mir- 100 and mir-221 are important regulators of the transition between the EMT and MET stem cell states.
- mir-93 induction of mir-93 in EMT SUM159 cells induces an MET in the ALDH-positive CSC population characterized by increased expression of E-Cadherin and Claudin, and down-regulation of mesenchymal genes, such as vimentin, N-Cadherin and Twist. It was found that mir-93 also inhibits TGFp signaling by targeting TGFpR2, an effect seen within twelve hours of mir-93 induction. This was followed by an EMT/MET transition in the Aldefluor-positive CSC population. Since TGFp is a major regulator of EMT, abrogation of this signaling pathway may facilitate MET.
- mirl06b-25 cluster including mir-93 is induced in the early stages of nuclear reprogramming of fibroblasts into IPS cells. This is accompanied by an EMT to MET conversion in these cells which is obligatory for reprogramming to occur. This suggests that this miRNA cluster may regulate EMT to MET in multiple biological contexts.
- expression of mir-100 or mir-221 in MCF 10A cells and several cancer cell lines resulted in a decrease of the ALDH-positive CSC population with a concomitant increase in the CD24 " CD44 + population accompanied by induction of EMT.
- mir- 100 effects are mediated by targeting BMPR2, SMARCA5 and SMARCD l , all of which may contribute to induction of EMT.
- CSCs may exist in either EMT or MET states, the inter-conversion of which is regulated by the microenvironment which in turn regulates CSC microRNA networks as illustrated in Figure 7B.
- EMT EMT
- MET states the inter-conversion of which is regulated by the microenvironment which in turn regulates CSC microRNA networks as illustrated in Figure 7B.
- alternative CSC states provides an explanation for how these cells promote tumor invasion as well as growth at metastatic sites. For example, it has been shown that bladder cancer cells selected for bone metastatic competence are overtly epithelial as compared to their parental cell. Similarly, human breast cancer, liver, lung and brain metastasis often express more E-cadherin than their corresponding primary tumors.
- CSCs CSCs to exist in alternative EMT and MET states, the transition of which is believed to be regulated by the microenvironment and mediated by miRNAs has important implications for understanding the role of the cells carcinogenesis, invasion and metastasis.
- alternative CSC states associated with expression of different protein markers has important implications for understanding the plasticity of CSCs.
- CSCs may be generated from non-CSC tumor populations through induction of EMT.
- the existence of alternative CSC state suggests that the acquisition of stem cell markers may reflect transition of CSC states rather than generation of CSCs from non-CSC populations.
- the existence of multiple stem cell states suggests the necessity of developing therapeutic strategies capable of effectively targeting CSCs in all of these states.
- microRNAs have been implicated in tumor development and microRNAs plays important roles in regulating cancer stem cells. Since CSCs have been shown to be involved in tumor initiation, tumor maintenance, metastasis, and therapeutic resistance, the regulation of microRNA networks in CSCs provides novel therapeutic targets.
- CSC states also has important therapeutic implications, since CSCs in these states may respond differently to therapeutic agents. Nevertheless, the complexity of regulatory pathways in CSCs, as well as the heterogeneity of these cell populations, suggests that it may be beneficial to combine multiple CSC-targeting agents to eliminate all CSC populations and thus improve the outcome for cancer patients.
- cancers from which cancer stem cells can be isolated or enriched, and targeted, according to the present invention include, but are not limited to, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), leukemias (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic, (granulocytic) leukemia, and chronic lymphocytic leukemia), and sarcomas and carcinomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosar
- lymphomas e.g., Hodgkin's disease and non
- lymphangioendotheliosarcoma synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma,
- a subject's e.g., a particular cancer patient's
- cancer stem cells e.g., once isolated and allowed to proliferate in vitro
- analyzing a subject's cancer stem cells is used as a diagnostic for the subject (e.g., the identification of biomarkers present within the cancer cells can be used to provide to the subject a prognosis (e.g., of morbidity or mortality associated with the cancer, or, the likelihood of the cancer to respond to a therapeutic treatment).
- a prognosis e.g., of morbidity or mortality associated with the cancer, or, the likelihood of the cancer to respond to a therapeutic treatment.
- the present invention provides methods for detection of expression of cancer stem cell biomarkers to identify if the patient has EMT, MET, EMT- MET cancer stem cells or combinations thereof.
- expression is measured directly (e.g., at the nucleic acid or protein level).
- expression is detected in tissue samples (e.g., biopsy tissue).
- expression is detected in bodily fluids (e.g., including but not limited to, plasma, serum, whole blood, mucus, and urine).
- the present invention further provides panels and kits for the detection of biomarkers.
- the presence of a cancer stem cell biomarker is used to provide a prognosis to a subject.
- the detection of a cancer stem cell biomarker in cancerous tissues may be indicative of a cancer that is or is not likely to metastasize.
- the expression level of a cancer stem cell biomarker may be indicative of a transformed cell, cancerous tissue or a cancer likely to metastasize.
- the information (e.g., state of the cancer cells from a subject) provided can also be used to direct the course of treatment. For example, if a subject is found to possess or lack a cancer stem cell biomarker that is likely to metastasize, therapies can be chosen to optimize the response to treatment (e.g., for subjects with a high probability of possessing a metastatic cancer more aggressive forms of treatment can be used).
- Cancer stem cell biomarkers identified as being up or down-regulated in cancer stem cells using the methods of the present invention are further characterized using microarray (e.g., nucleic acid or tissue microarray), immunohistochemistry, Northern blot analysis, siRNA or antisense RNA inhibition, mutation analysis, investigation of expression with clinical outcome, as well as other methods disclosed herein.
- microarray e.g., nucleic acid or tissue microarray
- immunohistochemistry e.g., nucleic acid or tissue microarray
- Northern blot analysis e.g., siRNA or antisense RNA inhibition
- mutation analysis e.g., investigation of expression with clinical outcome, as well as other methods disclosed herein.
- the present invention provides a panel for the analysis of a plurality of biomarkers.
- the panel allows for the simultaneous analysis of multiple biomarkers correlating with carcinogenesis, metastasis and/or angiogenesis associated with cancer.
- a panel may include biomarkers identified as correlating with cancerous tissue, metastatic cancer, localized cancer that is likely to metastasize, precancerous tissue that is likely to become cancerous, pre-cancerous tissue that is not likely to become cancerous, and cancerous tissues or cells likely or not likely to respond to treatment.
- panels may be analyzed alone or in combination in order to provide the best possible diagnosis and prognosis. Markers for inclusion on a panel are selected by screening for their predictive value using any suitable method.
- the panels contain reagents for detecting CD44, CD24, EpCam, CD49f, ALDH, mir-221, mir-110, and/or mir-93.
- cancer stem cell biomarkers are detected by measuring the levels of the cancer stem cell biomarker in cells and tissue (e.g., cancer cells and tissues).
- a cancer stem cell biomarker are monitored using antibodies or by detecting a cancer stem cell biomarker protein/nucleic acid (e.g., CD44, CD24, EpCam, CD49f, ALDH, mir-221, mir-110, and/or mir-93).
- detection is performed on cells or tissue after the cells or tissues are removed from the subject.
- detection is performed by visualizing the cancer stem cell biomarker in cells and tissues residing within the subject.
- cancer stem cell biomarker are detected by measuring the expression of corresponding mRNA in a tissue sample (e.g., cancerous tissue).
- RNA is detected by Northern blot analysis. Northern blot analysis involves the separation of RNA and hybridization of a complementary labeled probe.
- RNA (or corresponding cDNA) is detected by hybridization to a oligonucleotide probe.
- a variety of hybridization assays using a variety of technologies for hybridization and detection are available. For example, in some
- a TaqMan assay (PE Biosystems, Foster City, CA; See e.g., U.S. Patent Nos. 5,962,233 and 5,538,848, each of which is herein incorporated by reference) is utilized.
- the assay is performed during a PCR reaction.
- the TaqMan assay exploits the 5'-3' exonuclease activity of the AMPLITAQ GOLD DNA polymerase.
- a probe consisting of an
- oligonucleotide with a 5'-reporter dye e.g., a fluorescent dye
- a 3'-quencher dye is included in the PCR reaction.
- the 5'-3' nucleolytic activity of the AMPLITAQ GOLD polymerase cleaves the probe between the reporter and the quencher dye.
- the separation of the reporter dye from the quencher dye results in an increase of fluorescence.
- the signal accumulates with each cycle of PCR and can be monitored with a fluorimeter.
- RT-PCR reverse-transcriptase PCR
- RNA is enzymatically converted to complementary DNA or "cDNA" using a reverse transcriptase enzyme.
- the cDNA is then used as a template for a PCR reaction.
- PCR products can be detected by any suitable method, including but not limited to, gel electrophoresis and staining with a DNA specific stain or hybridization to a labeled probe.
- the quantitative reverse transcriptase PCR with standardized mixtures of competitive templates method described in U.S. Patents 5,639,606, 5,643,765, and 5,876,978 (each of which is herein incorporated by reference) is utilized.
- gene expression of a cancer stem cell biomarker is detected by measuring the expression of the corresponding protein or polypeptide.
- Protein expression may be detected by any suitable method.
- proteins are detected by immunohistochemistry.
- proteins are detected by their binding to an antibody raised against the protein.
- Antibody binding is detected by techniques known in the art (e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), "sandwich” immunoassays,
- immunoradiometric assays gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (e.g., using colloidal gold, enzyme or radioisotope labels, for example), Western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays, etc.), complement fixation assays, immunofluorescence assays, protein A assays, and Immunoelectrophoresis assays, etc.
- antibody binding is detected by detecting a label on the primary antibody.
- the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody.
- the secondary antibody is labeled. Many methods are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.
- an automated detection assay is utilized.
- Methods for the automation of immunoassays include those described in U.S. Patents 5,885,530, 4,981,785, 6, 159,750, and 5,358,691, each of which is herein incorporated by reference.
- the analysis and presentation of results is also automated.
- software that generates a prognosis based on the presence or absence of a series of proteins corresponding to cancer markers is utilized.
- the present invention provides kits for the detection and characterization of cancer stem cell biomarkers (e.g., CD44, CD24, EpCam, CD49f, ALDH, mir-221, mir-110, and/or mir-93).
- the kit contains cancer stem cells.
- the kits contain antibodies specific for a cancer stem cell biomarker, in addition to detection reagents and buffers.
- the kits contain reagents specific for the detection of mRNA or cDNA (e.g., oligonucleotide probes or primers).
- the kits contain all of the components necessary to perform a detection assay, including all controls, directions for performing assays, and any necessary software for analysis and presentation of results.
- in vivo imaging techniques are used to visualize the expression of a cancer stem cell biomarker in an animal (e.g., a human or non-human mammal).
- a cancer stem cell biomarker mRNA or protein is labeled using an labeled antibody specific for the cancer stem cell biomarker.
- a specifically bound and labeled antibody can be detected in an individual using an in vivo imaging method, including, but not limited to, radionuclide imaging, positron emission tomography, computerized axial tomography, X-ray or magnetic resonance imaging method, fluorescence detection, and chemiluminescent detection. Methods for generating antibodies to the cancer stem cell biomarkers of the present invention are described herein.
- the in vivo imaging methods of the present invention are useful in the diagnosis of cancers that express a cancer stem cell biomarker of the present invention (e.g., cancerous cells or tissue). In vivo imaging is used to visualize the presence of a biomarker indicative of a cancer stem cell. Such techniques allow for diagnosis without the use of a biopsy.
- the in vivo imaging methods of the present invention are also useful for providing prognoses to cancer patients. For example, the presence of a cancer stem cell biomarker indicative of an aggressive cancer likely to metastasize or likely to respond to a certain treatment can be detected.
- the in vivo imaging methods of the present invention can further be used to detect a cancer stem cell (e.g., one that has metastasized) in other parts of the body.
- reagents e.g., antibodies
- a cancer stem cell biomarker of the present invention are fluorescently labeled.
- the labeled antibodies are introduced into a subject (e.g., orally or parenterally). Fluorescently labeled antibodies are detected using any suitable method (e.g., using the apparatus described in U.S. Patent 6, 198, 107, herein incorporated by reference).
- flow-cytometry is utilized to monitor (e.g., detect) a marker (e.g., a cancer stem cell biomarker of the present invention).
- the use of flow-cytometry to identify and/or isolate and/or purify cell populations is well known in the art (See, e.g., Givan, Methods Mol Biol 263, 1-32 (2004)).
- antibodies are radioactively labeled.
- the use of antibodies for in vivo diagnosis is well known in the art. Sumerdon et ah, (Nucl. Med. Biol 17:247-254 (1990) have described an optimized antibody-chelator for the radioimmunoscintographic imaging of tumors using Indium- 1 1 1 as the label. Griffin et ah, (J Clin One 9:631-640 (1991)) have described the use of this agent in detecting tumors in patients suspected of having recurrent colorectal cancer. The use of similar agents with paramagnetic ions as labels for magnetic resonance imaging is known in the art (Lauffer, Magnetic Resonance in Medicine 22:339-342 (1991)).
- Radioactive labels such as Indium- 1 11, Technetium-99m, or Iodine- 131 can be used for planar scans or single photon emission computed tomography (SPECT).
- Positron emitting labels such as Fluorine- 19 can also be used for positron emission tomography (PET).
- PET positron emission tomography
- paramagnetic ions such as Gadolinium (III) or Manganese (II) can be used.
- An antibody against a biomarker of the present invention may be any monoclonal or polyclonal antibody, as long as it can recognize the cancer stem cell biomarker.
- Antibodies can be produced by using a cancer stem cell biomarker of the present invention as the antigen according to a conventional antibody or antiserum preparation process.
- Cancer stem cells e.g., populations representing both MET and EMT cancer stem cells
- test compounds include, but are not limited to, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, amino acids, peptides, oligopeptides, polypeptides, proteins, nucleosides, nucleotides, oligonucleotides, polynucleotides, including DNA and DNA fragments, RNA and RNA fragments and the like, lipids, retinoids, steroids, drug, antibody, prodrug, glycopeptides, glycoproteins, proteoglycans and the like, and synthetic analogues or derivatives thereof, including peptidomimetics, small molecule organic compounds and the like, and mixtures thereof (e.g., that is a candidate for use to treat or prevent a disease, illness, sickness, or
- Test compounds comprise both known and potential therapeutic compounds.
- a test compound can be determined to be therapeutic by screening using the screening methods of the present invention.
- cancer stem cells can be obtained from a subject with cancer. Once obtained, cancer stem cells can be cultured in vitro or in vivo and exposed to a test compound. The ability of test compounds to alter (e.g., increase or decrease) cancer stem cell growth or maintenance, as well as the effect on normal HSCs, can be assayed.
- test compounds e.g., from a library of compounds
- test compounds are screened for their ability to alter (e.g., eliminate or inhibit growth of) cancer stem cells, while concurrently monitoring the effect on HSCs (e.g., driving HSCs into quiescence). Screening in this way permits the identification of compounds that can be utilized (e.g., independently, in a pharmaceutical composition, or co-administered) for treating cancer (e.g., inhibiting or eliminating cancer stem cells while having no harmful effect on normal HSCs).
- test compounds can be solubilized and added to cancer stem cells (e.g., in vitro (e.g., in the culture medium), or, in vivo (e.g., to a recipient subject that has received a cancer stem cell graft)).
- various concentrations of the test compound are utilized to determine an efficacious dose.
- administration of the test compound is consistent over a period of time (e.g., administered to a recipient one, two or more times a day, or, added to media in vitro) so as to keep the concentration of the test compound constant.
- Alteration e.g., inhibiting growth or promoting death or permitting maintenance
- cancer stem cells can be monitored in vitro or in vivo.
- an increase or decrease in the number of cancer cells e.g., cancer stem cell progeny
- growth rate of cancer cells e.g., cancer stem cell progeny
- the effect of a test compound on cancer stem cells and normal HSCs can be measured by determining the number of cancer stem cells that persist in culture or in vivo after treatment (e.g., administration of the test compound).
- cancer stem cell and HSC status e.g., cell cycle status, cancer stem cell biomarker expression, etc.
- can be determined e.g., using compositions and methods described herein).
- Test compounds can be administered in vitro or in vitro at a variety of concentrations.
- test compounds are added to culture medium or to a subject so as to achieve a concentration from about 10 pg/ml to 1 ⁇ g/ml, or from about 1 ng/ml (or 1 ng/cc of blood) to 100 ng/ml (or 100 ng/cc of blood).
- test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone, which are resistant to enzymatic degradation but which nevertheless remain bioactive (See, e.g., Zuckennann et al, J. Med. Chem. 37: 2678-85
- test compound libraries employed in this invention may be prepared or obtained by any means including, but not limited to, combinatorial chemistry techniques, fermentation methods, plant and cellular extraction procedures and the like.
- Methods for making combinatorial libraries are well-known in the art (See, e.g., E. R. Felder, Chimia 1994, 48, 512-541; Gallop et al., J. Med. Chem. 1994, 37, 1233-1251; R. A. Houghten, Trends Genet. 1993, 9, 235-239; Houghten et al, Nature 1991, 354, 84-86; Lam et al, Nature 1991, 354, 82-84; Carell et al, Chem. Biol. 1995, 3, 171-183; Madden et al, Perspectives in Drug Discovery and Design 2, 269-282; Cwirla et al, Biochemistry 1990, 87, 6378-6382;
- test compounds may comprise suitable amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, test compounds may comprise suitable amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino
- pharmaceutically acceptable carriers comprising excipients and auxiliaries, that facilitate processing of the active compounds into preparations which can be used pharmaceutically.
- IL6, TGF , Hedgehog, WNT and/or Notch activity is necessary for maintaining EMT.
- Work conducted during embodiments of the present invention has shown that mir-100 over- expression can switch the breast cancer stem cells to EMT state which is characterized by EpCAM " and CD24 " CD44 + . The potential for inhibiting these pathways to alter CSC/EMT status and block resistance to chemotherapy provide insight to using combination treatment.
- the inhibitor for each of these pathways IL-6, TGF , Hedgehog, WNT and/or Notch
- Work conducted during development of embodiments of the present invention showed that Her2 -positive luminal cells have more BCSCs characterized by ALDH + .
- Data generated has shown that mir-93 overexpression can switch the breast cancer stem cells to MET state which is characterized by EpCAM + and ALDH + . Therefore, one may inhibit the her2 pathway to alter CSC/MET status and block resistance to chemotherapy and provide insight to using combination treatment.
- microRNA 100 (or mir-221) and microRNA93 can be utilized as biomarkers to help patients find the individualized combination therapy targeting both states of BCSCs and the bulk tumor cells.
- Such detecting can employ microRNA ISH staining with the slide section from paraffin-embedded clinical human breast tumor specimens, or can detect the microRNA expression level in patient blood serum by qRT- PCR. Based on different microRNA expression in the tumor specimens and blood, one can predict which patient will more likely develop distant metastasis and help determine the best combination therapy for the patients.
- This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein (e.g., a test compound that: eliminates or inhibits growth of a cancer stem cell while leaving unharmed (e.g., inducing quiescence of) normal stem cells; acts as a cancer stem cell biomarker modulating agent; an antisense cancer stem cell biomarker nucleic acid molecule; a siRNA molecule; a cancer stem cell biomarker specific antibody; or a cancer stem cell biomarker-binding partner) in an appropriate animal model to determine the efficacy, toxicity, side effects, or mechanism of action, of treatment with such an agent.
- novel agents identified by the above-described screening assays can be, e.g., used for treatments as described herein.
- compositions comprising a successfully identified test compound (e.g., a test compound identified that is capable of altering (e.g., inhibiting growth or eliminating) cancer stem cells while concurrently not harming (e.g., inducing quiescence of) normal HSCs), analogue or mimetic can be administered systemically or locally to alter cancer stem cell growth and induce cancer (e.g., tumor) cell death in cancer patients by targeting both EMT and MET cancer stem cells.
- a successfully identified test compound e.g., a test compound identified that is capable of altering (e.g., inhibiting growth or eliminating) cancer stem cells while concurrently not harming (e.g., inducing quiescence of) normal HSCs)
- analogue or mimetic can be administered systemically or locally to alter cancer stem cell growth and induce cancer (e.g., tumor) cell death in cancer patients by targeting both EMT and MET cancer stem cells.
- the present invention be limited by the particular route of administration. Indeed, a variety of administrative routes are contemplated to be useful in the present invention including, but not limited to, intravenously, intrathecally, intramuscularly, intraperitoneally as well as orally. Moreover, they can be administered alone or in combination with anti-proliferative drugs.
- Covalent binding can be accomplished by any one of many commercially available crosslinking compounds.
- compositions can be provided together with physiologically tolerable liquid, gel or solid carriers, diluents, adjuvants and excipients.
- therapeutic preparations can be administered to mammals for veterinary use, such as with domestic animals, and clinical use in humans in a manner similar to other therapeutic agents.
- dosage required for therapeutic efficacy will vary according to the type of use and mode of administration, as well as the particularized requirements of individual hosts.
- compositions are typically prepared as liquid solutions or suspensions, or in solid forms.
- Oral formulations for cancer usually will include such normally employed additives such as binders, fillers, carriers, preservatives, stabilizing agents, emulsifiers, buffers and excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like.
- These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, and typically contain l%-95% of active ingredient, preferably 2%- 70%.
- compositions are also prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared.
- the compositions of the present invention are often mixed with diluents or excipients which are physiological tolerable and compatible. Suitable diluents and excipients are, for example, water, saline, dextrose, glycerol, or the like, and
- compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents.
- auxiliary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents.
- Additional formulations which are suitable for other modes of administration, such as topical administration include salves, tinctures, creams, lotions, and, in some cases, suppositories.
- traditional binders, carriers and excipients may include, for example, polyalkylene glycols or triglycerides. It may be desirable to administer an analogue of a successfully identified test compound (e.g., a test compound identified that is capable of altering both EMT and MET cancer stem cells). A variety of designs for such mimetics are possible.
- cyclic peptides in which the necessary conformation for binding is stabilized by nonpeptides, are specifically contemplated.
- the present invention also contemplates synthetic mimicking compounds that are multimeric compounds that repeat the relevant peptide sequence.
- peptides can be synthesized by linking an amino group to a carboxyl group that has been activated by reaction with a coupling agent, such as dicyclohexyl-carbodiimide (DCC).
- DCC dicyclohexyl-carbodiimide
- the attack of a free amino group on the activated carboxyl leads to the formation of a peptide bond and the release of dicyclohexylurea. It may be important to protect potentially reactive groups other than the amino and carboxyl groups intended to react (e.g., the x-amino group of the component containing the activated carboxyl group can be blocked with a
- This protecting group can be subsequently removed by exposing the peptide to dilute acid, which leaves peptide bonds intact.
- peptides can be readily synthesized by a solid phase method by adding amino acids stepwise to a growing peptide chain that is linked to an insoluble matrix, such as polystyrene beads.
- the carboxyl-terminal amino acid (with an amino protecting group) of the desired peptide sequence is first anchored to the polystyrene beads.
- the protecting group of the amino acid is then removed.
- the next amino acid (with the protecting group) is added with the coupling agent. This is followed by a washing cycle. The cycle is repeated as necessary.
- the methods of the present invention can be practiced in vitro, ex vivo, or in vivo.
- the method of the present invention can be used in vitro to screen for compounds which are potentially useful for combinatorial use with a successfully identified test compound for treating cancer (e.g., lymphoma, leukemia, prostate, lung, stomach, breast, colon, and/or pancreatic cancer); to evaluate a test compound's efficacy in treating cancer; or to investigate the mechanism by which a test compound combats cancer (e.g., whether it does so by inducing apoptosis, by inducing differentiation, by decreasing proliferation, etc).
- cancer e.g., lymphoma, leukemia, prostate, lung, stomach, breast, colon, and/or pancreatic cancer
- a test compound's efficacy in treating cancer e.g., whether it does so by inducing apoptosis, by inducing differentiation, by decreasing proliferation, etc.
- one skilled in the art can apply the method of the present invention in vitro to evaluate the degree to which the compound induces apoptosis and/or decreases angiogenesis, proliferation of cancer cells; or one skilled in the art can apply the method of the present invention to determine whether the compound operates by inducing apoptosis, by decreasing proliferation and/or angiogenesis, or by a combination of these methods.
- a method of the present invention can be used in vivo to treat cancers, (e.g., including, but not limited to, lymphoma, leukemia, prostate cancer, lung cancer, stomach cancer, pancreatic cancer, breast cancer, and colon cancer).
- cancers e.g., including, but not limited to, lymphoma, leukemia, prostate cancer, lung cancer, stomach cancer, pancreatic cancer, breast cancer, and colon cancer.
- contacting can be carried out by administering a therapeutically effective amount of the compound to the human subject (e.g., by directly injecting the compound into a tumor or through systemic administration).
- the present invention provides high throughput screening of test compounds.
- test compounds e.g., from a test compound library, described above
- test compounds can be reacted with cancer stem cells, or portions thereof, and washed.
- Bound cancer stem cells are then detected by methods well known in the art, using commercially available machinery and methods (e.g., the Automated Assay Optimization (AAO) software platforms (Beckman, USA) that interface with liquid handlers to enable direct statistical analysis that optimizes the assays; modular systems from CRS Robotics Corp. Burlington, Ontario), liquid handling systems, readers, and incubators, from various companies using POLARA (CRS), an open architecture laboratory automation software for a Ultra High Throughput Screening System; 3P (Plug&Play),
- AAO Automated Assay Optimization
- assays measure a response the target cells (cancer stem cells or genetically modified cancer stem cells) provide (e.g., detectable evidence that a test compound may be efficacious).
- the detectable signal is compared to control cells and the detectable signal identified by subtraction analysis.
- the relative abundance of the differences between the "targeted” and “untargeted” aliquots can be simultaneously compared (e.g., using a “subtraction” analysis (differential analysis) technique such as differential display, representational difference analysis (RDA), GEM-Gene
- a “subtraction” analysis (differential analysis) technique such as differential display, representational difference analysis (RDA), GEM-Gene
- the subtraction analysis can include the methods of differential display, representational differential analysis (RDA), suppressive subtraction hybridization (SSH), serial analysis of gene expression (SAGE), gene expression microarray (GEM), nucleic acid chip technology, or direct sequencing).
- RDA representational differential analysis
- SSH suppressive subtraction hybridization
- SAGE serial analysis of gene expression
- GEM gene expression microarray
- the present invention provides method and compositions for co-administration of therapeutics, such as at least one therapeutic that targets cancer stem cells in the EMT stage and at least one therapeutic that targets cancer stem cells in the MET stage.
- a third anti-neoplastic agent is co-administered that kills cancer cells.
- a patient is treated for both types of cancer stem cells and bulk cancer cells in order to remove all types of cells with a particular treatment.
- a wide range of therapeutic agents find use with the present invention. Any therapeutic agent that can be co-administered with the agents of the present invention, or associated with the agents of the present invention is suitable for use in the methods of the present invention. Some embodiments of the present invention provide methods
- therapeutic methods for administering a therapeutic compound of the present invention and at least one additional therapeutic agent (e.g., including, but not limited to, chemotherapeutic antineoplastics, antimicrobials, antivirals, antifungals, and anti-inflammatory agents) and/or therapeutic technique (e.g., surgical intervention, radiotherapies).
- additional therapeutic agent e.g., including, but not limited to, chemotherapeutic antineoplastics, antimicrobials, antivirals, antifungals, and anti-inflammatory agents
- therapeutic technique e.g., surgical intervention, radiotherapies
- antineoplastic (e.g., anticancer) agents are contemplated for use in certain embodiments of the present invention.
- Anticancer agents suitable for use with the present invention include, but are not limited to, agents that induce apoptosis, agents that inhibit adenosine deaminase function, inhibit pyrimidine biosynthesis, inhibit purine ring biosynthesis, inhibit nucleotide interconversions, inhibit ribonucleotide reductase, inhibit thymidine monophosphate (TMP) synthesis, inhibit dihydrofolate reduction, inhibit DNA synthesis, form adducts with DNA, damage DNA, inhibit DNA repair, intercalate with DNA, deaminate asparagines, inhibit RNA synthesis, inhibit protein synthesis or stability, inhibit microtubule synthesis or function, and the like.
- exemplary anticancer agents suitable for use in compositions and methods of the present invention include, but are not limited to: 1) alkaloids, including microtubule inhibitors (e.g., vincristine, vinblastine, and vindesine, etc.), microtubule stabilizers (e.g., paclitaxel (TAXOL), and docetaxel, etc.), and chromatin function inhibitors, including topoisomerase inhibitors, such as epipodophyllotoxins (e.g., etoposide (VP- 16), and teniposide (VM-26), etc.), and agents that target topoisomerase I (e.g., camptothecin and isirinotecan (CPT-11), etc.); 2) covalent DNA-binding agents (alkylating agents), including nitrogen mustards (e.g., mechlorethamine, chlorambucil, cyclophosphamide, ifosphamide, and busulfan (MYLERAN),
- antimetabolites including antifolates (e.g., methotrexate, FOLEX, and MEXATE, etc.), purine antimetabolites (e.g., 6-mercaptopurine (6-MP, PURINETHOL), 6-thioguanine (6- TG), azathioprine, acyclovir, ganciclovir, chlorodeoxyadenosine, 2-chlorodeoxyadenosine (CdA), and 2'-deoxycoformycin (pentostatin), etc.), pyrimidine antagonists (e.g.,
- fluoropyrimidines e.g., 5-fluorouracil (ADRUCIL), 5-fluorodeoxyuridine (FdUrd)
- cytosine arabinosides e.g., CYTOSAR (ara-C) and fludarabine, etc.
- enzymes including L-asparaginase, and hydroxyurea, etc.
- hormones including glucocorticoids, antiestrogens (e.g., tamoxifen, etc.), nonsteroidal antiandrogens (e.g., flutamide, etc.), and aromatase inhibitors (e.g., anastrozole (ARIMIDEX), etc.); 7) platinum compounds (e.g., cisplatin and carboplatin, etc.); 8) monoclonal antibodies conjugated with anticancer drugs, toxins, and/or radionuclides, etc. ; 9) biological response modifiers (e.g., interferons (e.g., IFN-a, etc.) and interleukins (e.g., IL-2, etc.), etc.); 10) adoptive
- immunotherapy 11) hematopoietic growth factors; 12) agents that induce tumor cell differentiation (e.g., all-trans-retinoic acid, etc.); 13) gene therapy techniques; 14) antisense therapy techniques; 15) tumor vaccines; 16) therapies directed against tumor metastases (e.g., batimastat, etc.); 17) angiogenesis inhibitors; 18) proteosome inhibitors (e.g., VELCADE); 19) inhibitors of acetylation and/or methylation (e.g., HDAC inhibitors); 20) modulators of NF kappa B; 21) inhibitors of cell cycle regulation (e.g., CDK inhibitors); 22) modulators of p53 protein function; and 23) radiation.
- tumor cell differentiation e.g., all-trans-retinoic acid, etc.
- 13) gene therapy techniques 14
- antisense therapy techniques 15
- tumor vaccines 16) therapies directed against tumor metastases (e.g., batimastat, etc.); 17) angio
- any oncolytic agent used in a cancer therapy context finds use in the compositions and methods of the present invention.
- the U.S. Food and Drug Administration maintains a formulary of oncolytic agents approved for use in the United States.
- Table 1 provides a list of exemplary antineoplastic agents approved for use in the U.S. Those skilled in the art will appreciate that the "product labels" required on all U.S. approved
- chemotherapeutics describe approved indications, dosing information, toxicity data, and the like, for the exemplary agents.
- Mitomycin C Mutamycin Bristol-Myers Squibb mitomycin C Mitozytrex SuperGen, Inc., Dublin, CA
- Tositumomab I 131 Tositumomab Bexxar Corixa Corp., Seattle, WA (recombinant murine immunotherapeutic
- any and all combinations of one of the specific anti-cancer agents listed above (as the third therapeutic agent) with a specific EMT cancer stem cell agent (first therapeutic agent) and a specific MET cancer stem cell agent (second therapeutic agent) may be administered to a subject or packaged in a composition or kit.
- EMT epithelial transition
- MET mesenchymal epithelial transition
- MET CSCs are EpCAM CD49F (Figure 1) and express the CSC marker Aldehyde dehydrogenase (ALDH) ( Figure 3). Furthermore, it was demonstrated that these two states of CSCs are inter-convertible and they can regenerate each other in culture ( Figure 4). A subpopulation of cells expressing both CD44 + CD24 " and ALDH may represent cells in transition between these states.
- EpCAM + CD49f population is characterized by the highest expression of mir-93 by qRT-PCR.
- a TET on/off inducible system was established to over-express microRNAs in a lentiviral vector tagged with RFP. Utilizing this system, it was shown that forced over-expression of mir-93 increases the proportion of EpCAM + CD49f and ALDH + cells (Figure 5). Furthermore, it was demonstrated that expression levels of mir-100 are significant higher in EpCAM " CD49f and EpCAM " CD49f populations than in ⁇ 0 ⁇ 3 ⁇ 4 ⁇ 49 ⁇ and EpCAM + CD49f populations. Furthermore, forced over-expression of mir-100 increased the proportion of ⁇ ⁇ 49 ⁇ cells ( Figure 5).
- CD24 " CD44 + or ALDH expression share characteristics associated with “sternness.”
- CD24 " CD44 + and ALDH + CSC populations share common expression patterns across these subtypes.
- Cell culture Breast cancer cell line SUM 149 was from Asterland 24 and MCF10A was purchased from ATCC, which were cultured as previously described 25 .
- Flow Cytometry - Core biopsies and normal breast tissues were taken and placed
- Gene Expression Profiling used Affymetrix U133 Plus 2.0 human oligonucleotide microarrays. Preparation of cRNA, hybridizations, washes and detection were done as recommended by the supplier. Expression data were analyzed by the
- RNA from the sorted cells was reverse transcribed with 200U M-MLV Reverse Transcriptase (GibcoBRL) at 42°C for 1 hour in the presence of 5 mM each of dATP, dCTP, dGTP and dTTP, 4 ⁇ 5X 1st strand buffer (GibcoBRL), 0.01M DDT, 1U RNA Guard RNase inhibitor (GibcoBRL), and 2.5 ⁇ random primers in a total volume of 20 ⁇ 1. The reaction was terminated by heating to 95°C for 3 minutes.
- M-MLV Reverse Transcriptase M-MLV Reverse Transcriptase
- Real-time quantitative PCR (TaqManTM) primers and probes were purchased from Applied Biosytems as Assays-on-Demand TM Gene Expression Products. Real-time PCRs were performed following the supplier's instructions (Applied Biosystems). 20 ⁇ 1 of PCR mixture contained ⁇ of 2x TaqmanTM universal PCR Master Mix, ⁇ of 20x working stock of gene expression assay mix, and 50ng of RNA converted cDNA. PCR was performed in a ABI PRISM® 7900HT sequence detection system with 384- Well block module and automation accessory (Applied Biosystems).
- Immunostaining For ALDH1, CD24, CD44, and DAPI quadruple fluorescent staining, paraffin-embedded sections of breast tumors or normal breast tissues were deparaffinized in xylene and rehydrated in graded alcohol. Antigen enhancement was done by incubating the sections in citrate buffer pH 6.0 (Dakocytomation) as recommended. CD24 antibody (Neomarkers), ALDH1 antibody (BD biosciences), and CD44 antibody (Thermo Scientific) were used at a 1 :50 dilution and incubated for 1 hour.
- Alexafluor 647-, Alexafluor 546-, Alexafluor 488-labeled secondary antibodies were used at a 1 :200 dilution and incubated for 20 minutes. Nuclei were counterstained with DAPI/antifade (Invitrogen; blue color in the staining) and cover-slipped. Sections were examined with a fluorescent microscope (EVOS FL, AMG). Invasion Assay - Assays were done in triplicate in invasion chambers pre-coated with reduced growth factor matrix from BD Biosciences. Cells were added to the upper chamber in 200 mL of serum- free medium.
- 20,000 cancer cells were seeded on the coated chamber, and the lower chamber was filled with 600 mL of medium (Cambrex) with FBS. After 37 hours of incubation, the cells on the underside of the upper chambers were stained with the blue stain in the Cell Invasion Assay Kit (Chemicon; cat. #ECM550) and counted using light microscopy.
- medium Cell Invasion Assay Kit
- Cells were grown in Ham's F-12 medium (GIBCO INVITROGEN) with 5% fetal bovine serum (FBS), 5 mg/ml insulin, 1 mg/ml hydrocortisone, 10 mg/ml cholera toxin (Sigma, St Louis, MO, USA), 10 ng/ml epidermal growth factor (BD Biosciences), and 13 Pen/Strep/Fungizone Mix (GIBCO). Cells were fixed or collected for immunostaining after 12 days.
- 3-D Matrigel Culture - 3-D cultures in Matrigel were established as previously described 27 . Briefly, the sorted cells were suspended in 1ml of BD MatrigelTM Matrix (Cat. 354234, BD Biosciences, Palo Alto, CA) and Ham's F-12 medium (BioWhittaker) with 5% serum at a ratio of 1 : 1, and plated 1ml of the mixture into one well of 24-well cold plates and each group of cells was performed in quadruplicates. After the matrigel was solidified, 0.5ml of Ham's F-12 medium (BioWhittaker) with 5% serum was added to the top of the matrigel. The experiments were repeated with cells derived from at least three different patients.
- EMT and MET associated genes were compared in sorted CD24 " CD44 + and ALDH + tumor cell populations.
- EMT associated genes including vimentin, ZEB 1, ZEB2, CTNNB1 and MMP9 were significantly enriched in the CD24 " CD44 + populations while expression of these EMT genes were correspondingly decreased in the ALDH + populations.
- genes associated with the alternative MET state such as cadherin, occludin, claudins and desmoplakin, were elevated in ALDH + populations and correspondingly diminished in the CD24 " CD44 + cell populations.
- the proliferation marker Ki67 was preferentially expressed in ALDH + compared to CD24 " CD44 + cells.
- CD24 CD44 + primarily identifies EMT-like CSCs, whereas ALDH expression identifies MET-like proliferative CSCs. Importantly, these characteristics are independent of the molecular subtype of breast cancer. Previous studies have suggested that the relatively quiescent EMT-like CSCs may be particularly resistant to cytotoxic chemotherapy and radiation therapy 6 . This model is supported by a neo-adjuvant clinical trial which demonstrated that residual tumor cells in triple-negative breast cancer following chemotherapy or in luminal breast cancer following hormonal therapy express an EMT-like CSC profile 7 , suggesting that these divergent molecular subtypes of breast cancer contain similar therapy resistant CSC populations.
- ALDH1A1 the ALDH isoform most commonly expressed in human breast cancers 3 .
- CD24 " CD44 + and ALDH + identify largely non-overlapping cell populations, an observation supported by flow cytometry analysis of isolated tumor cell populations.
- CD24 " CD44 + cells were primarily located at the tumor invasive edge adjacent to stroma ( Figure 10E).
- ALDH1A1 + cells were located more centrally consistent with previous studies demonstrating that ALDH + CSC are generated by hypoxia in interior tumor zones 8 ( Figure 10E).
- a small subpopulation of cells were identified which simultaneously expressed CD24 " CD44 + and ALDH + ( Figure 10E) which may be indicative of CSC transitioning between epithelial and mesenchymal states.
- breast cancer cell lines were utilized as well as primary tumor xenografts. As was the case with primary tumors, breast cancer cell lines and primary xenografts contained
- CD24 " CD44 + and ALDH expressing cell populations with a minimal overlap Figure 1 1 A. Furthermore, as was the case with primary breast cancers, CD24 " CD44 + cells were enriched for expression of mesenchymal associated genes, while ALDH + cells demonstrated a reciprocal epithelial gene expression pattern (Figure 16). These results were confirmed by qRT-PCR ( Figure 17). To determine the degree of cellular plasticity between the epithelial and mesenchymal CSC states, CD24 " CD44 + and ALDH + populations were cultured, and the stability of the phenotypes was determined. As demonstrated in Figure 1 IB, in basal
- the EMT-like state characterized as CD24 " CD44 + displays a mesenchymal phenotype with increased invasive capacity, and low proliferative potential.
- the MET-like state characterized by ALDH expression displays an epithelial morphology and exhibits increased self-renewal capacity (Figure 1 ID). Transition between these states may be regulated by extrinsic signals generated in the tumor microenvironment. Cellular plasticity allowing transition between EMT and MET states may be required for tumors to successfully navigate the metastatic cascade as illustrated in Figure 1 IE. The relationship between CSC populations and their counterparts in the normal mammary gland remains controversial.
- a hierarchy of normal mammary cells has been described based on the expression of markers CD49f (alpha 6 integrin) and EpCAM 13 . These markers identify four populations in the normal mammary gland including EpCAM + CD49f epithelial cells, EpCAM + CD49f luminal progenitor cells, EpCAM " CD49f stem cells and EpCAM " CD49f stromal cells 13 .
- the non-transformed MCFIOA human mammary cell line was utilized to determine the relationship between these markers and the CD24 " CD44 + and ALDH + markers used to characterize CSCs.
- EpCAM + CD49f cells displayed an epithelial morphology (Figure 12A) and expressed E-cadherin ( Figure 12B), while EpCAM " CD49f cells displayed a mesenchymal morphology ( Figure 12A) and expressed the EMT marker vimentin ( Figure 12C).
- EpCAM + CD49f cells generated double- positive cells and vice versa ( Figure 12A).
- EpCAM " CD49f mesenchymal-like cells were enriched for the expression of CD24 " CD44 + ( Figure 12D), whereas the EpCAM + CD49f epithelial-like cells were enriched for ALDH expression ( Figure 12D). Furthermore, these populations were distinct with little overlap ( Figure 12E). Gene expression analysis of sorted CD24 " CD44 + and ALDH + populations demonstrated that these cells expressed genes characteristic of mesenchymal (basal) and epithelial phenotypes respectively ( Figure 12F). Expression of a subset of these genes was verified by qRT-PCR ( Figure 18).
- CD44 + cells were located in the basal cell layer in ductal structures, whereas ALDH + cells were located in a luminal location in the terminal end buds and at ductal branch points ( Figure 13E).
- ALDH + luminal breast stem cells may, therefore, represent a subset of
- EpCAM + CD49f cells capable of giving rise to breast cancers. Furthermore, the observation that different molecular subtypes of breast cancer contain stem cells with similar molecular characteristics suggests that these subtypes may share a common cell of origin. The mutation profile, therefore, rather than the cell of origin may determine the molecular subtype of breast cancer generated. This model is supported by recent whole genome analysis of breast cancers which reveal distinct mutations associated with different molecular subtypes which intern display distinct biological and clinical behaviors 22 . This Example also indicates that EpCAM + CD49f cells which have been previously characterized as luminal progenitors, in fact represents a heterogenous population that contains an ALDH + subpopulation that is more accurately characterized as a luminal stem cell.
- This Example further indicates that once tumors develop they are driven by CSC with the cellular plasticity to transition between EMT and MET states. These CSC states transitions may facilitate tumor invasion as well as growth at metastatic sites.
- ALDH1 is a marker of normal and malignant breast stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1 :555-567.
- ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, l(5):555-567.
- Lewis BP, Burge CB, Bartel DP conserveed seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120(1): 15-20.
- Kalluri R EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009, 119(6): 1417-1419.
- Axl is an essential epithelial-to-mesenchymal transition- induced regulator of breast cancer metastasis and patient survival.
- Doxorubicin in combination with a small TGFbeta inhibitor a potential novel therapy for metastatic breast cancer in mouse models.
- Li Z, Yang CS, Nakashima K, Rana TM Small RNA-mediated regulation of iPS cell generation. EMBO J 2011, 30(5):823-834.
- ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.
Abstract
Compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states are disclosed. In some methods, a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In certain methods, the different states of cancer stem cells are distinguished based on markers CD44+CD24-, EpCam-CD49P+ (for EMT cancers stem cells), ALDH+ and EPCam+CD49r- (for MET cancers stem cells), and CD44+CD24-ALDH+ (for EMT -MET cancer stem cells). In particular methods, micro RNAs are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).
Description
DIFFERENT STATES OF CANCER STEM CELLS
The present application claims priority to U.S. Provisional application serial number 61/596,796, filed February 9, 2012, which is herein incorporated by reference in its entirety.
This invention was made with government support under CA66233 and CA101860 awarded by the National Institutes of Health. The government has certain rights in the invention. FIELD OF THE INVENTION
The present invention relates to compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment, based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states.
BACKGROUND OF THE INVENTION
With over 200,000 new cases yearly, breast cancer is the most common malignancy of women in the United States (US). The past 20 years have seen significant reductions in mortality from breast cancer in the United States and elsewhere. This reduction has been largely due to improvement in early detection and the development of more effective adjuvant therapies. Despite the fact that there have been significant advances in the treatment of breast cancer, the fact remains that once metastatic, the disease remains incurable. Recent studies have provided strong support for the cancer stem cell hypothesis which suggests that breast cancers are driven by a subpopulation of cells which display stem cell properties. These properties include self-renewal which generates other cancer stem cells and differentiation which generates populations of cells forming the bulk of the tumor. There is increasing evidence that cancer stem cells are resistant to chemotherapy and radiation therapy and, thus, contribute to treatment resistance and relapse.
The development of biomarkers to identify CSCs, as well as validation of in vitro and mouse models, has facilitated the isolation and characterization of these cells from both murine and human tumors. Breast cancer stems cells have been characterized by expression of the cell surface markers ESA and CD44 in the absence of expression of the marker CD24. These cells have been termed "breast cancer stem cells" (BCSCs). As few as 200 ESA- positive CD44+/CD24-lin- cells were able to generate tumors in immunocompromised NOD-
SCID mice, whereas 100-fold more cells without these markers isolated from the same tumors were non-tumorigenic. Furthermore, the tumor-initiating populations regenerated tumors that recapitulated the heterogeneity of the initial tumor. The art has also developed an in vitro "mammosphere" assay as a means of quantitating normal and malignant stem cells. More recently, the art described the expression of aldehyde dehydrogenase (ALDH) as assessed by the Aldefluor assay (StemCell Technologies, Canada) or the isoform ALDH1 by immunohistochemistry (IHC) as a means of further identifying and enriching for tumor initiating CSC populations in human BCs. Interestingly, it was reported that these markers identify overlapping, but not identical cell populations. Furthermore, it has been found that these markers can be utilized to isolate CSC populations from established breast cancer cell lines, as well as primary tumor xenografts. The development and validation of breast cancer stem cell (BCSC) biomarkers, in vitro mammosphere formation assays, and xenograft models by the art has permitted assessment of chemotherapy and radiation resistance of BCSCs. These studies have demonstrated the relative resistance of BCSC to chemotherapy and radiation therapy. Furthermore, it has recently been demonstrated that the percent of BCSC as assessed either by CD44+/CD241ow mammosphere assays or by ALDH expression increases following neoadjuvant chemotherapy providing direct clinical evidence for the therapeutic resistance of BCSC. Together, these studies suggest that significant improvement in patient outcome will require the successful targeting of BCSCs.
SUMMARY OF THE INVENTION
The present invention relates to compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment, based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states. In some embodiments, a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In certain embodiments, the different states of cancer stem cells are distinguished based on markers CD44+CD24", EpCam"CD49F+ (for EMT cancers stem cells), ALDH+ (or ADLH1 isoform) and
EPCam+CD49 (for MET cancers stem cells), and CD44+CD24"ALDH+ (for EMT-MET cancer stem cells). In particular embodiments, micro RNAs are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).
In some embodiments, the present invention provides methods of reducing the frequency of EMT and MET type cancer stem cells in a subject with the EMT and MET type
cancer stem (or a subject suspected of having EMT and MET type cancer stem cells) cells comprising co-administering to the subject an effective amount of: a) a first therapeutic agent directed against EMT type cancer stem cells, and b) a second therapeutic agent directed against MET type cancer stem cells, wherein the frequency of both the EMT and the MET type cancer stem cells in the subject are reduced (e.g., tumor size is reduced).
In other embodiments, the first therapeutic agent, targeting EMT cancer stem cells, comprises an inhibitor of a protein or nucleic acid encoding a protein selected from the group consisting of: IL-6 and an IL-6 pathway member (e.g., IL-6 antibody, IL-6R antibody, STAT3 inhibitor), Notch and a Notch pathway member (e.g., GSI), Wnt and Wnt pathway members, Hedgehog and Hedgehog pathway members, and Tgf-β and Tgf-β pathway members. In certain embodiments, the first therapeutic is an agent targeting Notch (e.g., U.S. Pat. 8,088,617; WO2008100563, WO201 1088215, and WO20088091641, all of which are herein incorporated by reference); WNT (e.g., U.S. Pat. Pub. 201 10305695 and
WO201 1088123, both of which are herein incorporated by reference), frizzled (e.g.,
WO201 1123785 and WO2007142711, both of which are herein incorporated by reference in their entireties), jagged (e.g., WO2011063237 and WO2008140826, both of which are herein incorporated by reference in their entireties) and DLL4 (U.S. Pat. Pub. 20110165162, herein incorporated by reference in its entirety). In particular embodiments, the first therapeutic agent, targeting EMT cancer stem cells, is an antibody (or small molecule) being developed by Oncomed Pharmaceuticals selected from: Anti-DLL4 (OMP-21M18, demcizumab); Anti- DLL4/VEGF bispecific; Anti-Notch2/3 (OMP-59R5); Anti-Notchl; Anti-Fzd7 (OMP-18R5); and Fzd8Fc. Information about these therapeutic agents can be found on Oncomed
Pharmaceuticals web page.
In certain embodiments, the second therapeutic agent, targeting MET cancer stem cells, comprises a Pan-erb blocker (e.g., Canertinib dihydrochloride, Neratinib, JNJ-
28871063, PF00299804, PD168393, HKI-272, NT-1 12, etc.) or a Her-2 pathway inhibitor (e.g., HERCEPTIN). In certain embodiments, the second therapeutic targets BMPR (e.g., WO201 11 16212, herein incorporated by reference in its entirety). In particular embodiments, the first or second therapeutic agent is a cancer stem cell targeting agent against: i) human mesenchymal-epithelial transition receptor binder (e.g., U.S. Pat. Pub. 20110142840, herein incorporated by reference in its entirety), ii) G-protein coupled receptor (LGR) (e.g., WO2009005809, herein incorporated by reference in its entirety), iii) integrin beta 1 (e.g., WO20090091 14, herein incorporated by reference in its entirety), and iv) discoidin domain receptor 2 (e.g., WO2008070090, herein incorporated by reference in its entirety).
Any and all combinations of a specific EMT cancer stem cell targeting agent (such as those described above) and a specific MET cancer cell targeting agent (such as those described above) may be made and administered to a subject or packaged in a composition or kit. In certain embodiments, the first therapeutic agent is an IL6R antibody (e.g., tocilizumab) and the second therapeutic agent is anti-Her2 antibody (e.g., HERCEPTIN). Further, any and all combinations of first and second therapeutic agents may be co-administered with any additional bulk cancer killing agent, such as those described in Table 1 below. For example, a patient may be administered and IL6R antibody, an anti-HER2 antibody, and one or more compositions from Table 1.
In particular embodiments, the subject comprises bulk cancer cells that are not cancer stem cells, and wherein the method further comprises co-administering a third therapeutic agent to the subject, wherein the third therapeutic agent is capable of killing or inhibiting the bulk cancer cells, and wherein the frequency of the bulk cancer cells is reduced.
In certain embodiments, the EMT cancer stem cells are CD44 CD24" and EpCam" CD49F+. In further embodiments, the EMT cancer stem cells express at least one of the following: vimentin, N-cadherin, slug, snail, and twist. In additional embodiments, the EMT cancer stem cells express miR-221 and/or miR-100. In particular embodiments, the MET cancer stem cells are ALDH+ (or ALDH1+) and EpCam+CD49F+. In further embodiments, the MET cancer stem cells express miR-93. In some embodiments, the subject further comprises EMT-MET cancer stem cells, and the co-administering reduces the frequency of the EMT-MET cancer stem cells in the subject. In other embodiments, the EMT-MET cancer stem cells are characterized as CD44+CD24" and ALDH+. In certain embodiments, the subject has a solid tumor and the solid tumor comprises the EMT and MET type cancer stem cells.
In some embodiments, the present invention provides compositions, systems, and kits for reducing the frequency of EMT and MET type cancer stem cells in a subject comprising: a) a first therapeutic agent directed against EMT type cancer stem cells (e.g., anti-IL6 receptor antibody), and b) a second therapeutic agent directed against MET type cancer stem cells (e.g., anti-HER2 antibody). In particular embodiments, the first therapeutic agent comprises a Pan-erb blocker or a Her-2 pathway inhibitor. In other embodiments, the second therapeutic agent comprises an inhibitor of a protein or nucleic acid encoding a protein selected from the group consisting of: IL-6, Notch, Wnt, Hedgehog, or Tgf-β. In additional embodiments, the kits, system, and compositions further comprise a third therapeutic agent capable of killing or inhibiting bulk cancer cells that are not cancer stem cells.
In certain embodiments, the present invention provides methods of identifying a test compound useful for treating EMT and/or MET type cancer stem cells: a) providing a population of cancer cells, wherein the majority (e.g., greater than 50% ... 65% ... 75% ... 90% ... 95% ... 99% ... 99.8%) of cancer cells in the population are a type of cancer cell or mixture of cancer cells selected from the group consisting of: i) EMT type cancer stem cells, ii) MET type cancer stem cells, iii) a mixture of EMT and MET cancer stem cells, and iv) EMT -MET cancer stem cells; and b) administering the test compound to the cancer cells; c) monitoring the response of the cancer cells to the test compound; and d)
identifying a test compound that inhibits the cancer cells.
In some embodiments, the methods further comprise screening the test compound identified in step d) against a population of normal cells and/or population of normal stem cells to determine if the test compound harms the normal cells and/or normal stem cells. In certain embodiments, the EMT cancer stem cells over-express miR-100 and/or miR-221 (e.g., forced over-expression via an expression vector). In certain embodiments, the MET cancer stem cells over-express miR-93. In additional embodiments, altering the cancer cells comprises inhibiting proliferation of the cancer cells. In further embodiments, altering the cancer cells comprises inhibiting survival of the cancer cells. In additional embodiment, the monitoring the response of the cells is selected from the group consisting of monitoring the proliferation of the cells; monitoring the survival of the cells; monitoring the cell cycle status of the cells; monitoring gene expression in the cells; monitoring protein expression and/or activity in the cells; and monitoring cellular pathways. In further embodiments, the monitoring gene expression identifies a cancer stem cell biomarker. In additional embodiments, the monitoring gene expression comprises use of a microarray. In some embodiments, the monitoring gene expression comprises measuring mRNA. In further embodiments, the monitoring cellular pathways comprises measuring the activity of the pathways.
In certain embodiments, the test compound is selected from a test compound library comprising a plurality of test compounds. In additional embodiments, the test compound library is selected from a test compound library comprising carbohydrates, monosaccharides, oligosaccharides, polysaccharides, amino acids, peptides, oligopeptides, polypeptides, proteins, nucleosides, nucleotides, oligonucleotides, polynucleotides, lipids, retinoids, drugs, antibodies, prodrugs, steroids, glycopeptides, glycoproteins, proteoglycans, and synthetic small molecule organic compounds.
In some embodiments, the present invention provides methods comprising: assaying a sample from a subject with cancer and identifying the presence or absence of EMT, MET, and/or EMT -MET cancer stem cells in the sample. In certain embodiments, the presence of EMT cancer stem cells are identified in the sample, and wherein the method further comprises administering a therapeutic to the subject directed to EMT cancer stem cells. In additional embodiments, the presence of MET cancer stem cells are identified in the sample, and wherein the method further comprises administering a therapeutic to the subject directed to MET cancer stem cells. In further embodiments, the presence of both EMT and MET cancer stem cells, and/or the presence of EMT -MET cancer stem cells, are identified in the sample, and wherein the method further comprises administering a first therapeutic to the subject directed to EMT cancer stem cells and a second therapeutic to the subject directed to MET cancer stem cells.
In particular embodiments, the EMT cancer stem cells are identified based on being CD44+CD24" and EpCam"CD49F+. In further embodiments, the MET cancer stem cells are identified based on being ALDH+ and EpCam+CD49F+. In certain embodiments, the EMT cancer stem cells are identified based on expression of miR-100 and/or miR-221. In particular embodiments, the MET cancer stem cells are identified based on expression of miR-93. In some embodiments, the identifying comprises viewing results of an assay performed on a sample from the subject which shows which type or types of cancer stem cells are present.
In some embodiments, the present invention provides compositions comprising: an isolated cancer stem cell over-expressing miR-93, miR-100, and/or miR-221. In certain embodiments, the cancer stem cell comprises an expression vector configured for expressing miR-93, miR-100, and/or miR-221.
In additional embodiments, the present invention provides methods comprising: administering a composition to a subject, wherein the subject has cancer, and wherein the composition comprises an expression vector configured to express miR-93, miR-100, and/or miR-221.
In some embodiments, the present invention provides methods of converting a cancer stem cell from one type to another comprising: i) contacting a MET cancer stem cell with an miR-100, miR-9, and/or miR-221 expression vector such that miR-100, miR-9 and/or miR- 221 is over expressed by said MET cancer stem cell thereby converting said MET cancer stem cell to a EMT cancer stem cell; and/or ii) contacting an EMT cancer stem cell with a miR-93, miR-200, and/or miR-205 expression vector such that miR-93, miR-200, and/or
miR-205 is over expressed by said EMT cancer stem cell thereby converting said EMT cancer stem cell to a MET cancer stem cell.
In certain embodiments, the EMT cancer cells are identified by detecting elevated expression, and/or MET cancer stem cells are identified by detecting decreased expression, of at least one of the following markers: vimentin, N-cadherin, slug, snail, ZEB 1, ZEB2, CT B1, MMP2, MMP9, FOXC1, FOXC2, Fibronectin 1, and twist. In other
embodiments, the MET cancer cells are identified by detecting elevated expression, and/or EMT cancer cells are identified by detecting decreased expression of, of at least one of the following markers: EpCam, E-cadherin, occludin, desmoplakin, Ki67, cadherin 1, or a claudin.
In particular embodiments, the present invention provides methods of treating cancer in a subject comprising: treating a subject with antigen presenting cells such that at least some cancer cells in the subject are killed, wherein the antigen presenting cells have been exposed to: i) EMT and MET cancer stem cells or at least an antigenic portion of the EMT and MET cancer stem cells; and/or ii) EMT-MET cancer stem cells or at least an antigenic portion of the EMT-MET cancer stem cells.
In particular embodiments, the antigen presenting cells have been exposed to a lysate from the EMT and MET cancer stem cells, and/or the EMT-MET cancer stem cells. In particular embodiments, the antigen presenting cells comprise dendritic cells. In further embodiments, the antigen presenting cells comprise macrophages. In additional
embodiments, the antigen presenting cells comprise B-cells. In some embodiments, the subject is a human. In certain embodiments, the subject has a cancer selected from the group consisting of: melanoma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, liver cancer, brain cancer, skin cancer, and colon cancer. In particular embodiments, the methods further comprise treating the subject with a chemotherapeutic agent. In some embodiments, the methods further comprise treating the subject with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In additional embodiments, the methods further comprise treating the subject with radiation therapy.
In some embodiments, the present invention provides compositions, systems, and kits comprising: antigen presenting cells that have been exposed to: i) EMT and MET cancer stem cells or at least an antigenic portion of said EMT and MET cancer stem cells; and/or ii) EMT- MET cancer stem cells or at least an antigenic portion of said EMT-MET cancer stem cells. In further embodiments, the compositions, systems, and kits further comprise at least one component selected from: i) a device configured to emit radiation used during external
radiation cancer therapy; ii) a chemotherapeutic agent; iii) a first therapeutic that targets EMT cancer stem cells (e.g., as described herein); and iv) a second therapeutic that targets MET cancer stem cells (e.g., as described herein). DESCRIPTION OF THE DRAWINGS
Figure 1 shows a characterization of EMT and MET cells as described in Example 1. EpCAM+CD49 cells and EpCAM"CD49 cells were sorted by flow cytometry (A). 200k cells were plated in T25 flasks and phase micrographs were shown in (A). Total RNA was isolated from the sorted cells right after sorting and the expression MET marker (B) and EMT markers (C) were measured by qRT-PCR in both cell populations.
Figure 2 shows CD24"CD44+ cells are enriched in EMT population. Cells grown in T75 flasks at about 85% confluency were analyzed with Aldefluor, CD24 and CD44 as described in Example 1.
Figure 3 shows ALDH+ cells are enriched in MET population. Cells grown in T75 flasks at about 85% confluency were analyzed with Aldefluor, EpCAM and CD49f as described in Example 1.
Figure 4 shows the inter-conversion of EMT and MET cells. EpCAM+CD49f cells and EpCAM"CD49f cells were sorted by flow cytometry. 200k cells were plated in T75 flasks and cultured for 1 1 days, and then the cells were dissociated and analyzed for CD49f and EpCAM.
Figure 5 shows that the inter-conversion between EMT and MET is regulated by microRNAs. Cells were transduced with pTRIPZ-microRNA-RFP lentiviruses with inducible systems and selected with puromycin, and microRNAs were induced with or without (CONTROL) Doxycycline and analyzed for RFP, EpCAM and CD49f.
Figure 6 shows microRNAs regulate cell invasion in vitro. The invasive capability of pTRIPZ-mir-93-RFP cells or pTRIPZ-mir-100-RFP cells with or without (CONTROL) Doxycycline was assessed by matrigel invasion assay. 10000k cells were plated in Matrigel and serum was utilized as the attractant.
Figure 7A shows a non-limiting model in which breast cancer stem cells (BCSCs) can exist in two alternative states: one, an EMT state which is EpCAM"CD49f expresses the stem cell markers CD24"CD44+, and an MET population which is EpCAM+CD49 (double- positive) and expresses the CSC marker ALDH. Figure 7B shows the two stem cell states are interconvertable, which is regulated by the microRNA networks. Such as: mir-9, mir-100,
mir-221 and mir-155 can induce EMT stem cells; mir-200, mir-205 and mir-93 can induce MET stem cells.
Figure 8 shows a non-limiting hypothetical model in which CSCs located inside the tumor mass exist predominantly in the MET state in which they are highly proliferative and express ALDH (ALDH+), in contrast at the tumor invasive front are located with EMT CSCs which are characterized as CD24"CD44+ and are highly invasive, and mediates tumor invasion and metastasis. The intermediate CSCs (CD24"CD44+ALDH+) also reside inside the tumor mass, and they are highly proliferative with invasive potential.
Figure 9A shows the nucleic acid sequence of miR-93 (SEQ ID NO: l), figure 9B shows the nucleic acid sequence of miR-100 (SEQ ID NO:2), and figure 9C shows the nucleic acid sequence of miR-221 (SEQ ID NO: 3).
Figure 10. CD24"CD44+ and ALDH+ cells display reciprocal EMT-MET profiles in primary human breast cancer. (A) Venn diagram of the intersection between genes elevated in CD24"CD44+ compared with other flow-sorted cells (others) and genes diminished in ALDH+ compared with ALDH" cells (|fold change] > 1.5 for each comparison). (B) Venn diagram of the intersection between genes diminished in CD24"CD44+ vs. others and genes elevated in ALDH+ vs. ALDH". (C) Heat map of genes with opposite expression patterns between CD24"CD44+ and ALDH+ (from parts A and B). Each row represents a RNA transcript; each column represents a sample (red: high expression). (D) Expression of EMT/MET markers in CD24"CD44+ vs. others and ALDH+ vs. ALDH". (E) Localization of CD24 (Magenta), CD44 (Green), ALDH1 (Red), and DAPI (Blue) in clinical samples of human invasive breast carcinoma as accessed by immunofluorescence staining. Bar, lOOum.
Figure 1 1. Role of EMT-MET plasticity in tumor metastasis. Basal breast cancer cell line SUM 149 was immunostained with CD24 and CD44 antibodies and subsequently with ALDEFLUOR. The four cell subpopulations defined by the ALDEFLUOR and CD24"CD44+ phenotypes were separated by FACS. (A) The percentages shown in the diagram show the representation of the cell subpopulations in the total tumor cell population and the overlap between the ALDEFLUOR phenotype and the CD24"CD44+ phenotype. (B) The unsorted SUM 149 cells and the sorted CD24"CD44+ and ALDH+ populations as described in (A) were placed in culture for 10 days and resulting cells were re-analyzed by FACS for
ALDEFLUOR, CD24, CD44. (C) The sorted four populations from (A) were accessed for invasive capacity utilizing the matrigel invasion assay. (D-E) Hypothetical models show the characteristics of two different states of breast cancer stem cells and their metastatic potential. * P<0.05; Error bars represent mean ± STDEV.
Figure 12. Identification of EMT-MET states in non-transformed MCF10A cells. (A) Cells were immunostained utilizing EpCAM and CD49f antibodies, EpCAM+CD49f and EpCAM~CD49f cells separated by FACS and plated in culture for 10 days. FACS analysis for EpCAM and CD49f was then repeated. (B-C) Total RNA was extracted from the sorted EpCAM+CD49 cells and EpCAM"CD49 cells, and the expression level of E-Cadherin, Vimention and TBP was measured by qRT-PCR. (D) Cells were immunostained with EpCAM and CD49f antibodies, and subsequently stained with CD24/CD44 or
ALDEFLUOR. (E) Cells were immunostained with CD24 and CD44 antibodies and subsequently with ALDEFLUOR. The four cell subpopulations defined by the ALDEFLUOR and CD24"CD44+ phenotypes were separated by FACS. The percentages shown in the diagram depict cell subpopulations and the overlap between the ALDEFLUOR-positive phenotype and the CD24"CD44+ phenotype. (F) Total RNA was extracted from the four populations as described in (E) and used for Affymatrix array (Hul33 plus 2.0) analysis. The fold change for EMT/MET markers was compared between ALDH+ and ALDFf , CD24" CD44+ and others. * P<0.05; Error bars represent mean ± STDEV.
Figure 13. Normal human breast contained distinct basal and luminal stem cells which express EMT/MET markers respectively. (A) Cells isolated from reduction mammoplasty tissue were immunostained with Lineage markers (Lin ), EpCAM and CD49f antibodies, and were first gated based on viability (DAPL) and lineage markers. The sorted cells (Lin" EpCAM+CD49 cells and Lin"EpCAM"CD49f cells) were injected into the 4th mammary gland fatpads which were previously humanized with normal human breast fibroblasts. After about 2 months, mice were sacrificed and the outgrowths generated in the fatpads were accessed by Hematoxylin and eosin staining. (B) Cells were immunostained with EpCAM and CD49f antibodies, followed by CD24/CD44 or ALDEFLUOR. (C) Cells were immunostained with Lineage markers (Lin ), EpCAM and CD49f antibodies, and subsequently with ALDEFLUOR. The cells were first gated based on viability (DAPL) and lineage markers. The sorted cells (Lin"EpCAM+CD49f ALDH+ cells and Lin"
EpCAM+CD49 ALDH" cells) were grown in differentiating conditions on collage-coated plates for 12 days and the number of colonies generated was accessed. (D) Sorted cells (Lin" EpCAM+CD49 ALDH+ cells and Lin"EpCAM+CD49 ALDH" cells) were cultured in 3D Matrigel culture for 3 weeks and the number of branched structures generated were accessed. (E) Localization of CD24 (Magenta), CD44 (Green), ALDH1 (Red), and DAPI (Blue) in normal breast tissue as accessed by immunofluorescence staining. Yellow arrow, CD24" CD44+ cells; Red arrow, ALDH1+ cells. Bar, lOOum.
Figure 14A shows a venn diagram showing the intersection between genes elevated in cancer mammospheres vs. primary cancers, genes elevated in CD24- CD44+ vs. others, and genes elevated in ALDH+ vs. ALDH- cells (|fold change] > 1.5 for each comparison). Figure 14B is the same as 14A but for genes diminished in cancer mammospheres vs. primary cancers, genes diminished in CD24- CD44+ vs. others, and genes diminished in ALDH+ vs. ALDH- cells. P-value of overlap between any two datasets is smaller than 2.2E-16.
Figure 15 shows that specific EMT markers have opposite expression patterns in CD24-CD44+ and ALDH+ cells. (A) For CD24-CD44+ vs. others flow-sorted profile datasets, heat map of EMT markers (|fold change] > 1.5). (B) As with A but for ALDH+ vs. ALDH- profile datasets.
Figure 16 shows EMT/MET marker expression obtained with Affymatrix array Hul33 plus2.0. (A) Expression of EMT/MET markers in CD24-CD44+ vs. others and ALDH+ vs. ALDH- of SUM149 cell line. (B) Expression of EMT/MET markers in CD24- CD44+ vs. others and ALDH+ vs. ALDH- of primary xenograft MCI .
Figure 17 shows validation of gene expression results by qRT-PCR. To confirm gene expression results for EMT/MET markers, the mR A expression level for Vimentin, ZEB1, Claudin 3 and ki67 were measured in SUM 149 cells. (A) and primary xenograft MCI (B) sorted for ALDH+/ALDH-, CD24-CD44+/others by qRT-PCR. Gene expression levels measured by qRT-PCR confirm the results obtained with affymatrix array Hul33 plus2.0. Error bars represent mean ± STDEV.
Figure 18 shows results of validation of gene expression results by qRT-PCR. To confirm gene expression results for EMT/MET markers, mRNA expression level for Vimentin, ZEB 1, Claudin 3 and ki67 were measured in MCF10A cells sorted for
ALDH+/ALDH-, CD24-CD44+/others by qRT-PCR. Gene expression levels measured by qRT-PCR confirm the results obtained using DNA. Error bars represent mean ± STDEV.
Figure 19 shows results of characterization of CD24-CD44+ cells and ALDH+ epithelial cells isolated from normal breast tissues. (A) Cells were immunostained with CD24 and CD44 antibodies and were subsequently stained with ALDEFLUOR. The four cell subpopulations defined by the ALDEFLUOR and CD24-CD44+ phenotypes were separated by FACS. The percentages in the diagram represent the cell subpopulations as a
representative of the total tumor cell population and the overlap between the ALDEFLUOR phenotype and the CD24-CD44+ phenotype. (B) Expression of EMT/MET markers in CD24- CD44+ vs. others and ALDH+ vs. ALDH- of normal breast as accessed by Affymatrix array Hul33 plus2.0. (C) To confirm gene expression results for EMT/MET markers, the mRNA
expression level for Vimentin, ZEB1, Claudin 3 and ki67 were measured in a set of breast tumor cells sorted for ALDH+/ALDH-, CD24-CD44+/others by qRT-PCR. Gene expression levels measured by qRT-PCR confirm the results obtained with affymatrix array Hul33 plus2.0. Error bars represent mean ± STDEV.
Figure 20 shows results regarding evaluation of the differentiation potential of Lin-
EpCAM+CD49f+ALDH+ cells and Lin-EpCAM+CD49f+ALDH- cells isolated from normal breast tissue. Primary cells isolated from reduction mammoplasties were immunostained with Lineage markers (Lin-), EpCAM and CD49f antibodies, and were subsequently stained with ALDEFLUOR. The cells were first gated based on viability (DAPI-) and lineage markers. The sorted cells (Lin-EpCAM+CD49f+ALDH+ cells and Lin-
EpCAM+CD49f+ALDH- cells) were grown in differentiating conditions on collage-coated plates for 12 days and the grown colonies were stained by IHC with lineage-specific markers (ckl4-Purple, ckl8-Red).
Figure 21 shows results regarding evaluation of the branching morphogenesis of Lin- EpCAM+CD49f+ALDH+ cells and Lin-EpCAM+CD49f+ALDH- cells isolated from normal breast tissue. Primary cells isolated from reduction mammoplasties were immunostained with Lineage markers (Lin-), EpCAM and CD49f antibodies, and were subsequently stained with ALDEFLUOR. The cells were first gated based on viability (DAPI-) and lineage markers. The sorted cells (Lin-EpCAM+CD49f+ALDH+ cells and Lin-EpCAM+CD49f+ALDH- cells) were grown in 3D Matrigelfor 3 weeks.
DEFINITIONS
As used herein, the term "subject" refers to any animal (e.g., a mammal), including, but not limited to, humans, non-human primates, rodents, and the like (e.g., which is to be the recipient of a particular treatment, or from whom cancer stem cells are harvested). Typically, the terms "subject" and "patient" are used interchangeably, unless indicated otherwise herein.
As used herein, the term "subject is suspected of having cancer" refers to a subject that presents one or more signs or symptoms indicative of a cancer (e.g., a noticeable lump or mass) or is being screened for a cancer (e.g., during a routine physical). A subject suspected of having cancer may also have one or more risk factors. A subject suspected of having cancer has generally not been tested for cancer. However, a "subject suspected of having cancer" encompasses an individual who has received a preliminary diagnosis (e.g., a CT scan showing a mass) but for whom a confirmatory test (e.g., biopsy and/or histology) has not been done or for whom the stage of cancer is not known. The term further includes people
who once had cancer (e.g., an individual in remission). A "subject suspected of having cancer" is sometimes diagnosed with cancer and is sometimes found to not have cancer.
As used herein, the term "subject diagnosed with a cancer" refers to a subject who has been tested and found to have cancerous cells. The cancer may be diagnosed using any suitable method, including but not limited to, biopsy, x-ray, blood test, and the diagnostic methods of the present invention. A "preliminary diagnosis" is one based only on visual
(e.g., CT scan or the presence of a lump) and antigen tests.
As used herein, the term "cancer cells" refers to individual cells of a cancer. Such cells may include, for example, tumorigenic cells (e.g., capable of generating a tumor), leukemogenic cells (e.g., capable of generating leukemia), cancer stem cells (e.g., capable of forming new tumors or transferring disease upon transplantation into an
immunocompromised host), as well as cells that are not tumorigenic, leukemogenic or that are capable of forming new tumors or transferring disease upon transplantation (e.g., mesenchymal and endothelial cells).
As used herein, the term "characterizing tissue in a subject" refers to the identification of one or more properties of a tissue sample (e.g., including but not limited to, the presence of
EMT or MET cancer stem cells in the tissue).
As used herein, the term "providing a prognosis" refers to providing information regarding the impact of the presence of cancer (e.g., as determined by the diagnostic methods of the present invention) on a subject's future health (e.g., expected morbidity or mortality, the likelihood of getting cancer, and the risk of metastasis).
As used herein, the term "non-human animals" refers to all non-human animals including, but are not limited to, vertebrates such as rodents, non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, aves, etc.
As used herein, the term "effective amount" refers to the amount of a composition sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.
As used herein, the term "administration" refers to the act of giving a drug, prodrug, or other agent, or therapeutic treatment (e.g., compositions of the present invention) to a subject (e.g., a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs). Exemplary routes of administration to the human body can be through the eyes (ophthalmic), mouth
(oral), skin (transdermal), nose (nasal), lungs (inhalant), oral mucosa (buccal), ear, by
injection (e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.) and the like.
"Co-administration" refers to administration of more than one chemical agent or therapeutic treatment (e.g., radiation therapy) to a physiological system (e.g., a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs). "Co-administration" of the respective chemical agents and therapeutic treatments (e.g., radiation therapy) may be concurrent, or in any temporal order or physical combination.
"Enriched," as in an enriched population of cells, can be defined based upon the increased number of cells having a particular marker in a fractionated set of cells as compared with the number of cells having the marker in the unfractionated set of cells.
However, the term "enriched" can also be defined by tumorigenic function as the minimum number of cells that generate a cancer (e.g., a tumor) at a limited dilution frequency (e.g., in a mouse model). For example, if 500 cancer stem cells form tumors in 63% of test animals, but 5000 unfractionated tumor cells are required to form tumors in 63% of test animals, then the cancer stem cell population is 10-fold enriched for tumorigenic activity.
The terms "test compound" and "candidate compound" refer to any chemical entity, pharmaceutical, drug, and the like that is a candidate for use to treat or prevent a disease, illness, sickness, or disorder of bodily function (e.g., cancer (e.g., tumorigenic cells, leukemogenic cells or cancer stem cells)). Test compounds comprise both known and potential therapeutic compounds. A test compound can be determined to be therapeutic by screening using the screening methods of the present invention. Examples of test compounds include, but are not limited to, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, amino acids, peptides, oligopeptides, polypeptides, proteins, nucleosides, nucleotides, oligonucleotides, polynucleotides, including DNA and DNA fragments, RNA and RNA fragments and the like, lipids, retinoids, steroids, drug, antibody, prodrug, glycopeptides, glycoproteins, proteoglycans and the like, and synthetic analogues or derivatives thereof, including peptidomimetics, small molecule organic compounds and the like, and mixtures thereof (e.g., that is a candidate for use to treat or prevent a disease, illness, sickness, or disorder of bodily function (e.g., cancer (e.g., tumorigenic cells, leukemogenic cells or cancer stem cell growth)). Test compounds comprise both known and potential therapeutic compounds. A test compound can be determined to be therapeutic by screening using the screening methods of the present invention. A "known therapeutic compound" refers to a therapeutic compound that has been shown (e.g., through animal trials or prior experience with administration to humans) to be effective in such treatment or prevention. In
preferred embodiments, "test compounds" are anticancer agents. In particularly preferred embodiments, "test compounds" are anticancer agents that induce apoptosis in cells.
As used herein, the term "test compound library" refers to a mixture or collection of one or more compounds generated or obtained in any manner. Preferably, the library contains more than one compound or member. The test compound libraries employed in this invention may be prepared or obtained by any means including, but not limited to, combinatorial chemistry techniques, fermentation methods, plant and cellular extraction procedures and the like. Methods for making combinatorial libraries are well-known in the art (See, for example, E. R. Felder, Chimia 1994, 48, 512-541 ; Gallop et al, J. Med. Chem. 1994, 37, 1233-1251; R. A. Houghten, Trends Genet. 1993, 9, 235-239; Houghten et al, Nature 1991, 354, 84-86; Lam et al, Nature 1991, 354, 82-84; Carell et al, Chem. Biol. 1995, 3, 171-183; Madden et al, Perspectives in Drug Discovery and Design 2, 269-282; Cwirla et al, Biochemistry 1990, 87, 6378-6382; Brenner et al, Proc. Natl. Acad. Sci. USA 1992, 89, 5381-5383; Gordon et al, J. Med. Chem. 1994, 37, 1385-1401 ; Lebl et al, Biopolymers 1995, 37 177-198; and references cited therein. Each of these references is incorporated herein by reference in its entirety).
As used herein, the terms "drug" and "chemotherapeutic agent" refer to
pharmacologically active molecules that are used to diagnose, treat, or prevent diseases or pathological conditions in a physiological system (e.g., a subject, or in vivo, in vitro, or ex vivo cells, tissues, and organs). Drugs act by altering the physiology of a living organism, tissue, cell, or in vitro system to which the drug has been administered. It is intended that the terms "drug" and "chemotherapeutic agent" encompass anti-hyperproliferative and antineoplastic compounds as well as other biologically therapeutic compounds.
As used herein, the term "sample" is used in its broadest sense. In one sense, it is meant to include a specimen or culture obtained from any source, as well as biological and environmental samples. Biological samples may be obtained from animals (including humans) and encompass fluids, solids, tissues, and gases. Biological samples include blood products, such as plasma, serum and the like.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment, based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states.
In some embodiments, a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In certain embodiments, the different states of cancer stem cells are distinguished based on markers CD44+CD24", EpCam"CD49F+ (for EMT cancers stem cells), ALDH+ and EPCam+CD49 (for MET cancers stem cells), and CD44+CD24"ALDH+ (for EMT-MET cancer stem cells). In particular embodiments, micro R As are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).
There is increasing evidence that many human cancers, including breast cancer, are driven and maintained by cancer stem cells (CSCs) which mediate tumor metastasis and contribute to treatment resistance and relapse. The art described "breast cancer stem cells" (BCSCs) characterized by expression of the cell surface markers ESA and CD44 and the absence of expression of the marker CD24. More recently, it was demonstrated that breast cancer cells contain subpopulations with stem cell properties that can be isolated by virtue of their expression of Aldehyde dehydrogenase (ALDH) as assessed by the Aldefluor assay. Interestingly, these markers identify overlapping, but not identical cell populations.
Work conducted during development of embodiments of the present invention suggest that both normal and malignant breast stem cells exist in distinct, inter-convertible states (EMT and MET), the inter-conversion of which is regulated by microRNAs. EMT CSCs have a mesenchymal morphology, are largely quiescent, invasive and characterized by expression of the CSC markers CD24"CD44+ and are EpCAM-CD49f . In contrast, the MET (mesenchymal epithelial transition) state of CSCs is characterized by active self-renewal and expression of the CSC markers ALDH and EpCAM+CD49F+. A subpopulation of cells expressing both CD24"CD44+ and ALDH may represent cells in transition between these states. While not important to understand and practice the present invention and not limiting the present invention, it is believed that this transition is regulated by signals originating in the microenvironment which in turn modulate microRNA networks in the CSC populations. The existence of multiple stem cell states suggests the necessity of developing therapeutic strategies capable of effectively targeting CSCs in all of these states. In addition, since CSC states are regulated by miRNAs, these small non-coding RNAs may be useful therapeutic agents to target CSCs.
Until recently, the function of non-coding regions of the genome was unknown.
However, it is now clear that many of these regions code for microRNAs. Each microRNA is capable of regulating the expression of multiple proteins and as a result, can have very potent effects on cellular functions. The miRNA gene is first transcribed by RNA polymerase II into
a primary transcript (pri-miRNA) in the nucleus, where the hairpin stem-loop structure is processed into precursor miRNA (pre-miRNA) by a microprocessing complex, which includes Drosha and DGCR8. The 60-70 nt-long pre-miRNAs is exported from the nucleus. Within the cytoplasm, the RNAse III enzyme Dicer processes the pre-miRNA to yield the 18-25 nt mature miRNAs which mediate gene silencing through imperfect hybridization to 3' untranslated regions (3' UTR) in target mRNAs by modulating and modulate a variety of cellular processes including regulating m-RNA stability and proliferation, differentiation translation, microRNAs and apoptosis.
Work conducted during development of embodiments of the present invention determined that microRNAs regulate cancer stem cells (CSCs). Recent studies have demonstrated a link between dysregulated expression of miRNAs and carcinogenesis. A number of miRNAs have been shown to function as oncogenes or tumor suppressors during carcinogenesis. In addition, emerging evidence suggests that miRNAs also play essential roles in stem cell self-renewal and differentiation by negatively regulating the expression of key stem cell regulating genes. Furthermore, abnormal miRNA expression may result in dysregulation of self-renewal in cancer stem cells during cancer progression. Silber et al reported that mirl24 and mirl37 induce differentiation of neural and glioblastoma stem cells and induce cell cycle arrest. These results suggest that targeted delivery of mirl24 and mirl37 to glioblastoma cells may be therapeutically efficacious for the glioblastoma treatment. miRNA181 and miRNA 17-92 clusters were shown to be up-regulated in hepatocellular carcinoma (HCC) CSCs. More recently, Tang's group showed that prostate cancer stem and/or progenitor cell populations have lower levels of miR-34a and let-7b compared to bulk tumor cells. In addition, they reported that miR34a targets CD44, resulting in impaired tumor growth and decreased metastases in mouse models of prostate cancer. The increased survival of mice treated with systemically delivered miR34a suggests a novel strategy to target prostate CSCs, thereby inhibiting tumor growth and metastasis.
There have been a number of studies describing a role of microRNA in the regulation of normal and malignant breast stem cells. Hannon's group showed that both mir-205 and mir-22 are highly expressed in mouse mammary stem/progenitor cells whereas mir-93 and Let7 are depleted in this population. Rosen's group reported that miR-205 overexpression in mouse mammary cells led to an expansion of the progenitor cell population, decreased cell size and increased cellular proliferation. More recent studies have shown that overexpression of mir-200c reduced the clonogenic and tumor-initiation activities of BCSCs and suppressed mammary duct formation by normal mammary stem cells. This occurred through the down-
regulation of the polycomb gene Bmi-1, a target of mir-200c. This work demonstrated a molecular link between normal breast stem cells and BCSCs. Yu et al showed that Let7 is decreased in BCSCs and that overexpression of Let7 inhibits the cell proliferation, mammosphere formation, BCSC self-renewal and differentiation, and tumor formation and metastasis in NOD/SCID mice. These effects were shown to be mediated through down- regulation of the Let7 targets H-Ras and HMGA2. This group also demonstrated that expression of miR-30 markedly reduced BCSCs by targeting ubiquitin-conjugating enzyme 9 (UBC9) and integrin b3 (ITGB3). More complete inhibition of self-renewal and
mammosphere formation of BCSCs was observed when both Let7 and miR-30 were simultaneously introduced compared to each microRNA individually. The ability of these microRNAs to target BCSCs suggests that they may have significant therapeutic potential.
Epithelial to mesenchymal transition (EMT) is involved in many biological processes including embryonic development, wound healing and cancer progression. During EMT, epithelial cells lose cell-cell contacts and undergo cytoskeletal remodeling and polarity changes, resulting in acquisition of a mesenchymal morphology as well as enhanced migratory ability. Importantly, EMT is reversible and these cells can undergo a mesenchymal to epithelial transition (MET), so that polarized epithelium can be generated at a new site. Both EMT and MET play central roles in embryogenesis. During development, the process of epithelial-mesenchymal transition (EMT) is required for tissue and organ formation. The EMT state has been associated with loss of epithelial characteristics including apical basal polarity and expression of E-Cadherin and acquisition of mesenchymal characteristics including loss of polarity and increased expression of the transcription factors slug, snail and twist and mesenchymal proteins including vimentin and fibronectin. During early embryonic development, the mesoderm generated by EMTs develops into multiple tissue types, and later in development, mesodermal cells generate epithelial organs (e.g., kidney and ovary) by
METs. In adult tissues, TGF-β can induce EMT characterized by downregulation of epithelial markers such as E-cadherin and upregulation of EMT-inducing factors, such as Twist and Snail. It has been proposed that EMT plays an important role in tumorigenesis and progression. Furthermore, a number of developmental pathways such as the Wnt and HGF- cMet pathways which are frequently deregulated in cancers are also regulators of EMT. Both the inflammatory immune response and the hypoxic tumor environment induce EMT in cancers. It is increasingly recognized that EMT plays an important role in the metastasis of breast cancer and other types of carcinoma. EMT has also been implicated in therapeutic resistance and tumor recurrence. Since EMT is a key developmental program that is often
activated during cancer invasion and metastasis, and CSCs that maintain and initiate tumors have also been implicated in invasion and metastasis, the relationship between EMT and CSCs is an important question.
A defining characteristic of CSCs is their ability to self-renew, a property that endows these cells with the ability to initiate and sustain tumor growth. However, although the EMT state has been linked to tumor invasion and metastasis, EMT cells are largely quiescent. The differences in invasive and proliferative characteristics of CSCs and EMT cells has led to the proposition that CSCs and EMTs are mutually exclusive.
Recently it has been suggested that expression of the cell surface markers EpCAM and CD49f can be used to define functional populations of normal mouse and human mammary cells. Based on in vitro and mouse fat pad re-implantation studies it has been suggested that EpCAM-CD49f cells represent mammary stem cells, EpCAM+CD49+ (double-positive cells): luminal progenitors; EpCAM+CD49f : epithelial cells; and EpCAM" CD49f : stromal cells. However, double-positive (EpCAM+CD49f ) so-called luminal progenitor cells, have been found to give rise to basal as well as luminal cells when cultured in vitro. Furthermore, it has recently been reported that both the EpCAM" CD49f and EpCAM+CD49f fractions of normal human mammary cells have the ability to form complete mammary trees consisting of basal as well as luminal cells when transplanted into the fat pads of immunosuppressed mice, which have been "humanized" with normal mammary fibroblasts. These results suggest that in addition to luminal progenitors, the
EpCAM+CD49 population may also contain a sub-population with stem cell characteristics.
As described previously, CD24"CD44+ and ALDH identify overlapping, but not identical cell populations. Work conducted during the development of embodiments of the present invention generated data indicating that EpCAM+CD49f cells (MET) contain an ALDH enriched population, whereas CD24"CD44+ cells are mainly contained in EpCAM" CD49f population (EMT). These results suggest a model in which breast cancer stem cells can exist in two alternative states: one, an EMT state which is EpCAM"CD49f expresses the stem cell markers CD24"CD44+, and an MET population which is EpCAM+CD49 (double- positive) and expresses the CSC marker ALDH (Figure 7A).
There is substantial evidence linking BCSCs and EMT. BCSCs isolated from primary breast tumors and metastatic pleural effusions express EMT markers. However, there is less evidence linking BCSCs and MET. Consistent with the expression of EMT markers by BCSCs, these cells also express EMT related microR As. miR A expression profiling of BCSCs isolated from human breast tumors compared to the remaining breast cancer cells
revealed high levels of expression of EMT-inducing miR-155. Furthermore, mir-200 which is downregulated in BCSCs is associated with MET.
Work conducted during the development of embodiments of the present invention demonstrated that the double-positive EpCAM+CD49f population is characterized by the highest expression of mir-93 and that forced overexpression of mir-93 increases the proportion of EpCAM+CD49 and ALDH+ cells in non-transformed MCF- IOA cells as well as primary normal human mammary cells isolated from reduction mammoplasty specimens. Furthermore, it was demonstrated that expression levels of mir-221 and mir- 100 are significantly higher in EpCAM"CD49f and EpCAM"CD49f populations than in
EpCAM+CD49f and EpCAM+CD49f populations. Furthermore, forced over-expression of mir-100 or mir-221 increased the proportion of EpCAM" CD49f^ cells in non-transformed MCF- IOA cells as well as primary normal human mammary cells isolated from reduction mammoplasty specimens. This resulted in an increase in the proportion of CD247CD44+ CSC cells with a concomitant decrease in the ALDH+ CSC population. These results indicate that mir-93, mir- 100 and mir-221 are important regulators of the transition between the EMT and MET stem cell states. It was demonstrated that induction of mir-93 in EMT SUM159 cells induces an MET in the ALDH-positive CSC population characterized by increased expression of E-Cadherin and Claudin, and down-regulation of mesenchymal genes, such as vimentin, N-Cadherin and Twist. It was found that mir-93 also inhibits TGFp signaling by targeting TGFpR2, an effect seen within twelve hours of mir-93 induction. This was followed by an EMT/MET transition in the Aldefluor-positive CSC population. Since TGFp is a major regulator of EMT, abrogation of this signaling pathway may facilitate MET.
Of interest, it has been recently reported that the mirl06b-25 cluster including mir-93 is induced in the early stages of nuclear reprogramming of fibroblasts into IPS cells. This is accompanied by an EMT to MET conversion in these cells which is obligatory for reprogramming to occur. This suggests that this miRNA cluster may regulate EMT to MET in multiple biological contexts. Furthermore, expression of mir-100 or mir-221 in MCF 10A cells and several cancer cell lines resulted in a decrease of the ALDH-positive CSC population with a concomitant increase in the CD24"CD44+ population accompanied by induction of EMT. Work conducted during development of embodiments of the present invention demonstrated mir- 100 effects are mediated by targeting BMPR2, SMARCA5 and SMARCD l , all of which may contribute to induction of EMT.
The existence of reversible alternative states of CSCs provides an explanation for the seemingly disparate hypothesis concerning the relationship between CSCs and EMT. While
the present invention is not limited to any particular mechanism and an understanding of the mechanism is not necessary to practice the present invention, it is believed that CSCs may exist in either EMT or MET states, the inter-conversion of which is regulated by the microenvironment which in turn regulates CSC microRNA networks as illustrated in Figure 7B. The existence of alternative CSC states provides an explanation for how these cells promote tumor invasion as well as growth at metastatic sites. For example, it has been shown that bladder cancer cells selected for bone metastatic competence are overtly epithelial as compared to their parental cell. Similarly, human breast cancer, liver, lung and brain metastasis often express more E-cadherin than their corresponding primary tumors.
Again, while the present invention is not limited to any particular mechanism and an understanding of the mechanism is not necessary to use the present invention, a hypothetical model is proposed (Figure 8) in which CSCs located inside the tumor mass exist
predominantly in the MET state in which they are highly proliferative and express ALDH, in contrast at the tumor invasive front, factors such as TGF-β in the microenvironment induce EMT in the CSC populations. The population which is characterized as CD24"CD44+ is highly invasive and mediates tumor invastion and metastasis. The association of EMT and invasion is supported by studies demonstrating that down-regulation of mir-93 using a mirZIP vector or upregulation of mir-100 increases the invasiveness of cancer cells. Highly invasive EMT/CSCs enter the circulation and travel to distant organs where they form micrometastasis. This scenario is supported by studies showing that in women with breast cancer, bone micrometastasis express CSC markers such as CD24"CD44+ as well as EMT markers such as vimentin. These micrometastasis are largely quiescent as indicated by their lack of expression of markers of cellular proliferation such as Ki67. In order to enter a proliferative state, EMT/CSC cells undergo an MET transition in which they lose their invasive characteristics and acquire self-renewal capacity. Self-renewing MET/CSCs in turn drive tumor growth at metastatic sites. In this hypothetical model, the balance of EMT/MET states of CSCs regulated by miRNAs plays an important role in mediating tumor invasion and metastasis, as well as maintaining tumor dormancy or promoting tumor growth at metastatic sites.
The ability of CSCs to exist in alternative EMT and MET states, the transition of which is believed to be regulated by the microenvironment and mediated by miRNAs has important implications for understanding the role of the cells carcinogenesis, invasion and metastasis. In addition, the existence of alternative CSC states, associated with expression of different protein markers has important implications for understanding the plasticity of CSCs.
For example, it has been claimed that CSCs may be generated from non-CSC tumor populations through induction of EMT. However, the existence of alternative CSC state suggests that the acquisition of stem cell markers may reflect transition of CSC states rather than generation of CSCs from non-CSC populations. In addition, the existence of multiple stem cell states suggests the necessity of developing therapeutic strategies capable of effectively targeting CSCs in all of these states. Dysregulation of microRNAs has been implicated in tumor development and microRNAs plays important roles in regulating cancer stem cells. Since CSCs have been shown to be involved in tumor initiation, tumor maintenance, metastasis, and therapeutic resistance, the regulation of microRNA networks in CSCs provides novel therapeutic targets.
The existence of multiple CSC states also has important therapeutic implications, since CSCs in these states may respond differently to therapeutic agents. Nevertheless, the complexity of regulatory pathways in CSCs, as well as the heterogeneity of these cell populations, suggests that it may be beneficial to combine multiple CSC-targeting agents to eliminate all CSC populations and thus improve the outcome for cancer patients.
The principles of normal stem cell biology have been applied to isolate and characterize cancer stem cells. Examples of cancers from which cancer stem cells can be isolated or enriched, and targeted, according to the present invention include, but are not limited to, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), leukemias (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic, (granulocytic) leukemia, and chronic lymphocytic leukemia), and sarcomas and carcinomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma,
lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma). The invention is also
applicable to sarcomas and epithelial cancers, such as ovarian cancers and breast cancers, as well as to all solid tumors.
A subject's (e.g., a particular cancer patient's) cancer stem cells (e.g., once isolated and allowed to proliferate in vitro), can be analyzed and screened. For example, in some embodiments, analyzing a subject's cancer stem cells is used as a diagnostic for the subject (e.g., the identification of biomarkers present within the cancer cells can be used to provide to the subject a prognosis (e.g., of morbidity or mortality associated with the cancer, or, the likelihood of the cancer to respond to a therapeutic treatment).
Thus, in some embodiments, the present invention provides methods for detection of expression of cancer stem cell biomarkers to identify if the patient has EMT, MET, EMT- MET cancer stem cells or combinations thereof. In some embodiments, expression is measured directly (e.g., at the nucleic acid or protein level). In some embodiments, expression is detected in tissue samples (e.g., biopsy tissue). In other embodiments, expression is detected in bodily fluids (e.g., including but not limited to, plasma, serum, whole blood, mucus, and urine). The present invention further provides panels and kits for the detection of biomarkers. In certain embodiments, the presence of a cancer stem cell biomarker is used to provide a prognosis to a subject. For example, the detection of a cancer stem cell biomarker in cancerous tissues may be indicative of a cancer that is or is not likely to metastasize. In addition, the expression level of a cancer stem cell biomarker may be indicative of a transformed cell, cancerous tissue or a cancer likely to metastasize.
The information (e.g., state of the cancer cells from a subject) provided can also be used to direct the course of treatment. For example, if a subject is found to possess or lack a cancer stem cell biomarker that is likely to metastasize, therapies can be chosen to optimize the response to treatment (e.g., for subjects with a high probability of possessing a metastatic cancer more aggressive forms of treatment can be used).
Cancer stem cell biomarkers identified as being up or down-regulated in cancer stem cells using the methods of the present invention are further characterized using microarray (e.g., nucleic acid or tissue microarray), immunohistochemistry, Northern blot analysis, siRNA or antisense RNA inhibition, mutation analysis, investigation of expression with clinical outcome, as well as other methods disclosed herein.
In some embodiments, the present invention provides a panel for the analysis of a plurality of biomarkers. The panel allows for the simultaneous analysis of multiple biomarkers correlating with carcinogenesis, metastasis and/or angiogenesis associated with cancer. For example, a panel may include biomarkers identified as correlating with
cancerous tissue, metastatic cancer, localized cancer that is likely to metastasize, precancerous tissue that is likely to become cancerous, pre-cancerous tissue that is not likely to become cancerous, and cancerous tissues or cells likely or not likely to respond to treatment. Depending on the subject, panels may be analyzed alone or in combination in order to provide the best possible diagnosis and prognosis. Markers for inclusion on a panel are selected by screening for their predictive value using any suitable method. In certain embodiments, the panels contain reagents for detecting CD44, CD24, EpCam, CD49f, ALDH, mir-221, mir-110, and/or mir-93.
In some preferred embodiments, cancer stem cell biomarkers (e.g., including but not limited to, those disclosed herein) are detected by measuring the levels of the cancer stem cell biomarker in cells and tissue (e.g., cancer cells and tissues). For example, in some embodiments, a cancer stem cell biomarker are monitored using antibodies or by detecting a cancer stem cell biomarker protein/nucleic acid (e.g., CD44, CD24, EpCam, CD49f, ALDH, mir-221, mir-110, and/or mir-93). In some embodiments, detection is performed on cells or tissue after the cells or tissues are removed from the subject. In other embodiments, detection is performed by visualizing the cancer stem cell biomarker in cells and tissues residing within the subject.
In some preferred embodiments, cancer stem cell biomarker are detected by measuring the expression of corresponding mRNA in a tissue sample (e.g., cancerous tissue). In some embodiments, RNA is detected by Northern blot analysis. Northern blot analysis involves the separation of RNA and hybridization of a complementary labeled probe.
In still further embodiments, RNA (or corresponding cDNA) is detected by hybridization to a oligonucleotide probe. A variety of hybridization assays using a variety of technologies for hybridization and detection are available. For example, in some
embodiments, a TaqMan assay (PE Biosystems, Foster City, CA; See e.g., U.S. Patent Nos. 5,962,233 and 5,538,848, each of which is herein incorporated by reference) is utilized. The assay is performed during a PCR reaction. The TaqMan assay exploits the 5'-3' exonuclease activity of the AMPLITAQ GOLD DNA polymerase. A probe consisting of an
oligonucleotide with a 5'-reporter dye (e.g., a fluorescent dye) and a 3'-quencher dye is included in the PCR reaction. During PCR, if the probe is bound to its target, the 5'-3' nucleolytic activity of the AMPLITAQ GOLD polymerase cleaves the probe between the reporter and the quencher dye. The separation of the reporter dye from the quencher dye results in an increase of fluorescence. The signal accumulates with each cycle of PCR and can be monitored with a fluorimeter.
In yet other embodiments, reverse-transcriptase PCR (RT-PCR) is used to detect the expression of RNA. In RT-PCR, RNA is enzymatically converted to complementary DNA or "cDNA" using a reverse transcriptase enzyme. The cDNA is then used as a template for a PCR reaction. PCR products can be detected by any suitable method, including but not limited to, gel electrophoresis and staining with a DNA specific stain or hybridization to a labeled probe. In some embodiments, the quantitative reverse transcriptase PCR with standardized mixtures of competitive templates method described in U.S. Patents 5,639,606, 5,643,765, and 5,876,978 (each of which is herein incorporated by reference) is utilized.
In other embodiments, gene expression of a cancer stem cell biomarker is detected by measuring the expression of the corresponding protein or polypeptide. Protein expression may be detected by any suitable method. In some embodiments, proteins are detected by immunohistochemistry. In other embodiments, proteins are detected by their binding to an antibody raised against the protein.
Antibody binding is detected by techniques known in the art (e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), "sandwich" immunoassays,
immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (e.g., using colloidal gold, enzyme or radioisotope labels, for example), Western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays, etc.), complement fixation assays, immunofluorescence assays, protein A assays, and Immunoelectrophoresis assays, etc.
In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many methods are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.
In some embodiments, an automated detection assay is utilized. Methods for the automation of immunoassays include those described in U.S. Patents 5,885,530, 4,981,785, 6, 159,750, and 5,358,691, each of which is herein incorporated by reference. In some embodiments, the analysis and presentation of results is also automated. For example, in some embodiments, software that generates a prognosis based on the presence or absence of a series of proteins corresponding to cancer markers is utilized. In other embodiments, the immunoassay described in U.S. Patents 5,599,677 and 5,672,480; each of which is herein incorporated by reference.
In yet other embodiments, the present invention provides kits for the detection and characterization of cancer stem cell biomarkers (e.g., CD44, CD24, EpCam, CD49f, ALDH, mir-221, mir-110, and/or mir-93). In some preferred embodiments, the kit contains cancer stem cells. In some embodiments, the kits contain antibodies specific for a cancer stem cell biomarker, in addition to detection reagents and buffers. In other embodiments, the kits contain reagents specific for the detection of mRNA or cDNA (e.g., oligonucleotide probes or primers). In preferred embodiments, the kits contain all of the components necessary to perform a detection assay, including all controls, directions for performing assays, and any necessary software for analysis and presentation of results.
In some embodiments, in vivo imaging techniques are used to visualize the expression of a cancer stem cell biomarker in an animal (e.g., a human or non-human mammal). For example, in some embodiments, a cancer stem cell biomarker mRNA or protein is labeled using an labeled antibody specific for the cancer stem cell biomarker. A specifically bound and labeled antibody can be detected in an individual using an in vivo imaging method, including, but not limited to, radionuclide imaging, positron emission tomography, computerized axial tomography, X-ray or magnetic resonance imaging method, fluorescence detection, and chemiluminescent detection. Methods for generating antibodies to the cancer stem cell biomarkers of the present invention are described herein.
The in vivo imaging methods of the present invention are useful in the diagnosis of cancers that express a cancer stem cell biomarker of the present invention (e.g., cancerous cells or tissue). In vivo imaging is used to visualize the presence of a biomarker indicative of a cancer stem cell. Such techniques allow for diagnosis without the use of a biopsy. The in vivo imaging methods of the present invention are also useful for providing prognoses to cancer patients. For example, the presence of a cancer stem cell biomarker indicative of an aggressive cancer likely to metastasize or likely to respond to a certain treatment can be detected. The in vivo imaging methods of the present invention can further be used to detect a cancer stem cell (e.g., one that has metastasized) in other parts of the body.
In some embodiments, reagents (e.g., antibodies) specific for a cancer stem cell biomarker of the present invention are fluorescently labeled. The labeled antibodies are introduced into a subject (e.g., orally or parenterally). Fluorescently labeled antibodies are detected using any suitable method (e.g., using the apparatus described in U.S. Patent 6, 198, 107, herein incorporated by reference). In some embodiments, flow-cytometry is utilized to monitor (e.g., detect) a marker (e.g., a cancer stem cell biomarker of the present
invention). The use of flow-cytometry to identify and/or isolate and/or purify cell populations is well known in the art (See, e.g., Givan, Methods Mol Biol 263, 1-32 (2004)).
In other embodiments, antibodies are radioactively labeled. The use of antibodies for in vivo diagnosis is well known in the art. Sumerdon et ah, (Nucl. Med. Biol 17:247-254 (1990) have described an optimized antibody-chelator for the radioimmunoscintographic imaging of tumors using Indium- 1 1 1 as the label. Griffin et ah, (J Clin One 9:631-640 (1991)) have described the use of this agent in detecting tumors in patients suspected of having recurrent colorectal cancer. The use of similar agents with paramagnetic ions as labels for magnetic resonance imaging is known in the art (Lauffer, Magnetic Resonance in Medicine 22:339-342 (1991)). The label used will depend on the imaging modality chosen. Radioactive labels such as Indium- 1 11, Technetium-99m, or Iodine- 131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting labels such as Fluorine- 19 can also be used for positron emission tomography (PET). For MRI, paramagnetic ions such as Gadolinium (III) or Manganese (II) can be used.
An antibody against a biomarker of the present invention may be any monoclonal or polyclonal antibody, as long as it can recognize the cancer stem cell biomarker. Antibodies can be produced by using a cancer stem cell biomarker of the present invention as the antigen according to a conventional antibody or antiserum preparation process.
Cancer stem cells (e.g., populations representing both MET and EMT cancer stem cells) of the present invention can be used to determine the effect of test compounds (e.g., small molecule inhibitors, pharmaceuticals, biological agents, etc.). Examples of test compounds include, but are not limited to, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, amino acids, peptides, oligopeptides, polypeptides, proteins, nucleosides, nucleotides, oligonucleotides, polynucleotides, including DNA and DNA fragments, RNA and RNA fragments and the like, lipids, retinoids, steroids, drug, antibody, prodrug, glycopeptides, glycoproteins, proteoglycans and the like, and synthetic analogues or derivatives thereof, including peptidomimetics, small molecule organic compounds and the like, and mixtures thereof (e.g., that is a candidate for use to treat or prevent a disease, illness, sickness, or disorder of bodily function (e.g., cancer (e.g., cancer stem cell growth)). Test compounds comprise both known and potential therapeutic compounds. A test compound can be determined to be therapeutic by screening using the screening methods of the present invention. To determine the effect of a test compound on cancer stem cells, cancer stem cells can be obtained from a subject with cancer. Once obtained, cancer stem cells can be cultured in vitro or in vivo and exposed to a test compound.
The ability of test compounds to alter (e.g., increase or decrease) cancer stem cell growth or maintenance, as well as the effect on normal HSCs, can be assayed. For example, in some embodiments, test compounds (e.g., from a library of compounds) are screened for their ability to alter (e.g., eliminate or inhibit growth of) cancer stem cells, while concurrently monitoring the effect on HSCs (e.g., driving HSCs into quiescence). Screening in this way permits the identification of compounds that can be utilized (e.g., independently, in a pharmaceutical composition, or co-administered) for treating cancer (e.g., inhibiting or eliminating cancer stem cells while having no harmful effect on normal HSCs).
In some embodiments, test compounds can be solubilized and added to cancer stem cells (e.g., in vitro (e.g., in the culture medium), or, in vivo (e.g., to a recipient subject that has received a cancer stem cell graft)). In some embodiments, various concentrations of the test compound are utilized to determine an efficacious dose. In some embodiments, administration of the test compound is consistent over a period of time (e.g., administered to a recipient one, two or more times a day, or, added to media in vitro) so as to keep the concentration of the test compound constant.
Alteration (e.g., inhibiting growth or promoting death or permitting maintenance) of cancer stem cells, and normal stem cells, can be monitored in vitro or in vivo. For example, an increase or decrease in the number of cancer cells (e.g., cancer stem cell progeny) that form or an increase or decrease in the size of the foci in vitro, or growth rate of cancer cells (e.g., cancer stem cell progeny can be monitored. The effect of a test compound on cancer stem cells and normal HSCs can be measured by determining the number of cancer stem cells that persist in culture or in vivo after treatment (e.g., administration of the test compound). In addition, cancer stem cell and HSC status (e.g., cell cycle status, cancer stem cell biomarker expression, etc.) can be determined (e.g., using compositions and methods described herein).
Test compounds can be administered in vitro or in vitro at a variety of concentrations.
For example, in some embodiments, test compounds are added to culture medium or to a subject so as to achieve a concentration from about 10 pg/ml to 1 μg/ml, or from about 1 ng/ml (or 1 ng/cc of blood) to 100 ng/ml (or 100 ng/cc of blood).
The effects of a test compound can also be identified on the basis of a significant difference relative to a control regarding criteria such as the ratios of expressed phenotypes, cell viability, proliferation rate, number of cancer stem cells, cancer stem cell activity upon transplantation in vivo, cancer stem cell activity upon transplantation in culture, cell cycle distribution of cancer cells, and alterations in gene expression.
The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone, which are resistant to enzymatic degradation but which nevertheless remain bioactive (See, e.g., Zuckennann et al, J. Med. Chem. 37: 2678-85
(1994)); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the One-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library and peptoid library approaches are preferred for use with peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) Anticancer Drug Des. 12: 145).
Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al, Proc. Natl. Acad. Sci. U.S.A. 90:6909 (1993); Erb et al, Proc. Nad. Acad. Sci. USA 91 : 11422 (1994); Zuckermann et al, J. Med. Chem. 37:2678 (1994); Cho et al, Science 261 : 1303 (1993); Carrell et al, Angew. Chem. Int. Ed. Engl. 33.2059
(1994); Carell et al, Angew. Chem. Int. Ed. Engl. 33:2061 (1994); and Gallop et al, J. Med. Chem. 37: 1233 (1994), each of which is incorporated by reference herein in its entirety.
Alternatively, the test compound libraries employed in this invention may be prepared or obtained by any means including, but not limited to, combinatorial chemistry techniques, fermentation methods, plant and cellular extraction procedures and the like. Methods for making combinatorial libraries are well-known in the art (See, e.g., E. R. Felder, Chimia 1994, 48, 512-541; Gallop et al., J. Med. Chem. 1994, 37, 1233-1251; R. A. Houghten, Trends Genet. 1993, 9, 235-239; Houghten et al, Nature 1991, 354, 84-86; Lam et al, Nature 1991, 354, 82-84; Carell et al, Chem. Biol. 1995, 3, 171-183; Madden et al, Perspectives in Drug Discovery and Design 2, 269-282; Cwirla et al, Biochemistry 1990, 87, 6378-6382;
Brenner et al, Proc. Natl. Acad. Sci. USA 1992, 89, 5381-5383; Gordon et al., J. Med. Chem. 1994, 37, 1385-1401; Lebl et al, Biopolymers 1995, 37 177-198; and references cited therein. Each of these references is incorporated herein by reference in its entirety).
Libraries of test compounds may be presented in solution (e.g., Houghten,
Biotechniques 13 :412-421 (1992)), or on beads (Lam, Nature 354:82-84 (1991)), chips
(Fodor, Nature 364:555-556 (1993)), bacteria or spores (U.S. Patent No. 5,223,409; herein incorporated by reference), plasmids (Cull et al, Proc. Nad. Acad. Sci. USA 89: 18651869 (1992)) or on phage (Scott and Smith, Science 249:386-390 (1990); Devlin Science 249:404-
406 (1990); Cwirla et al, Proc. Natl. Acad. Sci. 87:6378-6382 (1990); Felici, J. Mol. Biol. 222:301 (1991)).
In addition to active ingredients, test compounds may comprise suitable
pharmaceutically acceptable carriers comprising excipients and auxiliaries, that facilitate processing of the active compounds into preparations which can be used pharmaceutically.
In certain embodiments, one can test whether inhibiting IL6, Notch, Wnt, Hedgehog or TGF can decrease EMT BCSCs induced with mir-100 overexpression by flow cytometry analysis for CD24-CD44+ and sensitize the tumor cells to chemotherapy both in vitro and in vivo. IL6, TGF , Hedgehog, WNT and/or Notch activity is necessary for maintaining EMT. Work conducted during embodiments of the present invention has shown that mir-100 over- expression can switch the breast cancer stem cells to EMT state which is characterized by EpCAM" and CD24"CD44+. The potential for inhibiting these pathways to alter CSC/EMT status and block resistance to chemotherapy provide insight to using combination treatment. One can establish cancer cell lines or cells from primary human breast cancer xenografts or fresh tumor tissues from different subtypes with inducible mir-100 overexpression, and treat them with the inhibitor for each of these pathways (IL-6, TGF , Hedgehog, WNT and/or Notch) docetaxel and combination to evaluate the percentage/absolute number change of EMT BCSCs and tumor growth. It may be that the EMT BCSCs by mir-100 overexpression will be sensitive to most or all of the inhibitors against to these pathways, which will sensitize the tumor's response to chemotherapy.
In some embodiments, one can test whether a Pan-erb blocker or Her2 pathway inhibitor can decrease MET BCSCs induced with mir-93 over-expression by flow cytometry analysis for ALDH+ and sensitize the tumor cells to chemotherapy both in vitro and in vivo. Work conducted during development of embodiments of the present invention showed that Her2 -positive luminal cells have more BCSCs characterized by ALDH+. Data generated has shown that mir-93 overexpression can switch the breast cancer stem cells to MET state which is characterized by EpCAM+ and ALDH+. Therefore, one may inhibit the her2 pathway to alter CSC/MET status and block resistance to chemotherapy and provide insight to using combination treatment. One could establish cancer cell lines or cells from primary human breast cancer xenografts or fresh tumor tissues from different subtypes with inducible mir-93 over-expression, and treat them with the Pan-erb blocker, docetaxel and combination to evaluate the percentage/absolute number change of MET BCSCs and tumor growth. It may be that the MET BCSCs by mir-93 over-expression will be sensitive to Pan-erb blockers, which will sensitize the tumor's response to chemotherapy.
In particular embodiments, one could combine the approaches described in the two paragraphs above to test whether combination therapy can decrease or eradiate all BCSCs by flow cytometry analysis for both CD24"CD44+ and ALDH+, and sensitize the tumor cells to chemotherapy both in vitro and in vivo. Since it has been shown that BCSCs exist in two states within a tumor, it is believed that targeting only one state of BCSCs will not be efficient. It is expected that this combination therapy will dramatically shrink the tumor and completely wipe out BCSCs and prevent the relapse.
In some embodiments, microRNA 100 (or mir-221) and microRNA93 can be utilized as biomarkers to help patients find the individualized combination therapy targeting both states of BCSCs and the bulk tumor cells. Such detecting can employ microRNA ISH staining with the slide section from paraffin-embedded clinical human breast tumor specimens, or can detect the microRNA expression level in patient blood serum by qRT- PCR. Based on different microRNA expression in the tumor specimens and blood, one can predict which patient will more likely develop distant metastasis and help determine the best combination therapy for the patients.
This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein (e.g., a test compound that: eliminates or inhibits growth of a cancer stem cell while leaving unharmed (e.g., inducing quiescence of) normal stem cells; acts as a cancer stem cell biomarker modulating agent; an antisense cancer stem cell biomarker nucleic acid molecule; a siRNA molecule; a cancer stem cell biomarker specific antibody; or a cancer stem cell biomarker-binding partner) in an appropriate animal model to determine the efficacy, toxicity, side effects, or mechanism of action, of treatment with such an agent. Furthermore, novel agents identified by the above-described screening assays can be, e.g., used for treatments as described herein.
It is contemplated that pharmaceutical compositions comprising a successfully identified test compound (e.g., a test compound identified that is capable of altering (e.g., inhibiting growth or eliminating) cancer stem cells while concurrently not harming (e.g., inducing quiescence of) normal HSCs), analogue or mimetic can be administered systemically or locally to alter cancer stem cell growth and induce cancer (e.g., tumor) cell death in cancer patients by targeting both EMT and MET cancer stem cells.
It is not intended that the present invention be limited by the particular route of administration. Indeed, a variety of administrative routes are contemplated to be useful in the present invention including, but not limited to, intravenously, intrathecally, intramuscularly,
intraperitoneally as well as orally. Moreover, they can be administered alone or in combination with anti-proliferative drugs.
Where combinations are contemplated, it is not intended that the present invention be limited by the particular nature of the combination. The present invention contemplates combinations as simple mixtures as well as chemical hybrids. An example of the latter is where a peptide or drug is covalently linked to a targeting carrier or to an active
pharmaceutical. Covalent binding can be accomplished by any one of many commercially available crosslinking compounds.
It is not intended that the present invention be limited by the particular nature of the therapeutic preparation. For example, such compositions can be provided together with physiologically tolerable liquid, gel or solid carriers, diluents, adjuvants and excipients.
These therapeutic preparations can be administered to mammals for veterinary use, such as with domestic animals, and clinical use in humans in a manner similar to other therapeutic agents. In general, the dosage required for therapeutic efficacy will vary according to the type of use and mode of administration, as well as the particularized requirements of individual hosts.
Such compositions are typically prepared as liquid solutions or suspensions, or in solid forms. Oral formulations for cancer usually will include such normally employed additives such as binders, fillers, carriers, preservatives, stabilizing agents, emulsifiers, buffers and excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, and typically contain l%-95% of active ingredient, preferably 2%- 70%. The compositions are also prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The compositions of the present invention are often mixed with diluents or excipients which are physiological tolerable and compatible. Suitable diluents and excipients are, for example, water, saline, dextrose, glycerol, or the like, and
combinations thereof. In addition, if desired the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents. Additional formulations which are suitable for other modes of administration, such as topical administration, include salves, tinctures, creams, lotions, and, in some cases, suppositories. For salves and creams, traditional binders, carriers and excipients may include, for example, polyalkylene glycols or triglycerides.
It may be desirable to administer an analogue of a successfully identified test compound (e.g., a test compound identified that is capable of altering both EMT and MET cancer stem cells). A variety of designs for such mimetics are possible. For example, cyclic peptides, in which the necessary conformation for binding is stabilized by nonpeptides, are specifically contemplated. (See, e.g., U.S. Pat. No. 5, 192,746 to Lobl et al, U.S. Pat. No. 5, 169,862 to Burke, Jr. et al., U.S. Patent No. 5,539,085 to Bischoff et al, U.S. Patent No. 5,576,423 to Aversa et al., U.S. Pat. No. 5,051,448 to Shashoua, and U.S. Patent No.
5,559, 103 to Gaeta et al, all hereby incorporated by reference, describe multiple methods for creating such compounds).
Synthesis of nonpeptide compounds that mimic peptide sequences is also known in the art. For example, Eldred et al, J. Med. Chem. 37:3882 (1994), describe nonpeptide antagonists that mimic the Arg-Gly-Asp sequence. Likewise, Ku et al, J. Med. Chem. 38:9 (1995) give further elucidation of the synthesis of a series of such compounds. Such nonpeptide compounds are specifically contemplated by the present invention.
The present invention also contemplates synthetic mimicking compounds that are multimeric compounds that repeat the relevant peptide sequence. As is known in the art, peptides can be synthesized by linking an amino group to a carboxyl group that has been activated by reaction with a coupling agent, such as dicyclohexyl-carbodiimide (DCC). The attack of a free amino group on the activated carboxyl leads to the formation of a peptide bond and the release of dicyclohexylurea. It may be important to protect potentially reactive groups other than the amino and carboxyl groups intended to react (e.g., the x-amino group of the component containing the activated carboxyl group can be blocked with a
tertbutyloxycarbonyl group). This protecting group can be subsequently removed by exposing the peptide to dilute acid, which leaves peptide bonds intact.
With this method, peptides can be readily synthesized by a solid phase method by adding amino acids stepwise to a growing peptide chain that is linked to an insoluble matrix, such as polystyrene beads. The carboxyl-terminal amino acid (with an amino protecting group) of the desired peptide sequence is first anchored to the polystyrene beads. The protecting group of the amino acid is then removed. The next amino acid (with the protecting group) is added with the coupling agent. This is followed by a washing cycle. The cycle is repeated as necessary.
The methods of the present invention can be practiced in vitro, ex vivo, or in vivo. For example, the method of the present invention can be used in vitro to screen for compounds which are potentially useful for combinatorial use with a successfully identified
test compound for treating cancer (e.g., lymphoma, leukemia, prostate, lung, stomach, breast, colon, and/or pancreatic cancer); to evaluate a test compound's efficacy in treating cancer; or to investigate the mechanism by which a test compound combats cancer (e.g., whether it does so by inducing apoptosis, by inducing differentiation, by decreasing proliferation, etc). For example, once a compound has been identified as a compound that works, one skilled in the art can apply the method of the present invention in vitro to evaluate the degree to which the compound induces apoptosis and/or decreases angiogenesis, proliferation of cancer cells; or one skilled in the art can apply the method of the present invention to determine whether the compound operates by inducing apoptosis, by decreasing proliferation and/or angiogenesis, or by a combination of these methods.
Alternatively, a method of the present invention can be used in vivo to treat cancers, (e.g., including, but not limited to, lymphoma, leukemia, prostate cancer, lung cancer, stomach cancer, pancreatic cancer, breast cancer, and colon cancer). In the case where a method of the present invention is carried out in vivo, for example, where the cancer cells are present in a human subject, contacting can be carried out by administering a therapeutically effective amount of the compound to the human subject (e.g., by directly injecting the compound into a tumor or through systemic administration).
In some embodiments, the present invention provides high throughput screening of test compounds. For example, in some embodiments, large numbers of different test compounds (e.g., from a test compound library, described above) are provided (e.g. attached to or synthesized) on a solid substrate. Test compounds can be reacted with cancer stem cells, or portions thereof, and washed. Bound cancer stem cells are then detected by methods well known in the art, using commercially available machinery and methods (e.g., the Automated Assay Optimization (AAO) software platforms (Beckman, USA) that interface with liquid handlers to enable direct statistical analysis that optimizes the assays; modular systems from CRS Robotics Corp. Burlington, Ontario), liquid handling systems, readers, and incubators, from various companies using POLARA (CRS), an open architecture laboratory automation software for a Ultra High Throughput Screening System; 3P (Plug&Play
Peripherals) technology, which is designed to allow the user to reconfigure the automation platform by plugging in new instruments (ROBOCON, Vienna, Austria); the Allegro system or STACCATO workstation (Zymark), which enables a wide range of discovery applications, including HTS, ultra HTS, and high-speed plate preparation; MICROLAB Vector software (Hamilton Co., Reno, Nev., USA) for laboratory automation programming and integration; and others).
In some embodiments, assays measure a response the target cells (cancer stem cells or genetically modified cancer stem cells) provide (e.g., detectable evidence that a test compound may be efficacious). In some embodiments, the detectable signal is compared to control cells and the detectable signal identified by subtraction analysis. The relative abundance of the differences between the "targeted" and "untargeted" aliquots can be simultaneously compared (e.g., using a "subtraction" analysis (differential analysis) technique such as differential display, representational difference analysis (RDA), GEM-Gene
Expression Microarrays (U.S. Pat. No. 5,545,531), suppressive subtraction hybridization (SSH) and direct sequencing (PCT patent application WO 96/17957). The subtraction analysis can include the methods of differential display, representational differential analysis (RDA), suppressive subtraction hybridization (SSH), serial analysis of gene expression (SAGE), gene expression microarray (GEM), nucleic acid chip technology, or direct sequencing).
In certain embodiments, the present invention provides method and compositions for co-administration of therapeutics, such as at least one therapeutic that targets cancer stem cells in the EMT stage and at least one therapeutic that targets cancer stem cells in the MET stage. In particular embodiments, a third anti-neoplastic agent is co-administered that kills cancer cells. In this regard, a patient is treated for both types of cancer stem cells and bulk cancer cells in order to remove all types of cells with a particular treatment.
A wide range of therapeutic agents find use with the present invention. Any therapeutic agent that can be co-administered with the agents of the present invention, or associated with the agents of the present invention is suitable for use in the methods of the present invention. Some embodiments of the present invention provide methods
(therapeutic methods, research methods, drug screening methods) for administering a therapeutic compound of the present invention and at least one additional therapeutic agent (e.g., including, but not limited to, chemotherapeutic antineoplastics, antimicrobials, antivirals, antifungals, and anti-inflammatory agents) and/or therapeutic technique (e.g., surgical intervention, radiotherapies).
Various classes of antineoplastic (e.g., anticancer) agents are contemplated for use in certain embodiments of the present invention. Anticancer agents suitable for use with the present invention include, but are not limited to, agents that induce apoptosis, agents that inhibit adenosine deaminase function, inhibit pyrimidine biosynthesis, inhibit purine ring biosynthesis, inhibit nucleotide interconversions, inhibit ribonucleotide reductase, inhibit thymidine monophosphate (TMP) synthesis, inhibit dihydrofolate reduction, inhibit DNA
synthesis, form adducts with DNA, damage DNA, inhibit DNA repair, intercalate with DNA, deaminate asparagines, inhibit RNA synthesis, inhibit protein synthesis or stability, inhibit microtubule synthesis or function, and the like.
In some embodiments, exemplary anticancer agents suitable for use in compositions and methods of the present invention include, but are not limited to: 1) alkaloids, including microtubule inhibitors (e.g., vincristine, vinblastine, and vindesine, etc.), microtubule stabilizers (e.g., paclitaxel (TAXOL), and docetaxel, etc.), and chromatin function inhibitors, including topoisomerase inhibitors, such as epipodophyllotoxins (e.g., etoposide (VP- 16), and teniposide (VM-26), etc.), and agents that target topoisomerase I (e.g., camptothecin and isirinotecan (CPT-11), etc.); 2) covalent DNA-binding agents (alkylating agents), including nitrogen mustards (e.g., mechlorethamine, chlorambucil, cyclophosphamide, ifosphamide, and busulfan (MYLERAN), etc.), nitrosoureas (e.g., carmustine, lomustine, and semustine, etc.), and other alkylating agents (e.g., dacarbazine, hydroxymethylmelamine, thiotepa, and mitomycin, etc.); 3) noncovalent DNA-binding agents (antitumor antibiotics), including nucleic acid inhibitors (e.g., dactinomycin (actinomycin D), etc.), anthracyclines (e.g., daunorubicin (daunomycin, and cerubidine), doxorubicin (adriamycin), and idarubicin (idamycin), etc.), anthracenediones (e.g., anthracycline analogues, such as mitoxantrone, etc.), bleomycins (BLENOXANE), etc., and plicamycin (mithramycin), etc. ; 4)
antimetabolites, including antifolates (e.g., methotrexate, FOLEX, and MEXATE, etc.), purine antimetabolites (e.g., 6-mercaptopurine (6-MP, PURINETHOL), 6-thioguanine (6- TG), azathioprine, acyclovir, ganciclovir, chlorodeoxyadenosine, 2-chlorodeoxyadenosine (CdA), and 2'-deoxycoformycin (pentostatin), etc.), pyrimidine antagonists (e.g.,
fluoropyrimidines (e.g., 5-fluorouracil (ADRUCIL), 5-fluorodeoxyuridine (FdUrd)
(floxuridine)) etc.), and cytosine arabinosides (e.g., CYTOSAR (ara-C) and fludarabine, etc.); 5) enzymes, including L-asparaginase, and hydroxyurea, etc. ; 6) hormones, including glucocorticoids, antiestrogens (e.g., tamoxifen, etc.), nonsteroidal antiandrogens (e.g., flutamide, etc.), and aromatase inhibitors (e.g., anastrozole (ARIMIDEX), etc.); 7) platinum compounds (e.g., cisplatin and carboplatin, etc.); 8) monoclonal antibodies conjugated with anticancer drugs, toxins, and/or radionuclides, etc. ; 9) biological response modifiers (e.g., interferons (e.g., IFN-a, etc.) and interleukins (e.g., IL-2, etc.), etc.); 10) adoptive
immunotherapy; 11) hematopoietic growth factors; 12) agents that induce tumor cell differentiation (e.g., all-trans-retinoic acid, etc.); 13) gene therapy techniques; 14) antisense therapy techniques; 15) tumor vaccines; 16) therapies directed against tumor metastases (e.g., batimastat, etc.); 17) angiogenesis inhibitors; 18) proteosome inhibitors (e.g., VELCADE);
19) inhibitors of acetylation and/or methylation (e.g., HDAC inhibitors); 20) modulators of NF kappa B; 21) inhibitors of cell cycle regulation (e.g., CDK inhibitors); 22) modulators of p53 protein function; and 23) radiation.
Any oncolytic agent used in a cancer therapy context finds use in the compositions and methods of the present invention. For example, the U.S. Food and Drug Administration maintains a formulary of oncolytic agents approved for use in the United States.
International counterpart agencies to the U.S.F.D.A. maintain similar formularies. Table 1 provides a list of exemplary antineoplastic agents approved for use in the U.S. Those skilled in the art will appreciate that the "product labels" required on all U.S. approved
chemotherapeutics describe approved indications, dosing information, toxicity data, and the like, for the exemplary agents.
TABLE 1
doxorubicin liposomal Doxil Sequus Pharmaceuticals, Inc.,
Menlo park, CA
dromostanolone propionate Dromo stanolone Eli Lilly & Company,
(17b-Hydroxy-2a-methyl-5a-androstan-3-one Indianapolis, IN
propionate)
dromostanolone propionate Masterone
Syntex, Corp., Palo Alto, CA injection
Elliott's B Solution Elliott's B Orphan Medical, Inc
Solution
Epirubicin Ellence Pharmacia & Upjohn Company
((8S-cis)-10-[(3-amino-2,3,6-trideoxy-a-L- arabino- hexopyranosyl)oxy]-7,8,9, 10-tetrahydro- 6,8,1 l-trihydroxy-8- (hydroxyacetyl)-l-methoxy- 5, 12-naphthacenedione hydrochloride)
Epoetin alfa Epogen Amgen, Inc
(recombinant peptide)
Estramustine Emcyt Pharmacia & Upjohn Company
(estra-1 ,3 ,5( 10)-triene-3, 17-diol( 17(beta))-, 3 - [bis(2-chloroethyl)carbamate] 17-(dihydrogen
phosphate), disodium salt, monohydrate, or
estradiol 3-[bis(2-chloroethyl)carbamate] 17- (dihydrogen phosphate), disodium salt,
monohydrate)
Etoposide phosphate Etopophos Bristol-Myers Squibb
(4'-Demethylepipodophyllotoxin 9-[4,6-0-(R)- ethylidene-(beta)-D-glucopyranoside], 4'- (dihydrogen phosphate))
etoposide, VP- 16 Vepesid Bristol-Myers Squibb
(4'-demethylepipodophyllotoxin 9-[4,6-0-(R)- ethylidene-(beta)-D-glucopyranoside])
Exemestane Aromasin Pharmacia & Upjohn Company
(6-methylenandrosta- 1 ,4-diene-3 , 17-dione)
Filgrastim Neupogen Amgen, Inc
(r-metHuG-CSF)
floxuridine (intraarterial) FUDR Roche
(N-[4-[[(2,4-diamino-6- pteridinyl)methyl]methylamino]benzoyl]-L- glutamic acid)
Methoxsalen Uvadex Therakos, Inc., Way Exton, Pa
(9-methoxy-7H-furo[3,2-g][l]-benzopyran-7-one)
Mitomycin C Mutamycin Bristol-Myers Squibb mitomycin C Mitozytrex SuperGen, Inc., Dublin, CA
Mitotane Lysodren Bristol-Myers Squibb
(1,1 -dichloro-2-(o-chlorophenyl)-2-(p- chlorophenyl) ethane)
Mitoxantrone Novantrone Immunex Corporation
(l,4-dihydroxy-5,8-bis[[2- [(2- hydroxyethyl)amino]ethyl]amino]-9,10- anthracenedione dihydrochloride)
Nandrolone phenpropionate Durabolin-50 Organon, Inc., West Orange, NJ
Nofetumomab Verluma Boehringer Ingelheim Pharma
KG, Germany
Oprelvekin Neumega Genetics Institute, Inc., (IL-11) Alexandria, VA
Oxaliplatin Eloxatin Sanofi Synthelabo, Inc., NY,
(cis-[(l ,2R)-l,2-cyclohexanediamine-N,N'] NY
[oxalato(2-)-0,0'] platinum)
Paclitaxel TAXOL Bristol-Myers Squibb
(5B, 20-Epoxy-l,2a, 4,7B, 10B, 13a- hexahydroxytax-1 l-en-9-one 4,10-diacetate 2- benzoate 13 -ester with (2R, 3 S)- N-benzoyl-3- phenylisoserine)
Pamidronate Aredia Novartis
(phosphonic acid (3-amino-l-hydroxypropylidene)
bis-, disodium salt, pentahydrate, (APD))
Pegademase Adagen Enzon Pharmaceuticals, Inc.,
((monomethoxypolyethylene glycol succinimidyl) (Pegademase Bridgewater, NJ
11 - 17 -adenosine deaminase) Bovine)
Pegaspargase Oncaspar Enzon
(3 ,4-dihydro-3 -methyl-4-oxoimidazo[5 , 1 -d] -as- tetrazine -8 -c arboxamide)
teniposide, VM-26 Vumon Bristol-Myers Squibb
(4'-demethylepipodophyllotoxin 9-[4,6-0-(R)-2- thenylidene-(beta)-D-glucopyranoside])
Testolactone Teslac Bristol-Myers Squibb
(13 -hydroxy-3-oxo- 13 , 17-secoandrosta- 1 ,4-dien- 17-oic acid [dgr ] -lactone)
Thioguanine, 6-TG Thioguanine Glaxo SmithKline
(2-amino-l,7-dihydro-6 H - purine-6-thione)
Thiotepa Thioplex Immunex Corporation
(Aziridine, Ι, , '-phosphinothioylidynetris-, or
Tris (1-aziridinyl) phosphine sulfide)
Topotecan HC1 Hycamtin Glaxo SmithKline
((S)-10-[(dimethylamino) methyl]-4-ethyl-4,9- dihydroxy-lH-pyrano[3', 4': 6,7] indolizino [1,2-b]
quinoline-3 , 14-(4H, 12H)-dione
monohydrochloride)
Toremifene Fareston Roberts Pharmaceutical Corp.,
(2-(p-[(Z)-4-chloro- 1 ,2-diphenyl- 1 -butenyl]- Eatontown, NJ
phenoxy)-N,N-dimethylethylamine citrate (1 : 1))
Tositumomab, I 131 Tositumomab Bexxar Corixa Corp., Seattle, WA (recombinant murine immunotherapeutic
monoclonal IgG2a lambda anti-CD20 antibody (I
131 is a radioimmunotherapeutic antibody))
Trastuzumab Herceptin Genentech, Inc
(recombinant monoclonal IgGi kappa anti-HER2
antibody)
Tretinoin, ATRA Vesanoid Roche
(all-trans retinoic acid)
Uracil Mustard Uracil Mustard Roberts Labs
Capsules
Valrubicin, N-trifluoroacetyladriamycin- 14- Valstar Anthra— > Medeva valerate
((2S-cis)-2- [ 1 ,2,3 ,4,6, 11 -hexahydro-2,5, 12- trihydroxy-7 methoxy-6,1 l-dioxo-[[4 2,3,6-
phosphonic acid monohydrate)
Any and all combinations of one of the specific anti-cancer agents listed above (as the third therapeutic agent) with a specific EMT cancer stem cell agent (first therapeutic agent) and a specific MET cancer stem cell agent (second therapeutic agent) may be administered to a subject or packaged in a composition or kit.
EXPERIMENTAL
The following example is provided in order to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.
Example 1
Cancer Stem Cells Have Different States
Utilizing primary breast tissue and established cell lines, it was demonstrated that both normal and malignant breast stem cells exist in distinct, inter-convertible states. The EMT state is characterized by expression of vimentin and N-cadherin, slug, snail and twist transcription factors. EMT CSCs have a mesenchymal morphology, are largely quiescent, invasive, EpCAM"CD49f (Figure 1) and are characterized by expression of the CSC markers CD44+CD24" (Figure 2). In contrast, the MET (mesenchymal epithelial transition) state of CSCs is characterized by an epithelial morphology and expression of E-cadherin and
EpCAM. MET CSCs are EpCAM CD49F (Figure 1) and express the CSC marker Aldehyde dehydrogenase (ALDH) (Figure 3). Furthermore, it was demonstrated that these two states of CSCs are inter-convertible and they can regenerate each other in culture (Figure 4). A subpopulation of cells expressing both CD44+CD24" and ALDH may represent cells in transition between these states.
It was further demonstrated that the EpCAM+CD49f population is characterized by the highest expression of mir-93 by qRT-PCR. A TET on/off inducible system was established to over-express microRNAs in a lentiviral vector tagged with RFP. Utilizing this system, it was shown that forced over-expression of mir-93 increases the proportion of EpCAM+CD49f and ALDH+ cells (Figure 5). Furthermore, it was demonstrated that expression levels of mir-100 are significant higher in EpCAM"CD49f and EpCAM"CD49f populations than in Ερ0ΑΜ¾Ο49ί^ and EpCAM+CD49f populations. Furthermore, forced over-expression of mir-100 increased the proportion of ΕρΟΑΜ ϋ49ί cells (Figure 5). This resulted in an increase in the proportion of CD24"CD44+ CSC cells with a concomitant decrease in the ALDH+ CSC population. These results indicate that mir-93 and mir-100 are important regulators of the transition between the EMT and MET stem cell states. It was demonstrated that the induction of mir-93 in EMT SUM 159 cells induces an MET in the ALDH-positive CSC population and decreased cell invasion assessed by in vitro matrigel assay (Figure 6). Furthermore, over-expression of mir-100 resulted in a decrease of the ALDH-positive CSC population with a concomitant increase in the CD24-CD44+ population accompanied by induction of EMT, and increased cell invasion in vitro (Figure 6).
Example 2
Characterization of the States of Cancer Stem Cells
In this Example gene expression profiling was performed for CD24"CD44+ and
ALDH+ expressing cell populations isolated from a total of 45 primary human breast cancers. Of 3677 RNA transcripts elevated in the CD24"CD44+ cell population, 1724 were diminished in the ALDH+ population (Figure 10A). Conversely, of the 5218 mRNA transcripts elevated in the ALDH+ population, 1362 were diminished in the CD24"CD44+ population (Figure 10B). Furthermore, the reciprocal gene expression patterns between CD24"CD44+ and
ALDH+ populations were independent of the molecular subtype of breast cancer (i.e. luminal ER/PR+, HER2+ or triple negative) (Figure IOC). Since sphere formation under anchorage independent conditions has been shown to be a property of tumor initiating cells, the expression profile of each of these cell populations was compared to those in tumor spheres
generated from primary human tumors. Even though many genes demonstrated opposite expression patterns in the CD24"CD44+and ALDH+ populations, a set of genes expressed in CD24"CD44+and ALDH+ populations displayed overlap with those from tumor sphere populations (Figure 14). This suggests that despite significant differences between cells characterized by CD24"CD44+ or ALDH expression, they share characteristics associated with "sternness." Furthermore, even though the different subtypes of breast cancer can be classified by virtue of differential gene expression patterns of bulk cell populations, the CD24"CD44+ and ALDH+ CSC populations share common expression patterns across these subtypes.
METHODS:
Patients and Clinical Samples. The following comparisons were made on breast cancer patients or breast cancer cell line samples: i) flow-sorted samples: CD24"CD44+ vs. all other flow-sorted cells obtained from GSE7513 in public Gene Expression Omnibus (GEO); ii) flow-sorted samples: ALDH+ vs. ALDH" obtained from 16 breast cancer patients; iii) flow- sorted samples: CD24"CD44+ vs. all other flow-sorted cells and ALDH+ vs. ALDH" from breast cell lines MCF 10A, SUM 149, primary xenograft MCI and normal breast epithelial cells from patients. Data Analysis. Gene expression arrays were analyzed using Partek Genomics Suite. For each of the profile datasets, the data was pretreated by Quantile normalization and made log2-base conversion. Principal and Components Analysis (PCA) was conducted to determine and remove outliers. The fold changes between groups was computed for CD24" CD44+ vs. all others and ALDH+ vs. ALDH" by ANOVA. Expression values were visualized as heat maps by intensity plot function in Partek.
Immunostaining. For ALDHl, CD24, CD44, and DAPI quadruple fluorescent staining, paraffin-embedded sections of breast tumors or normal breast tissues were deparaffinized in xylene and rehydrated in graded alcohol. Antigen enhancement was done by incubating the sections in citrate buffer pH 6.0 (Dakocytomation) as recommended. CD24 antibody
(Neomarkers), ALDHl antibody (BD biosciences), and CD44 antibody (Thermo Scientific) were used at a 1 :50 dilution and incubated for 1 hour. Alexafluor 647-, Alexafluor 546-, Alexafluor 488-labeled secondary antibodies (Invitrogen) were used at a 1 :200 dilution and incubated for 20 minutes. Nuclei were counterstained with DAPI/antifade (Invitrogen; blue
color in the staining) and cover-slipped. Sections were examined with a fluorescent microscope (EVOS FL, AMG).
Patients and Clinical Samples We made the following comparisons on breast cancer patients or breast cancer cell line samples: i) flow-sorted samples: CD24"CD44+ vs. all other flow- sorted cells obtained from GSE7513 in public Gene Expression Omnibus (GEO); ii) flow- sorted samples: ALDH+ vs. ALDH" obtained from 16 breast cancer patients; iii) flow-sorted samples: CD24"CD44+ vs. all other flow-sorted cells and ALDH+ vs. ALDH" from breast cell lines MCF 10A, SUM149, primary xenograft MCI and normal breast epithelial cells from patient.
Cell culture Breast cancer cell line SUM 149 was from Asterland 24 and MCF10A was purchased from ATCC, which were cultured as previously described25. Flow Cytometry - Core biopsies and normal breast tissues were taken and placed
immediately in cold RPMI-1640 supplemented with 10% heat-inactivated newborn calf serum (HINCS, Invitrogen). In summary, the samples were digested in collagenase and lxlO6 single cells were resuspended, incubated for 15 min with anti-CD44, anti-CD24, and anti- lineage mixture antibodies (PE-conjugated anti-CD2, CD3, CD 10, CD 16, CD 18, CD31, and CD 140B) (PharMingen) using the manufacturer's suggested concentrations, and then followed by Aldefluor assay as described before3, and analyzed using MoFlo Astrios flow cytometry. Side and forward scatter were used to eliminate debris and cell doublets, and the Lin cells were further analyzed for expression of the CD44/CD24 and ALDH markers. The detailed procedure for cell lines and cells from primary xenografts was described
previously25.
RNA extraction - Total RNA was isolated using RNeasy Micro Kit (Qiagen, Valencia, CA), and total RNA with enriched miRNA was isolated using miRNeasy mini Kit, according to the manufacturer's instructions.
Gene Expression Profiling - Gene expression analyses used Affymetrix U133 Plus 2.0 human oligonucleotide microarrays. Preparation of cRNA, hybridizations, washes and detection were done as recommended by the supplier. Expression data were analyzed by the
RobustMultichip Average method in R using Bioconductor and associated packages26.
Data Analysis - We analyzed gene expression arrays using Partek Genomics Suite. For each of the profile datasets, we pretreated the data by Quantile normalization and made log2-base conversion. Principal and Components Analysis (PCA) was conducted to determine and remove outliers. Fold changes were computed between groups CD24"CD44+ vs. all others and ALDH+ vs. ALDH" by ANOVA. Expression values were visualized as heat maps by intensity plot function in Partek.
Real-time quantitative PCR (qRT-PCR) - For reverse-transcriptase reactions, ^g of total RNA from the sorted cells was reverse transcribed with 200U M-MLV Reverse Transcriptase (GibcoBRL) at 42°C for 1 hour in the presence of 5 mM each of dATP, dCTP, dGTP and dTTP, 4 μΐ 5X 1st strand buffer (GibcoBRL), 0.01M DDT, 1U RNA Guard RNase inhibitor (GibcoBRL), and 2.5μΜ random primers in a total volume of 20μ1. The reaction was terminated by heating to 95°C for 3 minutes. Real-time quantitative PCR (TaqManTM) primers and probes were purchased from Applied Biosytems as Assays-on-Demand TM Gene Expression Products. Real-time PCRs were performed following the supplier's instructions (Applied Biosystems). 20μ1 of PCR mixture contained ΙΟμΙ of 2x TaqmanTM universal PCR Master Mix, Ιμΐ of 20x working stock of gene expression assay mix, and 50ng of RNA converted cDNA. PCR was performed in a ABI PRISM® 7900HT sequence detection system with 384- Well block module and automation accessory (Applied
Biosystems) by incubation at 50°C for 2 min and then 95°C for 10 min followed by 40 amplification cycles (15 s of denaturation at 95°C and 1 min of hybridization and elongation at 60°C). The reaction for each sample was performed in quadruplicates. Fluorescence of the PCR products was detected by the same apparatus. The number of cycles that it takes for amplification plot to reach the threshold limit, the Ct-value was used for quantification. TBP was used for normalization.
Immunostaining - For ALDH1, CD24, CD44, and DAPI quadruple fluorescent staining, paraffin-embedded sections of breast tumors or normal breast tissues were deparaffinized in xylene and rehydrated in graded alcohol. Antigen enhancement was done by incubating the sections in citrate buffer pH 6.0 (Dakocytomation) as recommended. CD24 antibody (Neomarkers), ALDH1 antibody (BD biosciences), and CD44 antibody (Thermo Scientific) were used at a 1 :50 dilution and incubated for 1 hour. Alexafluor 647-, Alexafluor 546-, Alexafluor 488-labeled secondary antibodies (Invitrogen) were used at a 1 :200 dilution and
incubated for 20 minutes. Nuclei were counterstained with DAPI/antifade (Invitrogen; blue color in the staining) and cover-slipped. Sections were examined with a fluorescent microscope (EVOS FL, AMG). Invasion Assay - Assays were done in triplicate in invasion chambers pre-coated with reduced growth factor matrix from BD Biosciences. Cells were added to the upper chamber in 200 mL of serum- free medium. For the invasion assay, 20,000 cancer cells were seeded on the coated chamber, and the lower chamber was filled with 600 mL of medium (Cambrex) with FBS. After 37 hours of incubation, the cells on the underside of the upper chambers were stained with the blue stain in the Cell Invasion Assay Kit (Chemicon; cat. #ECM550) and counted using light microscopy.
Normal breast derived cell implantation into the cleared fatpads of NOD-SCID mice - Three- week-old female NOD-SCID mice were anesthetized by an i.p. injection16. The no. 4 inguinal mammary glands were cleared and humanized with 2.5xl05 non-irradiated telomerase immortalized human mammary fibroblasts (a generous gift from John Stingl and Connie Eaves, Terry Fox Laboratory, Vancouver, British Columbia, Canada) and 2.5xl05 irradiated (4 Gy) fibroblasts as previously described16. A 60-day release estrogen pellet (0.18 mg/pellet, Innovative Research of America, Sarasota, FL) was placed s.c. on the back of the neck of the mouse by using a trocar, and the sorted cells were mixed with 2.5xl05 normal human mammary fibroblasts and resuspended in 50 ul of 1 : 1 Matrigel: 5% serum Ham's F-12 and injected into each of the cleared fatpads. All of the implantation experiments were repeated five times using cells from different patients with three mice implanted per patient sample. Differentiating Culture Conditions - Sorted single cell suspensions were plated on collagen- coated plates at a density of 2000 viable cells/10 cm diameter dish. Cells were grown in Ham's F-12 medium (GIBCO INVITROGEN) with 5% fetal bovine serum (FBS), 5 mg/ml insulin, 1 mg/ml hydrocortisone, 10 mg/ml cholera toxin (Sigma, St Louis, MO, USA), 10 ng/ml epidermal growth factor (BD Biosciences), and 13 Pen/Strep/Fungizone Mix (GIBCO). Cells were fixed or collected for immunostaining after 12 days.
3-D Matrigel Culture - 3-D cultures in Matrigel were established as previously described27. Briefly, the sorted cells were suspended in 1ml of BD Matrigel™ Matrix (Cat. 354234, BD Biosciences, Palo Alto, CA) and Ham's F-12 medium (BioWhittaker) with 5% serum at a
ratio of 1 : 1, and plated 1ml of the mixture into one well of 24-well cold plates and each group of cells was performed in quadruplicates. After the matrigel was solidified, 0.5ml of Ham's F-12 medium (BioWhittaker) with 5% serum was added to the top of the matrigel. The experiments were repeated with cells derived from at least three different patients.
Statistical Analysis - Results are presented as the mean±standard deviation (STDEV) for at least 3 repeated individual experiments for each group. Mean and STDEV was determined on the basis of an analysis of at least 3 replicates using Microsoft Excel. Statistical differences were determined by using ANOVA and Student's t test for independent samples. A value of P < 0.05 was considered statistically significant.
RESULTS:
The expression of EMT and MET associated genes were compared in sorted CD24" CD44+ and ALDH+ tumor cell populations. As shown in Figure 10D and Figure 15, EMT associated genes including vimentin, ZEB 1, ZEB2, CTNNB1 and MMP9 were significantly enriched in the CD24"CD44+ populations while expression of these EMT genes were correspondingly decreased in the ALDH+ populations. Conversely, genes associated with the alternative MET state such as cadherin, occludin, claudins and desmoplakin, were elevated in ALDH+ populations and correspondingly diminished in the CD24"CD44+ cell populations. The proliferation marker Ki67 was preferentially expressed in ALDH+ compared to CD24" CD44+ cells. These studies suggest that CD24"CD44+ primarily identifies EMT-like CSCs, whereas ALDH expression identifies MET-like proliferative CSCs. Importantly, these characteristics are independent of the molecular subtype of breast cancer. Previous studies have suggested that the relatively quiescent EMT-like CSCs may be particularly resistant to cytotoxic chemotherapy and radiation therapy6. This model is supported by a neo-adjuvant clinical trial which demonstrated that residual tumor cells in triple-negative breast cancer following chemotherapy or in luminal breast cancer following hormonal therapy express an EMT-like CSC profile7, suggesting that these divergent molecular subtypes of breast cancer contain similar therapy resistant CSC populations.
The above studies indicate that CD24"CD44+ and ALDH+ markers identify distinct
CSC populations. To determine the location of these populations within tumors,
immunofluorescence was performed utilizing antibodies against CD44, CD24 and
ALDH1A1, the ALDH isoform most commonly expressed in human breast cancers3. As assessed by immunofluorescence, CD24"CD44+ and ALDH+ identify largely non-overlapping
cell populations, an observation supported by flow cytometry analysis of isolated tumor cell populations. Furthermore, CD24"CD44+ cells were primarily located at the tumor invasive edge adjacent to stroma (Figure 10E). In contrast, ALDH1A1+ cells were located more centrally consistent with previous studies demonstrating that ALDH+ CSC are generated by hypoxia in interior tumor zones8 (Figure 10E). A small subpopulation of cells were identified which simultaneously expressed CD24"CD44+and ALDH+ (Figure 10E) which may be indicative of CSC transitioning between epithelial and mesenchymal states.
To further characterize the biological characteristics of these CSC populations, established breast cancer cell lines were utilized as well as primary tumor xenografts. As was the case with primary tumors, breast cancer cell lines and primary xenografts contained
CD24"CD44+ and ALDH expressing cell populations with a minimal overlap (Figure 1 1 A). Furthermore, as was the case with primary breast cancers, CD24"CD44+ cells were enriched for expression of mesenchymal associated genes, while ALDH+ cells demonstrated a reciprocal epithelial gene expression pattern (Figure 16). These results were confirmed by qRT-PCR (Figure 17). To determine the degree of cellular plasticity between the epithelial and mesenchymal CSC states, CD24"CD44+ and ALDH+ populations were cultured, and the stability of the phenotypes was determined. As demonstrated in Figure 1 IB, in basal
SUM149 cells, stem cell states were plastic in vitro and each enriched CSC population readily generated the other, resulting in cell populations which recapitulated those present in the original cell line (Figure 1 IB). This suggests that CSCs can transit between epithelial and mesenchymal states.
Matrigel invasion assay was utilized to determine the relationship between CSC states and tumor invasion. As shown in Figure 1 1C, tumor cells displaying either stem cell marker were more invasive than the bulk tumor population. Within CSC marker positive cells, CD24" CD44+ cells were significantly more invasive than ALDH+ cells with while cells displaying all three stem cell markers demonstrated the greatest invasive capacity.
Together, these studies suggest that CSCs exist in alternative EMT and MET-like states. The EMT-like state characterized as CD24"CD44+ displays a mesenchymal phenotype with increased invasive capacity, and low proliferative potential. Conversely, the MET-like state characterized by ALDH expression displays an epithelial morphology and exhibits increased self-renewal capacity (Figure 1 ID). Transition between these states may be regulated by extrinsic signals generated in the tumor microenvironment. Cellular plasticity allowing transition between EMT and MET states may be required for tumors to successfully navigate the metastatic cascade as illustrated in Figure 1 IE.
The relationship between CSC populations and their counterparts in the normal mammary gland remains controversial. A hierarchy of normal mammary cells has been described based on the expression of markers CD49f (alpha 6 integrin) and EpCAM13. These markers identify four populations in the normal mammary gland including EpCAM+CD49f epithelial cells, EpCAM+CD49f luminal progenitor cells, EpCAM"CD49f stem cells and EpCAM"CD49f stromal cells13. The non-transformed MCFIOA human mammary cell line was utilized to determine the relationship between these markers and the CD24"CD44+and ALDH+ markers used to characterize CSCs. As previously reported14'15, when placed in tissue culture, EpCAM+CD49f cells displayed an epithelial morphology (Figure 12A) and expressed E-cadherin (Figure 12B), while EpCAM"CD49f cells displayed a mesenchymal morphology (Figure 12A) and expressed the EMT marker vimentin (Figure 12C). However, these phenotypes were not stable in culture and EpCAM+CD49f cells generated double- positive cells and vice versa (Figure 12A). To determine the relationship between cell populations identified by expression of the markers and those expressing CSC markers CD24" CD44+ and ALDH+, serial flow cytometry using both sets of markers was performed.
EpCAM" CD49f mesenchymal-like cells were enriched for the expression of CD24"CD44+ (Figure 12D), whereas the EpCAM+CD49f epithelial-like cells were enriched for ALDH expression (Figure 12D). Furthermore, these populations were distinct with little overlap (Figure 12E). Gene expression analysis of sorted CD24"CD44+ and ALDH+ populations demonstrated that these cells expressed genes characteristic of mesenchymal (basal) and epithelial phenotypes respectively (Figure 12F). Expression of a subset of these genes was verified by qRT-PCR (Figure 18).
Next, the expression of these markers was examined in normal human mammary cell populations isolated from reduction mammoplasties. As was the case for MCFIOA cells, the normal mammary gland contains cell populations that can be identified by virtue of CD49f and EpCAM expression. EpCAM"CD49f cells expressed basal/mesenchymal markers, whereas EpCAM+CD49f cells primarily expressed epithelial markers (data not shown). To determine the differentiation potential of these cells they were transplanted into the cleared fat pads of NOD/SCID mice that had been humanized by addition of human mammary stromal cells16. Within the CD49 population, both EpCAM+ and EpCAM" cells were able to generate mammary structures containing both epithelial and myoepithelial cell layers (Figure 13 A). To further characterize these populations, the relationship between expression of CD49f and EpCAM with that of CD24"CD44+ and ALDH+ was determined.
As was the case with MCF10A cells, EpCAM~CD49 cells were enriched for CD24" CD44+, whereas EpCAM+CD49 cells were enriched for ALDH expression (Figure 13B) with little overlap between these populations (Figure 19A). Gene expression analysis of sorted CD24"CD44+ and ALDH+ cells demonstrated that these cell populations expressed genes characteristic of mesenchymal (basal) and epithelial phenotypes respectively (Figure 19B), findings which were verified by qRT-PCR (Figure 19C). Despite the observation that ALDH cells were predominantly contained within the EpCAM+CD49f population, this ALDH+ population constituted only 6% of total EpCAM+CD49f cells. Furthermore, within the EpCAM+CD49f population, only Aldefluor-positive cells were able to generate bi- lineage colonies in vitro (Figure 13C and Figure 20), and multilineage ductal/alveolar in 3D matrigel cultures (Figure 13D and Figure 21), consistent with a recent report17. These experiments indicate that in the normal mammary gland, the EpCAM+CD49f cell population is heterogeneous and is composed of an ALDH+ subcomponent which has high proliferative capacity as well as multilineage differentiation potential and an ALDH-negative component which is luminal restricted with lower proliferative potential.
To determine the cellular location of these populations in the normal mammary gland, immunofluorescence staining was performed utilizing antibodies against CD44, CD24 and ALDH1A1. CD24"CD44+ cells were located in the basal cell layer in ductal structures, whereas ALDH+ cells were located in a luminal location in the terminal end buds and at ductal branch points (Figure 13E).
Work conducted during this example suggests that human mammary glands display an organization where basal stem cells are CD24"CD44+, EpCAM"CD49f , and where luminal stem cells are ALDH+EpCAM+CD49 . The self-renewing proliferative state of the ALDH+ luminal stem cells may increase their susceptibility to mutation during
carcinogenesis. ALDH+ luminal breast stem cells may, therefore, represent a subset of
EpCAM+CD49f cells capable of giving rise to breast cancers. Furthermore, the observation that different molecular subtypes of breast cancer contain stem cells with similar molecular characteristics suggests that these subtypes may share a common cell of origin. The mutation profile, therefore, rather than the cell of origin may determine the molecular subtype of breast cancer generated. This model is supported by recent whole genome analysis of breast cancers which reveal distinct mutations associated with different molecular subtypes which intern display distinct biological and clinical behaviors22. This Example also indicates that EpCAM+CD49f cells which have been previously characterized as luminal progenitors, in fact represents a heterogenous population that contains an ALDH+ subpopulation that is more
accurately characterized as a luminal stem cell. The tumor initiating potential of cancer cells with this phenotype and the multilineage differentiation capacity of their normal counterparts supports this classification. This Example further indicates that once tumors develop they are driven by CSC with the cellular plasticity to transition between EMT and MET states. These CSC states transitions may facilitate tumor invasion as well as growth at metastatic sites.
REFERENCES:
1. (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute.
Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. The New England journal of medicine 2005, 353(17): 1784-1792.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003,
100(7):3983-3988.
4. Dontu G, Abdallah W, Foley J, Jackson K, Clarke M, Kawamura M, Wicha M: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes & Development 2003, 17(10): 1253-1270.
5. Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Schott A et al: ALDH1 is a marker of normal and malignant breast stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1 :555-567.
6. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS: Stem cells in normal breast development and breast cancer. Cell Prolif 2003, 36 Suppl 1 :59-72.
7. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M,
Jacquemier J, Viens P, Kleer CG, Liu S et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, l(5):555-567.
8. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J et al: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69(4): 1302-1313.
9. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG, Wicha MS: Regulation of mammary stem/progenitor cells by PTEN/Akt/beta- catenin signaling. PLoS Biol 2009, 7(6):el000121.
10. Phillips TM, McBride WH, Pajonk F: The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98(24): 1777-1785.
11. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EY: Cancer stem cells contribute to cisplatin resistance in Brcal/p53-mediated mouse mammary tumors. Cancer Res 2008, 68(9):3243-3250.
12. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res 2007, 67(3): 1030-
1037.
13. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S: Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009, 15(12):4234-4241.
14. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U: Nuclear export of microRNA precursors. Science 2004, 303(5654):95-98.
15. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120(1): 15-20.
16. Kato M, Slack FJ: microRNAs: small molecules with big roles - C. elegans to human cancer. Biol Cell 2008, 100(2):71-81.
17. Lowery AJ, Miller N, McNeill RE, Kerin MJ: MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 2008, 14(2):360-365.
18. Wiemer EA: The role of microRNAs in cancer: no small matter. Eur J Cancer 2007, 43(10): 1529-1544.
19. Hatfield S, Ruohola-Baker H: microRNA and stem cell function. Cell Tissue Res 2008, 331(l):57-66.
20. Croce CM, Calin GA: miRNAs, cancer, and stem cell division. Cell 2005, 122(l):6-7. 21. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J et al: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007,
131(6): 1109-1123.
22. Yu F, Yao FL, Zhu P., Zhang X., Pan Q., Gong C. , Huang Y., Hu X., Su F., Lieberman J. and Song E. : let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell 2007, 131 : 1109-1123.
23. Silber J, Lim DA, Petritsch C, Persson Al, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF et al: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008, 6: 14.
24. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH et al: Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009, 50(2):472-480.
25. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S et al: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011, 17(2):211-215.
26. Ibarra I, Erlich Y, Muthuswamy SK, Sachidanandam R, Hannon GJ: A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. Genes Dev 2007, 21(24):3238-3243.
27. Greene SB, Gunaratne PH, Hammond SM, Rosen JM: A putative role for microRNA- 205 in mammary epithelial cell progenitors. J Cell Sci 2010, 123(Pt 4):606-618.
28. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E et al: Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138(3):592-603.
29. Yu F, Deng H, Yao H, Liu Q, Su F, Song E: Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010, 29(29):4194-4204.
30. Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890.
31. Kalluri R: EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009, 119(6): 1417-1419.
32. Xu J, Lamouille S, Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009, 19(2): 156-172.
33. Davies JA: Mesenchyme to epithelium transition during development of the mammalian kidney tubule. Acta Anat (Basel) 1996, 156(3): 187-201.
34. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003, 15(6):740-746.
35. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117(7):927-939.
36. Shin SY, Rath O, Zebisch A, Choo SM, Kolch W, Cho KH: Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res 2010, 70(17):6715-6724.
37. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP: Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell
2009, 15(5):416-428.
38. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ:
Direct regulation of TWIST by HIF-1 alpha promotes metastasis. Nat Cell Biol 2008, 10(3):295-305.
39. Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT et al: Axl is an essential epithelial-to-mesenchymal transition- induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A
2010, 107(3): 1124-1 129.
40. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y: Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009, 15(3): 195-206.
41. Thompson EW, Newgreen DF, Tarin D: Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer research 2005, 65(14):5991-5995.
42. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138(4):645-659.
43. Skvortsova I, Skvortsov S, Raju U, Stasyk T, Riesterer O, Schottdorf EM, Popper BA, Schiestl B, Eichberger P, Debbage P et al: Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse. Radiother Oncol 2010, 96(1): 108-115.
44. Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K, Sun LZ:
Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS ONE 2010, 5(4):el0365.
45. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-715.
46. Tsuji T, Ibaragi S, Shima K, Hu MG, Katsurano M, Sasaki A, Hu GF: Epithelial- mesenchymal transition induced by growth suppressor pl2CDK2-APl promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res 2008, 68(24): 10377-10386.
47. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A et al: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15(8):907-913.
48. Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, Smith AE, Prat A, Perou CM, Gilmore H et al: Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci U S A 2011.
49. Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, Emich H, Costea DE, Mackenzie IC: Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 2011, 71(15):5317-5326.
50. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S: Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009, 11(4):R46.
51. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M et al: Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11(3):259-273.
52. Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF: Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol 201 1, 121(l):200-205.
53. Li Z, Yang CS, Nakashima K, Rana TM: Small RNA-mediated regulation of iPS cell generation. EMBO J 2011, 30(5):823-834.
54. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED:
Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006, 66(23): 1 1271-1 1278.
55. Chao YL, Shepard CR, Wells A: Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010, 9: 179.
56. Yates CC, Shepard CR, Stolz DB, Wells A: Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer 2007, 96(8): 1246-1252.
57. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R, Jr., Badve S, Nakshatri H: CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006, 8(5):R59. Additional References (see Example 2):
1. Reya, T., Morrison, S.J., Clarke, M.F. & Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature. 414(6859), 105-11 1 (2001).
2. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J. & Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100, 3983-3988 (2003).
3. Ginestier, C, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567 (2007).
4. Mani, S.A., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
5. Tsuji, T., et al. Epithelial-mesenchymal transition induced by growth suppressor pl2CDK2-APl promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res 68, 10377-10386 (2008).
6. Li, X., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100, 672-679 (2008).
7. Creighton, C.J., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106, 13820- 13825 (2009).
8. Conley, S.J., et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 109, 2784-2789 (2012).
9. Liu, S., et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 71, 614-624 (2011).
10. Ocana, O.H., et al. Metastatic colonization requires the repression of the epithelial- mesenchymal transition inducer prrxl . Cancer Cell 22, 709-724 (2012).
11. Tsai, J.H., Donaher, J.L., Murphy, D.A., Chau, S. & Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725-736 (2012).
12. Britschgi, A., et al. JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer. Cancer Cell 22, 796-81 1 (2012).
13. Lim, E., et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15, 907-913 (2009).
14. Keller, P. J., et al. Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci U S A 109, 2772-2777 (2012).
15. Keller, P. J., et al. Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. Breast Cancer Res 12, R87 (2010).
16. Liu, S., et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66, 6063-6071 (2006).
17. Shehata, M., et al. Phenotypic and functional characterization of the luminal cell hierarchy of the mammary gland. Breast Cancer Res 14, R134 (2012).
18. Vaillant, F., Lindeman, G.J. & Visvader, J.E. Jekyll or Hyde: does Matrigel provide a more or less physiological environment in mammary repopulating assays? Breast Cancer Res 13, 108 (201 1).
19. Hudson, D.L. Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis 7, 188-194 (2004).
20. Lawson, D.A., et al. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A 107, 2610-2615 (2010).
21. Wang, X., et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461, 495-500 (2009).
22. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
23. Liu, S., et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A 105, 1680-1685 (2008).
24. Neve, R.M., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
25. Liu, S., et al. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet 8, el002751 (2012).
26. Irizarry, R.A., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (Oxford, England) 4, 249-264 (2003). 27. Weaver, V.M. & Bissell, M.J. Functional culture models to study mechanisms governing apoptosis in normal and malignant mammary epithelial cells. Journal of Mammary Gland Biology and Neoplasia 4, 193-201 (1999).
All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described
compositions and methods of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the relevant fields are intended to be within the scope of the present invention.
Claims
1. A method of reducing the frequency of EMT and MET type cancer stem cells in a subject with said EMT and MET type cancer stem cells comprising co-administering to said subject an effective amount of:
a) a first therapeutic agent directed against EMT type cancer stem cells, and b) a second therapeutic agent directed against MET type cancer stem cells, wherein the frequency of both said EMT and said MET type cancer stem cells in said subject are reduced.
2. The method of Claim 1, wherein said first therapeutic agent comprises an inhibitor of a protein or nucleic acid encoding a protein selected from the group consisting of: IL-6, IL-6 receptor, Notch, Wnt, Hedgehog, or Tgf-β; or wherein said first therapeutic agent comprises an inhibitor of a protein or nucleic acid encoding a protein in the pathway of IL-6, IL-6 receptor, Notch, Wnt, Hedgehog, or Tgf-β.
3. The method of Claim 1, wherein said second therapeutic agent comprises a Pan-erb blocker or a Her-2 pathway inhibitor.
4. The method of Claim 1, wherein said subject comprises bulk cancer cells that are not cancer stem cells, and wherein the method further comprises co-administering a third therapeutic agent to said subject, wherein said third therapeutic agent is capable of killing or inhibiting said bulk cancer cells, and wherein the frequency of said bulk cancer cells is reduced.
5. The method of Claim 1, wherein said EMT cancer stem cells are CD44 D24" and EpCam"CD49F+.
6. The method of Claim 5, wherein said EMT cancer stem cells express elevated levels, and/or where the MET cancer stem cells decreased levels, of at least one of the following: vimentin, N-cadherin, slug, snail, ZEB l , ZEB2, CTNNB l, MMP2, MMP9, FOXCl , FOXC2, Fibronectin 1 , and twist.
7. The method of Claim 1, wherein said EMT cancer stem cells express miR-221 and/or miR-100.
8. The method of Claim 1, wherein said MET cancer stem cells are ALDH and EpCam+CD49F+.
9. The method of Claim 1, wherein said MET cancer stem cells express miR-93.
10. The method of Claim 1, wherein said subject further comprises EMT-MET cancer stem cells, and said co-administering reduces the frequency of said EMT-MET cancer stem cells in said subject.
11. The method of Claim 10, wherein said EMT-MET cancer stem cells are characterized as CD44+CD24" and ALDH+.
12. The method of Claim 1, wherein said first therapeutic agent is an IL6R antibody and said second therapeutic agent is anti-Her2 antibody.
13. A system for reducing the frequency of EMT and MET type cancer stem cells in a subject comprising:
a) a first therapeutic agent directed against EMT type cancer stem cells, and b) a second therapeutic agent directed against MET type cancer stem cells.
14. The system of Claim 13, wherein said first therapeutic agent comprises an inhibitor of a protein or nucleic acid encoding a protein selected from the group consisting of: IL-6, Notch, Wnt, Hedgehog, or Tgf-β; or wherein said first therapeutic agent comprises an inhibitor of a protein or nucleic acid encoding a protein in the pathway of IL-6, IL-6 receptor, Notch, Wnt, Hedgehog, or Tgf-β.
15. The system of Claim 13, wherein said second therapeutic agent comprises a Pan-erb blocker or a Her-2 pathway inhibitor.
16. The system of Claim 13, further comprising a third therapeutic agent capable of killing or inhibiting bulk cancer cells that are not cancer stem cells.
17. A method of identifying a test compound useful for treating EMT and/or MET type cancer stem cells:
a) providing a population of cancer cells, wherein the majority of cancer cells in said population are a type of cancer cell or mixture of cancer cells selected from the group consisting of:
i) EMT type cancer stem cells,
ii) MET type cancer stem cells,
iii) a mixture of EMT and MET cancer stem cells, and
iv) EMT-MET cancer stem cells; and
b) administering said test compound to said cancer cells;
c) monitoring the response of said cancer cells to said test compound; and d) identifying a test compound that inhibits cancer cells.
18. The method of Claim 17, further comprising screening said test compound identified in step d) against a population of normal cells and/or population of normal stem cells to determine if said test compound harms said normal cells and/or normal stem cells.
19. A method comprising: assaying a sample from a subject with cancer and identifying the presence or absence of EMT, MET, and/or EMT-MET cancer stem cells in said sample.
20. The method of Claim 19, wherein the presence of EMT cancer stem cells are identified in said sample, and wherein said method further comprises administering a therapeutic to said subject directed to EMT cancer stem cells.
21. The method of Claim 19, wherein the presence of MET cancer stem cells are identified in said sample, and wherein said method further comprises administering a therapeutic to said subject directed to MET cancer stem cells.
22. The method of Claim 19, wherein the presence of both EMT and MET cancer stem cells, and/or the presence of EMT-MET cancer stem cells, are identified in said sample, and wherein said method further comprises administering a first therapeutic to said subject directed to EMT cancer stem cells and a second therapeutic to said subject directed to MET cancer stem cells.
23. The method of Claim 19, wherein said EMT cancer stem cells are identified based on being CD44+CD24" and EpCam"CD49F+.
24. The method of Claim 19, wherein said MET cancer stem cells are identified based on being ALDH+ and EpCam+CD49F+.
25. The method of Claim 19, wherein said EMT cancer stem cells are identified based on expression of miR-100 and/or miR-221.
26. The method of Claim 19, wherein said MET cancer stem cells are identified based on expression of miR-93.
27. The method of Claim 19, wherein said EMT cancer cells are identified by detecting elevated expression, and/or MET cancer stem cells are identified by detecting decreased expression, of at least one of the following markers: vimentin, N-cadherin, slug, snail, ZEB l, ZEB2, CTNNB1, MMP2, MMP9, FOXC1, FOXC2, Fibronectin 1, and twist.
28. The method of Claim 19, wherein said MET cancer cells are identified by detecting elevated expression, and/or EMT cancer cells are identified by detecting decreased expression of, of at least one of the following markers: EpCam, E-cadherin, occludin, desmoplakin, Ki67, cadherin 1, or a claudin.
29. A method comprising: administering a composition to a subject, wherein said subject has cancer, and wherein said composition comprises an expression vector configured to express miR-93, miR-100, and/or miR-221.
30. A method of converting a cancer stem cell from one type to another comprising: i) contacting a MET cancer stem cell with an miR-100 and/or miR-221 expression vector such that miR-100 and/or miR-221 is over expressed by said MET cancer stem cell thereby converting said MET cancer stem cell to a EMT cancer stem cell; and/or ii) contacting an EMT cancer stem cell with a miR-93 expression vector such that miR-93 is over expressed by said EMT cancer stem cell thereby converting said EMT cancer stem cell to a MET cancer stem cell.
31. A method of treating cancer in a subject comprising:
treating a subject with antigen presenting cells such that at least some cancer cells in said subject are killed, wherein said antigen presenting cells have been exposed to: i) EMT and MET cancer stem cells or at least an antigenic portion of said EMT and MET cancer stem cells; and/or ii) EMT -MET cancer stem cells or at least an antigenic portion of said EMT-MET cancer stem cells.
32. The method of Claim 31, wherein said antigen presenting cells have been exposed to a lysate from said EMT and MET cancer stem cells, and/or said EMT-MET cancer stem cells.
33. The method of Claim 31, wherein said antigen presenting cells comprise dendritic cells.
34. The method of Claim 31, wherein said antigen presenting cells comprise
macrophages.
35. The method of Claim 31, wherein said antigen presenting cells comprise B-cells.
36. The method of Claim 31, wherein said subject is a human.
37. The method of Claim 31, wherein said subject has a cancer selected from the group consisting of: melanoma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, liver cancer, brain cancer, skin cancer, and colon cancer.
38. The method of Claim 31, further comprising treating said subject with a
chemotherapeutic agent.
39. The method of Claim 31, further comprising treating said subject with radiation therapy.
40. A composition comprising: antigen presenting cells that have been exposed to: i) EMT and MET cancer stem cells or at least an antigenic portion of said EMT and MET cancer stem cells; and/or ii) EMT-MET cancer stem cells or at least an antigenic portion of said EMT-MET cancer stem cells.
41. A system comprising:
a) antigen presenting cells that have been exposed to: i) EMT and MET cancer stem cells or at least an antigenic portion of said EMT and MET cancer stem cells; and/or ii) EMT-MET cancer stem cells or at least an antigenic portion of said EMT-MET cancer stem cells; and
b) at least one component selected from:
i) a device configured to emit radiation used during external radiation cancer therapy;
ii) a chemotherapeutic agent;
iii) a first therapeutic that targets EMT cancer stem cells; and iv) a second therapeutic that targets MET cancer stem cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/376,923 US9352039B2 (en) | 2012-02-09 | 2013-02-08 | Method of reducing the number of EMT and MET type breast cancer stem cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261596796P | 2012-02-09 | 2012-02-09 | |
US61/596,796 | 2012-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013119923A1 true WO2013119923A1 (en) | 2013-08-15 |
Family
ID=48948050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/025306 WO2013119923A1 (en) | 2012-02-09 | 2013-02-08 | Different states of cancer stem cells |
Country Status (2)
Country | Link |
---|---|
US (1) | US9352039B2 (en) |
WO (1) | WO2013119923A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015168255A1 (en) * | 2014-04-29 | 2015-11-05 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
CN105368853A (en) * | 2015-11-30 | 2016-03-02 | 成都山权江生物科技有限公司 | Marker related to auxiliary diagnosis of non-small cell lung cancer and application thereof |
WO2016034679A1 (en) * | 2014-09-03 | 2016-03-10 | Drk Blutspendedienst Baden-Württemberg-Hessen Ggmbh | Micro rna for the suppression of blood group antigens |
US10106778B2 (en) | 2012-11-08 | 2018-10-23 | Whitehead Institute For Biomedical Research | Selective targeting of cancer stem cells |
US11452713B2 (en) * | 2016-02-29 | 2022-09-27 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods for treating low-proliferative disseminated tumor cells |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3571508B8 (en) * | 2017-01-18 | 2023-05-24 | SRI International | Detecting cancer stem cells using a glycan biomarker |
US11197872B2 (en) | 2017-04-21 | 2021-12-14 | Lunella Biotech, Inc. | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) |
CN113302288A (en) * | 2018-11-12 | 2021-08-24 | 新加坡科技研究局 | Methods of controlling cellular state transitions in cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020051785A1 (en) * | 2000-03-20 | 2002-05-02 | The Regents Of The University Of California And Amgen Inc. | HER -2/neu overexpression abrogates growth inhibitory pathways |
US20100162416A1 (en) * | 2008-09-29 | 2010-06-24 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
US20110021607A1 (en) * | 2008-02-01 | 2011-01-27 | Michael Clarke | Methods and Compositions Relating to Carcinoma Stem Cells |
US20110143960A1 (en) * | 2009-12-10 | 2011-06-16 | Labarbera Daniel V | 3d-models for high-throughput screening drug discovery and development |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
US6270961B1 (en) | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5169862A (en) | 1989-07-07 | 1992-12-08 | Peptide Technologies Corporation | Analogs of viscosin and their uses |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
US5539085A (en) | 1993-08-20 | 1996-07-23 | Onyx Pharmaceuticals, Inc. | Bcl-2 and R-ras complex |
US5599677A (en) | 1993-12-29 | 1997-02-04 | Abbott Laboratories | Immunoassays for prostate specific antigen |
US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
AU2006308870B2 (en) | 2005-10-31 | 2012-08-16 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US8652472B2 (en) | 2006-12-05 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US8088617B2 (en) | 2007-01-24 | 2012-01-03 | Oncomed Pharmaceuticals, Inc. | Antibodies that bind the glutamate ligand binding region of Notch1 |
US20090208491A1 (en) | 2007-02-14 | 2009-08-20 | Austin Gurney | Compositions and Methods for Diagnosing and Treating Cancer |
EP2155249A4 (en) | 2007-05-15 | 2011-11-16 | Oncomed Pharm Inc | Compositions and methods for diagnosing and treating cancer |
US8158758B2 (en) | 2007-07-02 | 2012-04-17 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
WO2009009114A2 (en) | 2007-07-12 | 2009-01-15 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
US8455623B2 (en) | 2008-05-21 | 2013-06-04 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US8945569B2 (en) | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
EP2506875A4 (en) | 2009-12-01 | 2013-11-27 | Oncomed Pharm Inc | Methods for treating cancers comprising k-ras mutations |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
WO2011088215A2 (en) | 2010-01-13 | 2011-07-21 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
NZ602700A (en) | 2010-04-01 | 2014-10-31 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
US20130309246A1 (en) * | 2011-02-02 | 2013-11-21 | The Trustees Of Princeton University | Jagged1 as a marker and therapeutic target for breast cancer bone metastasis |
-
2013
- 2013-02-08 US US14/376,923 patent/US9352039B2/en active Active
- 2013-02-08 WO PCT/US2013/025306 patent/WO2013119923A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020051785A1 (en) * | 2000-03-20 | 2002-05-02 | The Regents Of The University Of California And Amgen Inc. | HER -2/neu overexpression abrogates growth inhibitory pathways |
US20110021607A1 (en) * | 2008-02-01 | 2011-01-27 | Michael Clarke | Methods and Compositions Relating to Carcinoma Stem Cells |
US20100162416A1 (en) * | 2008-09-29 | 2010-06-24 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
US20110143960A1 (en) * | 2009-12-10 | 2011-06-16 | Labarbera Daniel V | 3d-models for high-throughput screening drug discovery and development |
Non-Patent Citations (1)
Title |
---|
PETROCCA ET AL.: "Emerging Role of miR-106b-25/miR-17-92 Clusters in the Control of Transforming Growth Factor.beta. Signaling.", CANCER RES, vol. 68, no. 20, 15 October 2008 (2008-10-15), pages 8191 - 8194, XP055078293 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10106778B2 (en) | 2012-11-08 | 2018-10-23 | Whitehead Institute For Biomedical Research | Selective targeting of cancer stem cells |
WO2015168255A1 (en) * | 2014-04-29 | 2015-11-05 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
US20170049745A1 (en) * | 2014-04-29 | 2017-02-23 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
US10398672B2 (en) | 2014-04-29 | 2019-09-03 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
WO2016034679A1 (en) * | 2014-09-03 | 2016-03-10 | Drk Blutspendedienst Baden-Württemberg-Hessen Ggmbh | Micro rna for the suppression of blood group antigens |
CN105368853A (en) * | 2015-11-30 | 2016-03-02 | 成都山权江生物科技有限公司 | Marker related to auxiliary diagnosis of non-small cell lung cancer and application thereof |
CN105368853B (en) * | 2015-11-30 | 2018-12-25 | 成都山权江生物科技有限公司 | One kind marker relevant to non-small cell lung cancer auxiliary diagnosis and its application |
US11452713B2 (en) * | 2016-02-29 | 2022-09-27 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods for treating low-proliferative disseminated tumor cells |
Also Published As
Publication number | Publication date |
---|---|
US20150125469A1 (en) | 2015-05-07 |
US9352039B2 (en) | 2016-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9352039B2 (en) | Method of reducing the number of EMT and MET type breast cancer stem cells | |
JP6599334B2 (en) | Methods and assays for circulating tumor cells in the blood | |
Li et al. | Mesenchymal stem cell-derived exosomal microRNA-3940-5p inhibits colorectal cancer metastasis by targeting integrin α6 | |
Shi et al. | Circular RNA ANAPC7 inhibits tumor growth and muscle wasting via PHLPP2–AKT–TGF-β signaling Axis in pancreatic cancer | |
Mohapatra et al. | CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis | |
US20110021607A1 (en) | Methods and Compositions Relating to Carcinoma Stem Cells | |
AU2010222632B2 (en) | Methods using Axl as a biomarker of epithelial-to-mesnchymal transition | |
US20190071668A1 (en) | Compositions and methods for identification, assessment, prevention, and treatment of cancer using slncr isoforms | |
Zhou et al. | Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression | |
US20120035244A1 (en) | Parp1 targeted therapy | |
Xie et al. | ITGB1 drives hepatocellular carcinoma progression by modulating cell cycle process through PXN/YWHAZ/AKT pathways | |
Zhou et al. | Interleukin-23 receptor signaling mediates cancer dormancy and radioresistance in human esophageal squamous carcinoma cells via the Wnt/Notch pathway | |
Chen et al. | DNA methylation of cannabinoid receptor interacting protein 1 promotes pathogenesis of intrahepatic cholangiocarcinoma through suppressing Parkin‐dependent pyruvate kinase M2 ubiquitination | |
KR101925125B1 (en) | Biomarker composition for diagnosing colon cancer or prognosing metastasis of colon cancer comprising NCKAP1 | |
Wang et al. | PAQR5 inhibits the growth and metastasis of clear cell renal cell carcinoma by suppressing the JAK/STAT3 signaling pathway | |
Wu et al. | DAB2IP decreases cell growth and migration and increases sensitivity to chemotherapeutic drugs in colorectal cancer | |
WO2022266639A1 (en) | Methods and compositions for treating melanoma | |
Zhang et al. | PYCR1 promotes the malignant progression of lung cancer through the JAK-STAT3 signaling pathway via PRODH-dependent glutamine synthesize | |
Hu et al. | LncRNA NR2F1-AS1 was involved in azacitidine resistance of THP-1 cells by targeting IGF1 with miR-483-3p | |
Ma et al. | Ginsenoside Rk3 Inhibits the Extramedullary Infiltration of Acute Monocytic Leukemia Cell via miR-3677-5p/CXCL12 Axis | |
Zhu et al. | LncRNA TRG-AS1 inhibits bone metastasis of breast cancer by the miR-877–5p/WISP2 axis | |
CN111534587A (en) | Molecular marker 5-tRF-His, breast cancer detection kit and application thereof | |
Suresh Babu et al. | Enhanced Epithelial-to-Mesenchymal Transition and Chemoresistance in Advanced Retinoblastoma Tumors Is Driven by miR-181a. Cancers (Basel), 2022. 14 (20) | |
XIE et al. | Cell cycle arrest and senescence in P53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) through p53-dependent pathway | |
Chen et al. | High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13746393 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14376923 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13746393 Country of ref document: EP Kind code of ref document: A1 |